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Abstract
Approaches to the identification of genetic variants associated with complex brain diseases have
evolved in recent decades. This evolution was supported by advancements in medical imaging and
genotyping technologies that result in rich data production in the field of imaging genetics and
radiogenomics. Studies in these fields have taken different designs and directions from genome-
wide associations to studying the complex interplay between genetics and structural connectivity
of a wide range of brain-related diseases. Nevertheless, such combinations of heterogeneous, high
dimensional and inter-related data has introduced new challenges which cannot be handled with
traditional statistical methods. In this thesis, we proposed analysis pipelines and methodologies to
study the causal relationship between neuroimaging features, including tumour characteristics and
connectomics, genetics and clinical factors in brain-related diseases. In doing so, we adopted two
longitudinal study designs and modelled the association between Alzheimer’s disease progression
and genetic factors, utilising local and global brain connectivity networks. In addition to that, we
performed a multi-stage radiogenomic analysis in glioblastoma using non-parametric statistical
methods. To address some limitations in the methods, we adopted the Structural Equation Model
and developed a mathematical model to examine the inter-correlation between neuroimaging and
multi-omic characteristics of brain-related diseases. Our findings have successfully identified risk
genes that were previously reported in the literature of Alzheimer’s and glioblastoma diseases,
and discovered potential risk variants which associate with disease progression. More specifically,
we found some loci in the genes CDH18, ANTXR2 and IGF1, located in Chromosomes 5, 4 and
12, to have effect on the brain connectivity over time in Alzheimer’s disease. We also found
that the expression of APP, HFE, PLAU and BLMH have significant effects on the structural
connectivity of local areas in the brain, these are the left Heschl gyrus, right anterior cingulate
gyrus, left fusiform gyrus and left Heschl gyrus, respectively. These potential association patterns
could be useful for early disease diagnosis, treatment and neurodegeneration prediction. More
importantly, we identified gaps in the imaging genetics methodologies, we proposed a mathemat-
ical model accounting for these limitations and evaluated the model which produced promising
results. Our proposed flexible model, BiGen, addresses the gaps in the existing tools by combining
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neuroimaging, genetics, environmental, and phenotype information to a single complex analysis,
accounting for the heterogeneity, inter-correlation, and non-linearity of the variables. Moreover,
BiGen adopts an important assumption which is hardly met in the literature of imaging genetics,
and that is, all the four variables are assumed to be latent constructs, that means they can not
be observed directly from the data, and are measured through observed indicators. This is an
important assumption in both neuroimaging, behavioural and genetic studies, and it is one of the
reasons why BiGen is flexible and can easily be extended to include more indicators and latent
constructs in the context of brain-related diseases.
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1.1 Hypothetical and illustrative figure of the different stages in AD; preclinical, MCI
and dementia, and the associated changes and biomarkers over time (the order
of brain changes from earliest to latest: beta-amyloid accumulation, synaptic
dysfunction, tau protein collection, brain structure, cognitive and clinical funtion).
The top figures* show the amount of change in the brain, as AD progresses,
compared to the healthy brain (left figure). . . . . . . . . . . . . . . . . . . . . 8
1.2 An illustrative figure* of the main brain regions; the four lobes (frontal, temporal,
parietal and occipital) and the cerebellum. . . . . . . . . . . . . . . . . . . . . 9
2.1 Example of a multi-modal MRI brain scan and its corresponding expert segmen-
tation labels. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.2 Illustrative examples of spatial distribution (left) and texture (right) patterns. . . 24
2.3 Schematic representation of the study’s analysis workflow. Step (a) was done
using spatial features, while step (e) was done using radiomic features. . . . . . 25
2.4 A Manhattan (left) and qq-plot (right) of the associations between the tumor
spatial distribution patterns, and gene expression. The plot is showing the meta-
analysis results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.5 A Manhattan (left) and qq-plot (right) of the associations between the tumor
texture features, and gene expression. The plot is showing the meta-analysis results. 28
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The human brain is a very complex organ that controls bodily activities and systems. It uses
about 20% of the body’s energy and contains a total of 100 billion neurons supported by 1,000
billion glial cells. The cerebral cortex, which is the outer layer of the brain, contains about
one-sixth to one-third of the total neurons in the brain. The brain has four main lobes; these
are temporal, occipital, parietal and frontal lobe. It consists of many regions, which include
ganglia, cerebellum, Broca’s area, corpus callosum, medulla oblongata, amygdala, hypothalamus
and thalamus. Various brain diseases might affect different regions of the brain, and depending
on the function mapped to that region, bodily activities are affected, and certain symptoms arise
(Herculano-Houzel, 2009).
Brain diseases come in many forms; they include traumas, seizures, strokes, tumors and brain
cancers, neurodegenerative conditions and psychiatric disorders. Neurodegenerative diseases af-
fect the brain cells and cause neuron death and damage. Examples of neurodegenerative disorders
include amyotrophic lateral sclerosis, dementia, Alzheimer’s, Parkinson’s and Huntington’s dis-
eases. Brain tumors can be benign or malignant, and are caused by the abnormal growth of cells
in the brain. Benign tumors are mostly slow growing and they can originate in different parts of
the brain. The most common type of benign tumors are meningiomas, and they start growing
from the lining of the brain. Malignant brain tumors, on the other hand, are aggressive, and
they invade nearby tissues (e.g. glioblastoma). Other types of brain diseases include viral or
bacteria infections, which can cause inflammation around, or within, the brain (e.g. meningitis
and encephalitis). Traumas are injuries that disturb the brain function. One type of trauma is
concussion, which affects the cognition ability and causes confusion and unconsciousness. Intrac-
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erebral haemorrhage is a different type of trauma which causes bleeding in the brain. Autoimmune
conditions, such as multiple sclerosis, are other types of brain disorders that cause the immune
system to attack the nerve cells (McDonald et al., 2001; Goetz, 2007).
Here, we focus on studying two main aspects of brain diseases, that is, genetics and neuroimaging
characteristics, as well as studying their complex interplay and relationship with other environ-
mental and clinical factors. Specifically, we intend to extract neuroimaging phenotypes of brain
structure and study their causal relationship with some multi-omic data. Multi-omic data refer to
the information extracted from either the genome, proteome, transcriptome or metabolome, we
focus here on gene expressions and single nucleotide polymorphisms. In this thesis, we decided
to narrow our focus to one focal lesion disease, namely glioblastoma multiforme, and one disease
affecting more widespread regions across the brain, namely Alzheimer’s disease. This way we will
be able to study different structures of the brain, identify potential genetic risk factors which
are responsible for changes in brain structure, and get easy access to imaging genetics datasets.
We studied the two diseases and tested different hypotheses to understand the association be-
tween neuroimaging characteristics and multi-omic factors. In doing so, we identified the need
for a unified model to study the complex interplay between genetic, environmental and clinical,
neuroimaging and phenotype features. We introduce a novel model which can test complex
hypotheses in the field of imaging genetics, study the effect of interaction terms on the final phe-
notype, and accommodate heterogeneous data types including phenotype measurements, brain
connectivity, environmental and multi-omic factors.
1.2 Alzheimer’s Disease
1.2.1 Clinical Characteristics. Alzheimer’s Disease (AD) is a central nervous system degen-
erative disorder that occurs in the brain, and worsens over time. It is suspected to develop 20
years before the disease symptoms appear (Braak et al., 2011; Reiman et al., 2012; Gordon et al.,
2018). Specifically, AD is thought to start by slight changes in the patient’s brain; however,
those changes are not noticeable at first. Eventually, after years, the nerve cells in the brain (or;
neurons) start to die in different regions of the brain. Consequently, the disease symptoms start
to arise. As a result of the amount of change that occurs in the brain, caused by the death and
destruction of the neurons, the symptoms worsen and differ. This results in cognitive decline in
many functions, including memory, learning and thinking (Gaugler et al., 2019).
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Symptoms of Alzheimer’s Disease
Symptoms of AD start to occur as the brain cells, or neurons, involved start to die or damage.
As the disease progresses, neurons in different regions in the brain continue to die, and symptoms
worsen. The early symptoms of AD mainly affect the cognitive function of patients. These include
memory loss of recent events, problem-solving and task management difficulties, confusion of
dates and times, poor judgement, misplacing things, changes in personality, and being socially
inactive. Eventually, the symptoms start to affect the patients’ bodily functions, such as walking
and swallowing. Ultimately, AD leads to death (Gaugler et al., 2019).
Stages of the Disease
There are three stages of AD, namely; preclinical AD (Sperling et al., 2011), mild cognitive
impairment (MCI) due to AD (Albert et al., 2011) and dementia due to AD (McKhann et al.,
2011). Although research is still ongoing to understand and diagnose the preclinical stage, the
symptoms of AD are not observable at this stage. However, perceptible changes, or biomarkers, in
the brain, blood and cerebrospinal fluid start to become noticeable. In the MCI and dementia due
to AD stages, symptoms are present and observable, these include subtle cognitive decline, e.g.
thinking disabilities, as well as further changes in brain, such as elevated levels of beta-amyloid (or
Amyloid beta; Aβ)1 protein. The symptoms do not interfere much in everyday activities at the
MCI stage, and patients can function independently, but they worsen at the stage of dementia,
when the decline in daily activities, cognitive and behavioural disabilities become observable.
These worsen as the disease progresses, and depend on the degree of damage in the neurons
around the brain. Even though 60% to 80% of dementia cases are due to Alzheimer’s, not all
dementias are caused by Alzheimer’s, nor will all individuals diagnosed with MCI develop AD
(Wilson et al., 2012). Nevertheless, people who are diagnosed with MCI and have memory
problems are more likely to develop AD and dementia (Kantarci et al., 2009).
Statistics and Facts
The progression of AD is somehow subtle and slow. The average postdiagnosis survival duration
of an AD dementia patient who is aged 65, or older, is about 4 to 8 years - with no significant
differences between males and females or between ethnicity. There are, however, some patients
who live up to 20 years after diagnosis. The average mortality rate was shown to be 10.7 per
100 person-years in AD, that is, in every 100 individuals in the population 10.7 are expected to
1See Section 1.2.3 and Section 1.2.4 for more details about Aβ.
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die every year, and is higher among the elderly (Brookmeyer et al., 2002; Helzner et al., 2008).
Among all causes of death in the category of the population of age more than 80 years, 61%
are expected to be in AD patients, while they form 30% of deaths in the general population.
Between the age of 70 to 80 years, AD patients spend 40% of the time in the most severe stage
of dementia, while they spend 30% of the time in the mild and moderate stages (Arrighi et al.,
2010). In the United States, AD is the fifth-leading cause of death for those older than 65 years.
Overall, AD is the sixth highest cause of death after heart disease, cancer, unintentional injuries,
chronic lower respiratory disease and stroke, ranked according to the number of deaths (Murphy
et al., 2018). The increase in AD death rate since 2000 is 31% for those aged from 65 to 74
years, 57% for 75 to 84 years old, and 86% for patients older than 85 years (for Disease Control
et al., 2018).
According to the 2019 Alzheimer’s Disease Facts and Figures, reported by Gaugler et al. (2019),
the deaths in AD might be more than what has been reported by official sources. Patients live
with the disease as it progresses, or they die because of it. Therefore, AD increases the status of
poor health and morbidity.
Diagnosis
Several factors are being used as biomarkers to diagnose AD at its different stages. Depending on
the biomarker of interest, the method of diagnosis is determined. In the preclinical stage of AD
and the more advanced stages, a number of biomarkers are present and detectable. The most
important of these biomarkers is the amount of Aβ and tau proteins in the brain. The former
can be measured through positron emission tomography (PET) amyloid imaging2. PET imaging
uses functional nuclear techniques to monitor the metabolic process in the brain or other organs
in the body. The level of some proteins (e.g. tau and Aβ) in fluids, such as the cerebrospinal
fluid (CSF) can be detected through the CSF assays (Sperling et al., 2011).
Another biomarker is the level of glucose metabolism in the brain. This biomarker is measured
using the radiotracer fluorodeoxyglucose (FDG) PET or functional magnetic resonance imaging
(fMRI). The cerebral blood flow in the brain is associated with neuronal activation which can also
be used in the diagnosis of AD; fMRI triggers the changes in blood flow to observe activities in
the brain. Sperling et al. (2011) and McKhann et al. (2011) explained the need for more research
in clarifying the performance and optimization of the current diagnostic technique, urging for a
better way to determine standardized thresholds to distinguish between AD stages. Moreover,
current research is trying to find a simpler, cheaper and more efficient way of diagnosing AD,
2See Section 1.4.1 for more details about neuroimaging techniques in Alzheimer’s.
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such as through blood tests (Gaugler et al., 2019).
In dementia due to AD, subtle cognitive decline is observable. The cognitive changes can be
determined by different ways, such as; 1) obtaining family and medical history in cognitive and
behavioural changes, 2) asking family members to provide information about the observed changes
in thinking and functionality of the patient, and, 3) cognitive and physical neurologic tests (McK-
hann et al., 2011). What makes a distinction between MCI (Albert et al., 2011) and dementia
due to AD is that, in dementia, the cognitive changes are significant. Meaning that they interfere
in the patient’s daily activity. The latter is measured by a skilled clinician, who meets the patients
and other family members to evaluate the patient’s circumstances and daily affairs.
1.2.2 Treatment. So far, no medication can stop or slow down the damage and destruction of
brain cells (Gaugler et al., 2019), even though some drugs exist, namely, memantine, donepezil,
tacrine, rivastigmine, a combination of memantine and donepezil, tacrine and galantamine. The
memantine is effective in preventing the excess stimulation that contributes to damaging neurons,
by blocking some receptors in the brain. All remaining drugs help in slowing down the disease
symptoms temporarily through increasing the number of neurotransmitters3 in the brain.
Moreover, non-pharmacologic therapy exists for Alzheimer’s dementia that does not require med-
ication. This type of therapy can slow down the cognitive decline, improve the quality of daily
life and reduce behavioural symptoms, e.g. aggression, depression and sleep disturbance. Such
therapies include computerized training to improve memory, exercising, or changing lighting to
reduce sleep disorders. Exercising was shown to reduce the overall cognitive decline in AD (Farina
et al., 2014). However, they do not stop or slow the disease progression or the neuron damage.
1.2.3 Brain Changes. There are known biological changes in the brain of an AD patient which
affect the neurons by either disrupting their functionality or by killing the neurons. The changes
start to take place much earlier than the symptoms arise, that is 18 to 22 years before the onset
of symptoms. In other words, the brain is able to compensate for those changes without affecting
the patient’s cognitive function. However, when more regions in the brain are affected, the patient
reaches a point where the brain can no longer compensate for such changes. Hence, a subtle
change in cognitive and other symptoms become observable (Gordon et al., 2018).
The healthy human brain consists of roughly 100 billion neurons. They are highly connected
through branching extensions - each neuron has its branching extension attached to it. Information
is transmitted around the brain using those connections - also called synapses - in the form of
3Neurotransmitters are endogenous chemicals in the brain with a major role in enabling neurotransmission.
They send chemical messages between neurons. They also facilitate communications between a neuron and a
muscle or gland cell.
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bursts of chemicals released from one neuron to another. Overall, the brain contains 100 trillion
synapses. A single neuron has around 7,000 synaptic connections to enhance communication
with other neurons. Accordingly, neuronal circuits are formed and facilitate the cellular basis of
emotions, memory, vision, movements and other sensations (National Institute on Aging).
The abnormal accumulation of toxic beta-amyloid proteins (called beta-amyloid plaques) between
neurons and the abnormal gathering of tau proteins (forming the tau tangles) inside neurons
are two main factors characterizing brain change in AD. In a healthy brain, tau stabilizes the
microtubules, which are tiny cellular structures that support neurons, and guide nutrients and
molecules from the cell body to dendrites. However, in the Alzheimer’s brain, abnormal chemicals
cause tau to detach from microtubules and form tangles within the neuron, thereby, blocking the
nutrient transport inside neurons. Beta-amyloid, on the other hand, has different forms, which
result from the break down of amyloid precursor protein (APP). The beta-amyloid 42 is especially
toxic and may contribute to brain cell death in Alzheimer’s. Although ongoing research is still
trying to understand how beta-amyloid causes cell death, it appears that cell death happens as a
result of the abnormal levels of beta-amyloid protein clumps. This unusual accumulation forms
the plaques between neurons and disrupts the cell function.
The tau tangles accumulate at the areas in the brain that are involved in memory. However, when
the beta-amyloid plaques reach a certain amount, tau tangles are believed to spread rapidly in
neurons throughout the brain. This complex interplay is found to form the basis of AD progression
and brain changes (National Institute on Aging). Figure 1.1 explains and visualizes the progress
of AD and its different clinical stages. An annotated figure that illustrates the brain regions is
show in Figure 1.2.
Some other brain changes that might occur in AD are chronic inflammation and shrinkage (or,
atrophy). The inflammation occurs as a result of the activation of microglia. Microglia is an
immune cell in the brain activated by tau tangles and beta-amyloid plaques. Microglia cells try to
clear the waste caused by dead and dying neurons, or clean the protein collections and plaques.
Inflammation happens when microglia is not able to clear all the debris caused. Atrophy, on the
other hand, occurs when the loss of neurons as the disease progresses is significant. Specifically,
when the brain regions start to shrink (National Institute on Aging).
1.2.4 Risk Factors and Genetic Causes. Though AD is not a normal part of ageing, one of
its known risk factors is growing older (Hebert et al., 2010); there is a higher risk of developing
AD after the age of 65. Moreover, carriers of the ε4 form (or allele) of the apolipoprotein E
(ApoE ) gene are at higher risk of developing the disease compared to non-carriers (Saunders
et al., 1993). ApoE is the coding gene for a protein responsible for transporting cholesterol in
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Figure 1.1: Hypothetical and illustrative figure of the different stages in AD; preclinical, MCI
and dementia, and the associated changes and biomarkers over time (the order of brain changes
from earliest to latest: beta-amyloid accumulation, synaptic dysfunction, tau protein collection,
brain structure, cognitive and clinical funtion). The top figures* show the amount of change in
the brain, as AD progresses, compared to the healthy brain (left figure).
* The top three figures were obtained from Vecteezy and are available here:
https://www.vecteezy.com/vector-art/292445-an-anatomy-of-human-brain
the bloodstream. Family history is another strong risk factor (Fratiglioni et al., 1993); individuals
who are members of families with an AD history have a higher likelihood of having the disease.
Stroke, high cholesterol, blood pressure, heart disease and head injuries can also contribute to
the risk of developing AD and dementia. However, AD is a chronic and complex disorder and
is believed to develop as a result of many factors, rather than a single factor, including complex
genetic interplay (Van Cauwenberghe et al., 2016).
Known Susceptibility Genes
As per a recent study by Van Cauwenberghe et al. (2016), the ApoE gene has three major allelic
variants; ε2, ε3 and ε4. These result in six possible ApoE genotypes; three in the heterozygous
states (ε2/ε3, ε2/ε4 and ε3/ε4), and three homozygous (ε2/ε2, ε3/ε3 and ε4/ε4). Those allelic
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Figure 1.2: An illustrative figure* of the main brain regions; the four lobes (frontal, temporal,
parietal and occipital) and the cerebellum.
* Source: https://blog.cognifit.com/frontal-lobe/
variants play different roles in affecting Alzheimer’s; having the ε4 in both alleles increases one’s
risk of developing AD.
ApoE ε4 was shown to increase and regulate the onset of cellular deposition of Aβ as the
patient ages (Morris et al., 2010). However, this is not sufficient for predicting the disease in
asymptomatic individuals. Carriers of two ε4 alleles have a 12 fold higher risk of developing AD
compared to carriers of two ε3 alleles, while carriers of one ε4 have 3 times the risk. On the other
hand, ε2 of ApoE has a high protective effect for AD; those who carry ε2 allele have a lower risk
of developing AD, as shown by Corder et al. (1994).
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A small percentage of AD cases, roughly 1%, develop due to mutations4 in either the APP,
presenilin 1 (PSEN1) or presenilin 2 (PSEN2) genes, all of which contribute to Aβ processing
(Bekris et al., 2010). If the mutations in APP and PSEN1 are present, there is a 100% chance of
developing AD, while the presence of a PSEN2 mutation implies a 95% chance of developing the
disease (Goldman et al., 2011). Other studies (Van Cauwenberghe et al., 2016) have identified
genetic variants through genome-wide association studies (GWASs) in some genes as potential
risk factors for AD development, such as SORL1, ABCA7 and PLD3. GWAS is the study in
which single nucleotide polymorphisms (SNPs) are tested along the genome for associations with
a trait (phenotype, or disease) of interest (Hirschhorn and Daly, 2005). A SNP is the smallest
form of genetic variation, which occurs at a single locus. However, the biological contribution of
these genetic factors to AD progression remains unclear (Bekris et al., 2010).
1.3 Glioblastoma Multiforme
1.3.1 Clinical Characteristics. Glioma is considered to be the most common primary brain
tumor, 70 % of which are malignant. It evolves from the supportive cerebral cells and is one of
the structural disorders of the central nervous system. The diversity of glioma patients allows the
classification of the disease in many ways. Considering the severity of the disease, gliomas can
be classified into three categories; diffuse low-grade gliomas, anaplastic glioma and glioblastoma
multiforme (Stupp et al., 2010). Although glioblastoma multiforme (GBM; or glioblastoma) is
generally not very common; it is most common among adults (average of 55 years), with a mean
survival of 15 months.
Epidemiology
GBM accounts for 50% of glioma cases, patients can develop the disease at any age, with a higher
incidence between 55 and 60 years (Ohgaki and Kleihues, 2005). Globally, GBM is a rare disease
with an incidence of less than 10 per 100,000 individuals. The disease has a poor diagnosis, and
has a survival of 14-15 months after diagnosis (Thakkar et al., 2014). Malignant gliomas are
responsible for 2.5% of the deaths due to cancer, and are the third highest cause of death due
to cancer among patients from 15 to 34 years old (Davis, 2016).
According to the American Cancer Society, the estimated number of brain and other central
nervous system cancer new cases is 23,820, with an expected 17,760 deaths in 2019 (Siegel
4A genetic mutation is an alteration of the nucleotides that make up the sequence of a gene.
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et al., 2019). GBM incidence is higher in men than in women with a ratio of 1.26: 1 (Ohgaki and
Kleihues, 2005; Thakkar et al., 2014). Incidence of GBM is believed to be higher in the western
world, though this could be due to better health reporting of cases in the western world than in
developing countries. Some studies report that GBM incidence in Black Africans is less than that
in other ethnic groups, e.g. Asians, Caucasians and Latinos. It is especially high in Caucasians
resident in industrial areas (Iacob and Dinca, 2009; Ohgaki and Kleihues, 2005).
Symptoms and Diagnoses
Symptoms and presentation of GBM cases vary depending on the associated anatomical structures
involved as well as the location and size of the tumor. Patients’ complaints might include seizures,
headaches, lethargy, nausea, hemiparesis, sight issues, memory problems, or personality changes.
The surrounding edema from the tumor might cause more neurological damage than the tumor
itself (Young et al., 2015). Some diagnostic strategies include high steroid doses accompanied
by gastrointestinal protectant, or dexamethasone 10 mg IV followed by dexamethasone 6 mg
every 6 hours (Young et al., 2015), these help to improve the observed symptoms of GBM, and
hence, facilitate diagnosis. Patients with seizures can be diagnosed using antiepileptic drugs
(AEDs) (Perry et al., 2006). Also, prescription of corticosteroids at the diagnosis stage is useful
in controlling vasogenic edema accompanying signs. Other common diagnostic strategies include
imaging techniques5 and testing a sample tissue (biopsy) from the tumor, during or before surgery
(using a needle), to determine the cell types of the tumor and the level of aggressiveness.
Classification of Glioma and Glioblastoma
The world health organization (WHO) classification of gliomas uses the level of malignancy, and
has four grades (I, II, III and IV). Grade I tumors are normally curable by surgery, and have
low-level proliferative activity. Patients with glioma grade II have a low proliferative activity,
infiltrative tumor and often recur. Grade III and IV are malignant tumors and invasive. The
fourth grade includes glioblastoma, and is the most aggressive type, invasive and fatal (Louis
et al., 2007).
Verhaak et al. (2010) utilized a GBM dataset from the Cancer Genome Atlas (TCGA) and
analyzed the molecular heterogeneity of GBM. They classified the disease into different molec-
ular subtypes, including proneural, classical, and mesenchymal. These subtypes are based on
the expression of platelet derived growth factor receptor alpha/ isocitrate dehydrogenase 1
5See Section 1.4.2 for more information about imaging techniques in GBM.
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(PDGFRA)/IDH1), the epidermal growth factor receptor (EGFR) and neurofibromin 1 (NF1),
respectively. Besides these three, a fourth subtype described by Verhaak et al. (2010) is neural.
These four subtypes respond differently to aggressive treatment protocols (e.g. surgery, radiation
or chemotherapy) with the classical being the most responsive and proneural receiving no benefits
from the treatment. Accordingly, this suggests that therapeutic strategies should consider the
genetic profiles and molecular subtype of tumors.
1.3.2 Treatment. So far, the standard treatment of GBM cases is restricted to surgical resection
followed by chemoradiation (a combination of chemotherapy and radiation). The type, size,
location of the tumor, and areas affected in the brain are used in planning surgical resection.
Although imaging-guided surgery can reduce the disease symptoms and improve the overall sur-
vival, it is not sufficient to cure the disease by itself. Moreover, 80% of GBM cases experience
relapse in 2-3 cm around the original lesion (Iacob and Dinca, 2009; Davis, 2016; Hanif et al.,
2017), and tumors located in areas like brain stem, eloquent cortex, or basal ganglia are not
amenable to resection (Mrugala, 2013). Tumors larger than 6cm show negative effects on sur-
vival (Ellor et al., 2014). Additionally, age and other prognostic factors of GBM have been shown
to manipulate survival.
Weeks after surgery, a combination of radiotherapy and chemotherapy are used to kill the re-
maining tumor cells. In particular, the temozolomide, an oral chemotherapy, and stereotactic
radiotherapy improve the overall survival (Iacob and Dinca, 2009; Scott et al., 2011; Chinot
et al., 2014). Hegi et al. (2005) compared temozolomide effects on GBM patients with and
without methylated Methyl Guanine Methyl Transferase (MGMT ) in tumor cells. MGMT is an
essential DNA repair protein which protects tumor cells from alkylating chemotherapeutic agents.
Iacob and Dinca (2009) found that temozolomide benefits those with a methylated MGMT pro-
moter. There are limitations and side effects accompanying radiation therapy, such as permanent
neuron damage. This damage is a result of the resistance of some tumors and their invasive
nature (Iacob and Dinca, 2009). Temozolomide has its side effects too.
Other types of treatment include clinical trials, in which newly designed drugs with unknown side
effects are tried on GBM patients, however, this might be risky (Davis, 2016). Palliative (or
supportive) care is also used to improve the patient’s quality of life, and relief from pain or other
symptoms. Palliative care goes in parallel with other aggressive treatments.
Despite all therapies, these tumors come back for 70% of cases after about a year, and only 5%
survive up to 5 years (Thakkar et al., 2014). Most GBM patients succumb to the disease in one
year, especially the elderly (Louis et al., 2007). In the case of recurrence, re-resection could be
an option for some patients with unclear survival outcomes. Radiation and chemotherapy might
Section 1.4. The Science of Neuroimaging Page 13
also be possible, with some risks accompanying radiation necrosis (Davis, 2016).
1.3.3 Risk Factors and Etiology. The journey of discovering potential risk factors for GBM
has not been conclusive, and very little is known so far on this matter. The exposure to ionizing
radiation is confirmed to be a physical factor that increases glioma risk (Ellor et al., 2014).
Patients usually develop radiation-induced GBM after years of therapeutic radiation from another
condition or cancer. Overall, the risk of developing GBM as a result of radiation is 2.5%, with an
estimated 116 cases since 1960 (Salvati et al., 2003). Other chemicals and environmental factors
include exposure to smoking, vinyl chloride, petroleum refining, pesticides and synthetic rubber
manufacturing, however, these factors barely associate with glioma. It is known that less than
1% of glioma patients have a known hereditary disease. Nevertheless, there is an increased risk of
developing glioma with some genetic disorders, such as neurofibromatosis 1 and 2, Li-Fraumeni
syndrome, retinoblastoma, tuberous sclerosis and Turcot syndrome (Ellor et al., 2014).
Additionally, there are other genetic disturbances associated with cell division and growth in
glioma. Examples of such are mutations in genes such as TP53, alpha thalassemia-mental re-
tardation syndrome X-linked (ATRX ), the retinoblastoma 1 (RB1), NF1, the tumor suppressor
phosphatase and tensin homolog (PTEN) and telomerase reverse transcriptase (TERT ) gene.
Other genetic factors represent the loss of genetic materials in chromosome 10q, amplification of
EGFR or alteration in signalling pathways which stimulate cancer cell division and growth, such as
the p53 (TP53), PDGFRA, PI3 Kinase, and Met. Additionally, there are common alterations in
tumor suppression pathways including p53, retinoblastoma, and cyclin dependent kinase inhibitor
2A (CDKN2A). The primary function of these genes is to prevent uncontrolled growth of cancer
cells, however, they are prevented from functioning as a result of the alterations (Nayak et al.,
2004; Network et al., 2008; Verhaak et al., 2010). The deregulation of G1/S checkpoints in
the cell cycle (YP Lam, 2000) has also been associated with GBM development. Although any
combination of the above mentioned factors contributes to the development of GBM, there is
high variability within a single tumor, and among different GBM tumors.
1.4 The Science of Neuroimaging
Neuroimaging, or brain imaging, is a rapidly evolving field and newly developed branch in neuro-
science, medicine and psychology. It allows imaging of the function or structure of the nervous
system. Brain imaging is a non-invasive and very powerful tool that positively contributes to the
management of brain-related diseases. Structural and functional imaging are two broad categories
of neuroimaging. The main focus areas of structural imaging are, 1) to image the structure of
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the central nervous system, 2) to diagnose brain diseases and conditions, such as tumors and
injuries. Functional brain images provide detailed information about lesions, metabolic diseases,
neurological and cognitive psychology (Mabray et al., 2015).
Different types of magnetic resonance imaging (MRI) are commonly used in clinical diagnosis,
surgery planning, clinical management, and in following up of brain tumors. They are structural
brain imaging that can also visualise functional activities in the brain. MRI is a medical technique
which can facilitate disease diagnosis and progression monitoring. It is particularly used in creating
images of the physiological process and anatomy of the brain or other organs in the body, using
magnetic fields. In most brain diseases and injuries, MRI and other imaging techniques, alongside
their measurable characteristics, are adequate in determining the brain structure and function, as
well as the anatomical relationships of its different regions.
1.4.1 Neuroimaging Techniques in Alzheimer’s Disease. Besides fMRI and PET imaging
(see Section 1.2.1), diffusion tensor imaging (DTI) provides further characterization of brain activ-
ities and structure. DTI maps the diffusion of water molecules in three dimensions, accounting for
the spatial distribution and controlling for the anisotropy (Alexander et al., 2007). More recently,
DTI is used in quantifying the connectivity patterns in the brain. This is used in the context of
AD, other psychiatric disorders, brain injuries, cancers and a healthy brain. More specifically, DTI
techniques are used to reconstruct connectivity information among different parts of the brain in
a representation called the connectome (Sporns et al., 2005). The connectome is a network of
the brain where nodes represents the different and distinct parts of the brain, and the links are
the number of water tracts connecting all pairs of nodes.
1.4.2 Glioblastoma and Brain Tumor Imaging. Different forms of MRI and other types of
medical imaging are used to characterize brain tumors in a variety of ways. DTI, fMRI and
connectomics are similarly used in tumor imaging (Watanabe et al., 1992; Hart et al., 2015).
More specifically, from MRI modalities such as T1, T2 and even the connectome, characteristic
features can be determined. MRI imaging modalities help detect the tumor characteristics, it
specifically provides information about the shape, size, and location of the tumor in the brain
with less radiation exposure. T1 MRI modality provides easy structural annotation of the healthy
brain tissues and it makes the tumor border brighter, while the T2 MRI brightens the edema region.
Generally, manual segmentation can be carried out by expert radiologists, through segmenting
edema from T2 images and Fluid-attenuated Inversion Recovery (FLAIR). The enhancing and
non-enhancing structures can be segmented and determined to evaluate specific damage related
to the tumor. For example, the VASARI features (Visually Accessible REMBRANDT [Repository
for Molecular Brain Neoplasia Data] Images) can be used (Gutman et al., 2013). These features
include major and minor axis length of the gross tumor core, the proportion of enhancing and
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non-enhancing, and the proportion of necrotic tissue (Eisenhauer et al., 2009; Wen et al., 2010;
Macdonald et al., 1990). The proportions are estimated using the voxels of the three types of
intra-tumoral regions: enhanced, non-enhanced and necrotic, therefore, excluding the edema.
Ellingson et al. (2014) reported consensus rules on how to define different types of damage to
MRI modalities. More recently, the connectome has also been used to provide further information
for surgical planning (Hart et al., 2015).
1.5 Imaging Genetics and Radiogenomics
In AD, and other brain diseases (e.g. psychiatric disorders), imaging genetics is the study of
the integrated associations between genetic variants, structural or functional neuroimaging phe-
notypes and other factors to study the effects of genes on brain connectivity, cognition and
behaviour (Thompson et al., 2010; Bedenbender et al., 2011). Imaging genetics has many forms
and can take different study designs, and hence, has different dimensionality. It can be conducted
as candidate genes association studies with neuroimaging characteristics, or genome-wide variant
association studies (Thompson et al., 2010). The imaging part in imaging genetics studies can
be a single phenotype (such as hippocampal volume) (Stein et al., 2012) or voxel-wise imaging
features. The latter design tests the associations between genetic variants and each voxel in the
brain (Stein et al., 2010).
The term radiogenomics, on the other hand, refers to one of two types of studies; 1) the asso-
ciation studies focusing on the response of genetic variations to radiation therapy (Andreassen
et al., 2002), 2) the studies which focus on associating gene expression to cancer imaging char-
acteristics, and this design can be used in GBM diagnosis (Diehn et al., 2008). Radiogenomics
is used in GBM, and other types of cancer, to identify imaging biomarkers in order to infer the
genomics of the disease without the need for biopsy (Chow et al., 2018).
1.6 GWAS Challenges
The past decade has witnessed a significant success of GWAS in discovering thousands of disease-
associated variants in a wide range of complex diseases (Visscher et al., 2017). Such discoveries
have contributed to improving our understanding of population genetics, the underlying biology
of complex diseases, and the discovery of new therapeutics (Visscher et al., 2017). Despite the
substantial progress in identifying novel and replicable associations between complex diseases and
genetic variants, GWAS has some limitations. One of these is that GWAS mainly studies the
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association of one SNP at a time, although GWAS successfully identified significant variants,
such variants have small effects on the disease, and usually very large sample sizes are required.
Consequently, with the contribution of other factors, GWAS only captures a small part of the
heritability of complex phenotypes (Manolio et al., 2009). The genetic heritability is defined as
the proportion of observed phenotype variation that is due to genotype, this remains small in
GWA studies.
Besides small sample size, the above mentioned challenges could be due to lack of complexity in
the statistical methods that are used by GWAS. This deficit is caused by either limited knowledge
of environmental factors, not involving the complex interplay between other genetic factors, and
also considering only the main effects of the SNPs. Recently, Marigorta et al. (2018) highlighted
other challenges raised by GWAS, such as the methodological and biological issues, that is, GWAS
findings are highly reproducible, however, the ability of these discoveries to predict phenotypes
and contribute to precision medicine is limited.
1.7 Project Motivation
In the field of molecular biology, different types of data are increasingly produced to study the
human genome variation, and its relationship to other factors and phenotypes. These data are
collected and processed to answer different biological questions and to investigate a wide range
of hypotheses. Moreover, such data are often collected together with other environmental and
clinical information. These consequently led researchers to pose new biological questions and
hypotheses, and hence, to develop new methods that aim at incorporating different data types
with genetic information.
In the case of brain disorders; brain imaging is usually released along with genetic data. Many
approaches have been proposed for integrating both multi-omic and neuroimaging features mod-
elling their association - including, but not limited to, GWA studies. However, they have not
overcome the challenges of high dimensionality or the existence of collinearity within and be-
tween multiple datasets. Hence, developing new methodologies to address computational issues
in brain-related diseases and uncover the genetic architecture of complex diseases is now essential.
Statistics show that patients with AD can become dependent for a long duration before death.
This contributes to the public health burden and increases the cases of disability and poor health
in the population. Understanding the changes in the brain and their association with other
factors in AD contributes to the development and improvement of effective treatments. It can
also facilitate early detection of brain changes and enable clinicians to closely observe disease
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progression.
The genetic heterogeneity in glioblastomas form the basis of treatment specification and clinical
outcomes. Obtaining a biopsy to identify the genetic profile of the tumor often takes time in
assessment, and might depend on the surgical planning. Radiogenomics is a non-invasive, fast
and rapid technique for genetic heterogeneity characterization. The main challenges in treating
GBM are the tumor location in the brain and the differences in tumor characteristics between and
within patients. Hence, the integration of brain tumor imaging and genetic data are crucial to
better understand the complex molecular heterogeneity underlying glioblastoma. This can also
facilitate personalized therapy and improve our understanding of disease prognosis.
Genetic association studies have contributed to and improved our understanding of complex
brain disease and identified dozens of disease-associated variants in AD and GBM. However,
those variants contribute little to the genetic heritabilty of these diseases. In the past decade,
imaging genetics and radiogenomics have proven their ability to produce replicatable findings. In
this project, we focus on studying the brain structure in connection with the genetics of two brain
diseases; AD, which spreads in different areas of the brain, and GBM, which is a focal lesion that
affects a particular area in the brain.
Here, we aimed to integrate a wide range of neuroimaging characteristics and multi-omic data,
to better understand their associations in the context of brain-related diseases. In particular, we
present various association study designs and analysis pipelines in imaging genetics and radio-
genomics using datasets provided by TCGA, The Cancer Image Archive (TCIA) and Alzheimer’s
Neuroimaging Initiative (ADNI). We also propose a robust and unbiased imaging genetics model,
using the idea of the structural equation model (SEM). Our model can analyse different scenarios
and test different hypotheses of association patterns.
1.8 Project Outline
In this thesis, we first study a brain disease with local lesions (we consider GBM), then we
look at a widespread brain disease which affects the overall brain structure, we consider AD
in this part. We test different hypothesis to understand the association between neuroimaging
characteristics (e.g. brain connectivity and tumour texture and spatial characteristics) and multi-
omic factors (including genome-wide variations and transcriptomic data). We observe the need
for a single unified model to study the complex interplay between genetic, environmental and
clinical, neuroimaging and phenotype features. We introduce a novel model which can test
complex hypotheses in the field of imaging genetics, study the effect of interaction terms on the
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final phenotype, and accommodate heterogeneous data types including phenotype measurements,
brain connectivity, environmental and multi-omic factors. Our model is fast, simple, flexible and
assumes no distribution of the data.
This thesis has four main chapters (Chapter 2 to Chapter 5), besides the Introduction (Chapter
1) and General Discussion (Chapter 6). In Chapter 2, we use Spearman’s correlation coefficient
test to carry out a multi-stage radiogenomic association analysis, in order to understand the
relationship between gene-wide expression and a wide range of spatial and texture features of
tumor imaging in a GBM dataset. Chapter 3 and Chapter 4 aim to study the contribution of
genetics to the progression of AD utilizing imaging genetics study designs. These chapters propose
two longitudinal analysis pipelines to examine the associations between structural connectome
changes and genetics factors in AD.
We propose a novel mathematical approach in Chapter 5, which integrates brain imaging, specifi-
cally global brain connectivity, genetic and clinical features using the SEM. We apply the proposed
method to the same ADNI dataset we used in Chapter 3 and Chapter 4, alongside a simulated
dataset. Finally, the General Discussion (Chapter 6), briefly concludes and discusses all the work
completed in this thesis.
Chapter 2 was published as a book chapter in Brainlesion: Glioma, Multiple Sclerosis, Stroke and
Traumatic Brain Injuries. Chapter 3 was published in Nature Scientific Reports. Chapter 4 is
under review, and Chapter 5 was put in BioRxiv.
Chapter 2
Multi-Stage Association Analysis of
Glioblastoma Gene Expression with
Texture and Spatial Patterns
Abstract
Glioblastoma is the most aggressive malignant primary brain tumor with a poor prognosis.
Glioblastoma heterogeneous neuroimaging, pathologic, and molecular features provide opportu-
nities for subclassification, prognostication, and the development of targeted therapies. Magnetic
resonance imaging has the capability of quantifying specific phenotypic imaging features of these
tumors. Additional insight into disease mechanism can be gained by exploring genetics foun-
dations. Here, we use gene expression to evaluate the associations with various quantitative
imaging phenomic features extracted from magnetic resonance imaging. We highlight a novel
correlation by carrying out multi-stage genome-wide association tests at the gene-level through a
non-parametric correlation framework that allows testing multiple hypotheses about the integrated
relationship of imaging phenotype-genotype more efficiently and less expensive computationally.
Our results showed that several novel genes previously associated with glioblastoma and other
types of cancers, such as LRRC46 (chromosome 17), EPGN (chromosome 4) and TUBA1C
(chromosome 12), all also shows strong association with our radiomic tumor features.
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2.1 Introduction
Gliomas are the most common type of primary adult brain tumors that arise from glial cells.
Gliomas have a very heterogeneous landscape, and they can be classified according to their grade
into low-grade glioma, anaplastic glioma, and glioblastoma. The most common and aggressive
type of glioma in adults is glioblastoma (GBM), which gives the affected patient an average
survival time of only 10 to 18 months. The known molecular classification of GBM into classical,
mesenchymal, neural and proneural subtypes is relatively accepted to be related to the expression
of EGFR, NF1 and PDGFRA/IDH1 genes (Verhaak et al., 2010).
Imaging, specifically magnetic resonance imaging (MRI), can offer promising biomarkers reflecting
underlying tumor pathology and biological function. If imaging phenotypes of GBM obtained
from routine clinical MRI studies can be associated with specific gene expression signatures,
quantitative imaging phenotypes will serve as non-invasive surrogates for cancer genomic events
and provide valuable information as to the diagnosis, prognosis, and optimal treatment.
Several radiogenomic studies have been carried out for many diseases (Stein et al., 2010; Liu et al.,
2009; Batmanghelich et al., 2013; Elsheikh et al., 2018a; Zinn et al., 2011; Gutman et al., 2013;
Macyszyn et al., 2015; Binder et al., 2018; Bakas et al., 2017b). For instance for schizophre-
nia pairs of SNP/Gene and MRI features have been mapped through a linear regression model
using PLINK (Stein et al., 2010), genes near significant SNPs were localized. Parallel-ICA, a
method that jointly analyse the independent component in multi-modalities through maximising
inter-modality correlation and independence,showed promising results (Liu et al., 2009). Bat-
manghelich et al. (2013) proposed a Bayesian framework to relate imaging and genetic data
to phenotypes exploiting connection among these data modalities simultaneously in Alzheimers.
Recently, correlations of connectomic features have been related to genes which are known to be
related to Alzheimer progression (Elsheikh et al., 2018a). In contrast to Alzheimer’s disease and
schizophrenia, glioma lesions are generally not spread all over the brain, and local features from
MRI can be used. An imaging-genomic analysis study (Zinn et al., 2011) performed by using
the tumor volume in T2-weighted FLuid-Attenuated Inversion Recovery (T2-FLAIR) images and
large-scale genetic and micro-RNA expression probes demonstrated the potential for molecular
subtyping and showed that the high median expression of the POSTN gene results in a signifi-
cant decrease in survival, and for that they used ANOVA and Tukey-Kramer test. Other studies
(Gutman et al., 2013; Macyszyn et al., 2015) showed correlations between image feature annota-
tions and expression of genes with glioma molecular subtypes (Verhaak et al., 2010). Specifically,
Gutman et al. (2013) found a significant association between contrast-enhanced tumor and these
molecular subtypes (Verhaak et al., 2010), where proneural type expressed by PDGFRA/IDH1
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gene showed low levels of contrast enhancement, and the classical type (i.e., primarily described
by EGFR amplification) correlates with the increased percentage of contrast enhancement. The
study used Fisher exact statistics.
Recent population-based studies have assessed the anatomical location of GBM in relation to
distinct clinically-relevant molecular characteristics, and have identified the spatial distribution of
the tumors being descriptive of their molecular status (Macyszyn et al., 2015; Network, 2015;
Ellingson et al., 2012; Ellingson, 2015; Steed et al., 2016; Bilello et al., 2016; Akbari et al., 2018).
Furthermore, the emerging research direction of radiomics has shown promise that texture analysis
of the various tumor sub-regions in radiographic imaging can also be informative of the tumor’s
molecular characterization (Aerts, 2016; Lambin et al., 2012; Aerts et al., 2014).
Furthermore, using MRI features for GBM lesions, including texture and shape features, Itakura
et al. (2015) proposed a classification imaging method and found three clusters of GBM patients.
In their method, they integrate copy number and gene expression data to estimate the molecular
pathway activity and show that the three clusters reveal not only different molecular characteristics
but also different survival probabilities.
Here, we specifically chose to study the association of gene expression with both the location
and texture features of the tumor as the anatomic distribution of gliomas was shown to be
heterogeneous within the brain Larjavaara et al. (2007). On the other hand, there are differences
in the expression profiles of genes between the invasive and tumor cells in gliomas Hoelzinger
et al. (2005). Therefore, studying the genetics underlying the invasion of tumor in association
with gene expression might give insights to targeted therapies. The purpose of this chapter
is to identify significant associations between gene expression, across the whole genome, and
quantitative imaging phenomic features extracted from multi-modal MRI brain scans of patients
diagnosed with de novo primary GBM. In line with the pre-mentioned studies, here we focus on
evaluating the spatial location and texture features of GBM and investigate their associations
with gene expression.
2.2 Materials and Methods
2.2.1 Data. For the quantitative association analysis conducted here, we utilized a retrospec-
tive cohort of 135 de novo primary GBM patients from the TCGA-GBM collection (Scarpace
et al., 2016), with available pre-operative multi-modal MRI scans in The Cancer Imaging Archive
(TCIA) (Clark et al., 2013) and corresponding molecular characterization in The Cancer Genome
Atlas (TGCA). The multi-modal MRI data we utilized comprise native (T1) and post-contrast
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T1-weighted (T1Gd), T2-weighted (T2), and T2-FLAIR modalities. T1 and T2 MRI imaging
modalities help to detect the tumor characteristics, they specifically provide information about
the shape, size, and location the tumor in the brain with less radiation exposure. T1 provides easy
structural annotation of the healthy brain tissues and it makes the tumor border brighter, while the
T2 MRI brightens the edema region. The TCGA-GBM subset of 135 patients were identified by
Bakas et al. (2017c) as brain scans without any surgically-imposed cavity, and their co-registered
and skull-stripped imaging were provided in the TCIA Analysis Results together with expert man-
ually annotated segmentation labels for the various histologically-distinct tumor sub-regions, i.e.
enhancing tumor (ET), non-enhancing tumor (NET), peritumoral edematous/invaded tissue (ED)
(Figure 2.1) (Bakas et al., 2017c,a). The total sample size of GBM patients reduced to 88 after
evaluating patients that had available imaging (Scarpace et al., 2016) and corresponding gene
expression. In total, we assessed expression energies for 17815 genes, 11 distinct descriptors
of tumor spatial location (Figure 2.2), and 517 radiomic/texture features (Figure 2.2) for each
patient’s brain tumor scan (Davatzikos et al., 2018; Bakas et al., 2017c,a).
Figure 2.1: Example of a multi-modal MRI brain scan and its corresponding expert segmentation
labels.
2.2.2 Quantitative Imaging Phenomic Features.
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Radiomic/Texture Features.
We extracted an extensive panel of quantitative texture features, volumetrically (in 3D), for
each tumor sub-region as provided by the expert annotations, across all available modalities.
Specifically, the texture features we evaluated i) capture global characteristics (i.e., variance,
skewness, kurtosis) of each sub-region’s intensity distribution on each modality, and ii) include
features based on Gray-Level Co-occurrence Matrix (GLCM) which is a matrix that describes the
distribution of co-occuring pixel values in gray tone (Haralick et al., 1973) (Figure 2.2), Gray-
Level Run-Length Matrix (GLRLM) whose two dimensions are the gray level and run length,
each element in the matrix represents the number of pixels with in gray-level for all possible
run length values (Galloway, 1974; Chu et al., 1990; Dasarathy and Holder, 1991; Tang, 1998),
Gray-Level Size Zone Matrix (GLSZM) which uses 3D brain images to provide information about
homogeneous zones in gray matter (Chu et al., 1990; Dasarathy and Holder, 1991; Tang, 1998),
and Neighborhood Gray-Tone Difference Matrix (NGTDM) which indicates the gray-tone spatial
distribution of voxel intensities (Amadasun and King, 1989).
Spatial Distribution Patterns.
Beyond texture features, we collected discrete spatial information about the anatomical loca-
tion of each tumor on each brain scan (Figure 2.2). To obtain these spatial distribution pat-
terns we registered all brain tumor scans in a standardized healthy atlas space using an iterative
Expectation-Maximization framework (Bakas et al., 2015), while incorporating a biophysical tu-
mor growth model (based on a reaction-diffusion-advection model (Hogea et al., 2008, 2007a,b))
to account for tumor mass effects in the brain parenchyma. We then retrieved the spatial dis-
tribution of each tumor according to the discretized anatomical locations of the i) specific lobes
(i.e., frontal, temporal, parietal, occipital), ii) insula, iii) basal ganglia, iv) fornix, v) cerebellum,
and vi) brain stem. In addition, we also included as distinct features the distances of i) the tumor
core (defined as the union of ET and NET), and ii) the ED, from the ventricles.
To produce these quantitative features we have utilized GLISTRboost. Specifically, in the process
to produce segmentations of the various tumor sub-regions, the generative part (Gooya et al.,
2012) of GLISTRboost, following an Expectation-Maximization framework registers a healthy
population probabilistic atlas of glioma patients’ brain scans while incorporating a biophysical
glioma growth model to account for mass effects. Then, after converting the predicted seg-
mentation in the healthy atlas space, the percentage of the tumor core (i.e., enhancing and
non-enhancing tumor) is calculated on each of the brain lobes in this healthy atlas.
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Figure 2.2: Illustrative examples of spatial distribution (left) and texture (right) patterns.
2.2.3 Data Analysis. Initially, we combined the two types of data (imaging - genetics) using
the patient ID as a primary column. As a first stage, we used the gene expression and the spatial
distribution patterns to perform a non-parametric test of association. To assess the associations,
we computed the Spearman correlation coefficient (rs) between the gene expression, individually,
with each of the spatial distribution patterns described in Section 3.2. We then assessed the
significance of the correlation coefficient by calculating the p-values as described below.
For each quantitative feature and each gene, we obtained the p-value associated with Spearman
correlation coefficient test statistic, which is the p-value of the correlation between a single gene
expression with a single feature of the tumor’s location in the brain. The Spearman correlation









Where di is the difference between the ranks of xi and yi, and N is 88; representing the number
of GBM patients (Kendall et al., 1948). rs can take any real value between +1 and −1; +1
represents a strong positive association, −1 means a perfect negative association and 0 indicates
no association between the ranks of x and y. Our hypothesis of interest is:
H0 : There is no association between the gene expression and the tumor’s feature under study
vs
Ha: There is an association between the gene expression and the tumor’s feature under study,
alternatively:
H0: rs = 0 vs H0: rs 6= 0
Section 2.2. Materials and Methods Page 25
Figure 2.3: Schematic representation of the study’s analysis workflow. Step (a) was done using
spatial features, while step (e) was done using radiomic features.






tc follows approximately the Student’s t distribution with a N − 2 degrees of freedom under the
null hypothesis (Kendall et al., 1948). At a certain significance level, the calculated value of
tc can be compared to the table value obtained from the Student’s t distribution (as described
previously). The significance of rs can also be determined using the p-value, which is simply the
integration, or the area under the curve from tc to infinity.
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Briefly, in this first stage, the association test was initially conducted to six features of the
tumor location (Section 3.2.2). More specifically, for each gene, we computed six p-values, then
considered only the minimum p-value at each gene (see Figure 2.3 for the analysis workflow).
The latter is referred to as meta-analysis in Figure 2.3 (step(c)). All results reported in Section
2.3 use the summary statistics of the meta-analysis. Moreover, out of all the association results,
we excluded all the genes with p-values greater than or equal 0.05. Here we meant to exclude
the genes that have very low (and not significant) association with the spatial pattern, which we
believe is an important phenotype. This step is referred to as (d) in Figure 2.3. In the second
stage, we proceeded with all the genes with p-value less than 0.05, excluding the least significant
genes, and we carried the same analysis as in the first stage but using the radiomic features
(Section 3.2.2. Table 2.1 shows the thresholds (at both 5% and 10% significance level), along
with the number of genes used and remaining in each stage.
Table 2.1: Number of genes, 5% and 10% thresholds used at each stage of the analysis.
Feature
No. genes used Phenotypes 5% threshold 10% threshold genes after trim
Location 15009 11 0.000000303 (3.03e−7) 0.000000606 (6.06e−7) 5401
Texture 5401 517 0.000000018 (1.8e−8) 0.000000036 (3.6e−8) 5370
It is worth mentioning that, out of the total number of genes, we were able to annotate 15009
genes and assign them to their defined physical locations in the DNA. We continued with the
first stage of the analysis using those genes (Table 2.1).
2.3 Results
The incidence of tumors specific for region is summarized in Table 2.2. The Manhattan plot
for the p-values obtained from the meta-analysis is illustrated in Figure 2.4. The plot shows two
horizontal lines which associate with the thresholds of 5% significance level ( α=0.05
no. genes×phenptypes ;top
line), and 10% significance level ( α=0.10
no.genes×phenptypes ; bottom line), after correcting for multiple
comparisons. The x-axis is the physical position of genes in the DNA, and the y-axis is the
negative log10 of the p-values. Figure 2.4 also shows the qq-plot of all the genes used in the
association analysis. Likewise, each dot corresponds to a p-value of a single gene and −log10 of
the p-value is used instead. The qq-plot is reported with each Manhattan plot, and it compares
the observed distribution of p-values (y-axis) to the expected distribution (x-axis), for each gene
tested, where the diagonal line is the null distribution.
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Table 2.2: Number and percentage of patients with tumor per brain region
Location
Full name Number %
Vent TC Tumor core (from the ventricles) 88 100.00
Vent ED Peritumoral edema (from the ventricles) 88 100.00
Frontal Frontal lobe 63 71.59
Temporal Temporal lobe 70 79.55
Parietal Parietal lobe 62 70.45
Basal Basal ganglia 55 62.50
Insula Insula 43 48.86
Fornix Fornix 26 29.55
Occipital Occipital lobe 35 39.77
Cerebellum Cerebellum 8 9.09
Brainstem Brain stem 24 27.27
Figure 2.4: A Manhattan (left) and qq-plot (right) of the associations between the tumor spatial
distribution patterns, and gene expression. The plot is showing the meta-analysis results.
Table 2.3 shows (only) the top ten p-values and the corresponding genes of the first stage of the
analysis. In this stage, none of the p-values was less than 3.03e−7 or 6.06e−7 (see table 2.1);
therefore, no gene was significantly associated with any of the features. Table 2.3 reports the
gene symbol, its start and end position, the associated p-value and feature, and the chromosome.
We then pruned the genes used in the previous stage to a smaller set, by removing the genes that
have p-values less than 0.05. With the 5401 genes remaining, we took over the second stage
and repeated the same analysis with the texture characteristics of the tumor. The Manhattan
and qq-plot for the texture features are shown in Figure 2.5, and Table 2.4 shows the top 10
significant genes. There were no significant hits in this stage as well.
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Table 2.3: Top 10 genes: non-parametric association between genes and brain tumor location
features in glioblastoma ordered according to the absolute value of rs.
Gene Results are sorted according to p-value.
start end rs p-value Spatial Pattern Chr
TCN1 59620272 59634048 0.454 8.814e-06 DIST Vent TC chr11
OR2AE1 99473609 99474680 -0.438 2.010e-05 SPATIAL Basal G chr7
KIF13A 17759413 17987854 -0.435 2.271e-05 SPATIAL Basal G chr6
NCBP2 196662272 196669468 0.432 2.619e-05 SPATIAL Occipital chr3
RLN2 5299867 5304969 0.426 3.527e-05 SPATIAL Basal G chr9
KCNK9 140613080 140715299 0.426 3.533e-05 SPATIAL Parietal chr8
B3GALT6 1167628 1170421 -0.423 3.938e-05 SPATIAL Brain stem chr1
FOXD3 63788729 63790797 0.414 6.0483e-05 SPATIAL Parietal chr1
KISS1R 917286 921015 0.414 6.078e-05 SPATIAL Brain stem chr19
PLEKHA8 30067019 30170096 -0.413 6.362-05 SPATIAL Insula chr7
Figure 2.5: A Manhattan (left) and qq-plot (right) of the associations between the tumor texture
features, and gene expression. The plot is showing the meta-analysis results.
2.4 Discussion
GBM is a fatal malignant disease that so far is incurable. The identification of genetic risk factors
that affect the tumor characteristics improves our understanding of the underlying biological
processes for GBM, and may contribute to therapeutic discovery. In this study, we proposed a
framework that allows quantifying the non-parametric correlations to test associations between
gene expression and different quantitative imaging phenomic characteristics of GBM. Our result
has shown a high genetic enrichment through the Manhattan and qq-plots, especially for the
texture features (Figure 2.5).
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Table 2.4: Top 10 genes: The association of gene expression with texture features of specific
GBM sub-regions from specific modalities ordered according to the absolute value of rs.
Gene Results are sorted according to p-value
Start End rs p-value Feature Region (MRI) Chr
LRRC46 45908992 45915079 0.537 7.102e-08 GLCM Variance ED (T2) chr17
USP38 144106069 144144983 -0.511 3.648e-07 GLSZM SZLGE ED (T1Gd) chr4
EPGN 75174189 75181024 0.501 6.542e-07 GLSZM LGZE ED (T1Gd ) chr4
TUBA1C 49582518 49667114 0.4999 7.096e-07 GLRLM RLV NET (T1) chr12
ZNF284 44576296 44593766 -0.498 7.907e-07 GLRLM LGRE NET (T1Gd) chr19
IPO8 30781921 30848920 -0.490 1.243e-06 GLRLM GLV ET (T2) chr12
MMP7 102391238 102401484 0.490 1.260e-06 GLCM Auto Corr. ET (T1Gd) chr11
TLL2 98124362 98273675 0.489 1.342e-06 GLSZM LGZE NET (T1Gd) chr10
TRIM55 67039130 67087720 0.488 1.408e-06 GLSZM LGZE ED (T1Gd) chr8
UBAP1 34179002 34252521 -0.486 1.582e-06 GLSZM SZLGE ET (T2) chr9
Though our results did not highlight genes that significantly associated with the tumor texture
features, top hits include LRRC46, USP38, EPGN, TUBA1C, ZNF284, IPO8, MMP7, TLL2,
TRIM55 and UBAP1 (Table 2.4). EPGN expression (rs = 0.501, p-value= 6.542e − 07) asso-
ciates with GLSZM LGZE in the T1Gd modality (Table 2.4). EPGN was previously reported to
be one of the top ten upregulated genes after EBLN1 silencing in oligodendroglia cells (He et al.,
2016). Moreover, the emergence of EPGN was identified in another study by Duhem-Tonnelle
et al. (2010) in an EGF ligand expression profile, between glioblastoma cell lines and biopsies.
Located at chromosome 4, USP38 (rs = −0.511, p-value= 3.648e − 07) was associated with
GLSZM SZLGE, the modulated USP38 is known for its involvement in cell growth and stress in
the proteasome system (Carminati et al., 2010).
Moreover, as it is illustrated in the Manhattan plot of the spatial features of the tumor (Figure
2.4 and Table 2.3), no gene shows significant association with any of the location features. In
addition to the latter, the number of GBM lesions in the cerebellum in clinical settings are quite
rare (Drabycz et al., 2010), as also shown in our summary Table 2.2. Our study can provide some
insight into this rare type of GBM lesion. Nevertheless, the investigation excluding the patients
having those lesions should be repeated in future work.
As the understanding of gliomagenesis grows, several medical imaging biomarkers and genetic
variations can be identified, and new hypotheses can be formed. Our proposed genome-wide
association framework aims at identifying differentially expressed genes that significantly correlate
with various aspects of GBM. The identification of such genes may contribute to the development
of targeted therapies that focus on the resistance mechanisms of individual patients.
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Through the systematic testing of associations and shrinking of the number of genes at every
stage, this pipeline facilitates the evaluation of various hypotheses and reduces the computational
complexity. In future work, we plan to extend the study by integrating more quantitative imaging
phenomic tumor characteristics, inclusive of morphological, intensity, and volumetric descriptors,
as well as parameters derived by biophysical tumor growth modeling.
Chapter 3
Genome-Wide Association Study of
Brain Connectivity Changes for
Alzheimer’s Disease
Abstract
Variations in the human genome have been found to be an essential factor that affects suscep-
tibility to Alzheimer’s disease. Genome-wide association studies (GWAS) have identified genetic
loci that significantly contribute to the risk of Alzheimers. The availability of genetic data, cou-
pled with brain imaging technologies have opened the door for further discoveries, by using data
integration methodologies and new study designs. Although methods have been proposed for in-
tegrating image characteristics and genetic information for studying Alzheimers, the measurement
of disease is often taken at a single time point, therefore, not allowing the disease progression
to be taken into consideration. In longitudinal settings, we analyzed neuroimaging and single
nucleotide polymorphism datasets obtained from the Alzheimer’s Disease Neuroimaging Initiative
for three clinical stages of the disease, including healthy control, early mild cognitive impairment
and Alzheimer’s disease subjects. We conducted a GWAS regressing the absolute change of
global connectivity metrics on the genetic variants, and used the GWAS summary statistics to
compute the gene and pathway scores. We observed significant associations between the change
in structural brain connectivity defined by tractography and genes, which have previously been re-
ported to biologically manipulate the risk and progression of certain neurodegenerative disorders,
including Alzheimer’s disease.
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3.1 Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease with believed onset in the hippocampus.
It subsequently spreads to the temporal, parietal, and prefrontal cortex (Raj et al., 2015). Symp-
toms of the disease worsen over time, and as the patient’s condition declines, AD ultimately leads
to death. Causes of the disease are yet unclear, and it has even been hypothesised to be related
to external bacteria (Dominy et al., 2019). However, 70% of AD risk is believed to be contributed
by complex genetic risk factors (Ballard et al., 2011). The protein encoded by the apolipoprotein
E (ApoE ) gene, located on chromosome 19, carries cholesterol in the brain, affecting diverse
cellular processes. Carriers of the ApoE allele ε4 have three times the risk of developing AD
compared to non-carriers (Corder et al., 1993). Although ApoE ε4 is the primary genetic risk
factor that contributes to the development of late-onset AD; its effect accounts for only 27.3%
of the overall disease heritability, which is estimated to be 80% (Lambert et al., 2013).
In order to estimate the remaining heritability of AD, many attempts have been made to uncover
additional genetic risk factors. Genome-wide studies have successfully identified single nucleotide
polymorphisms (SNPs) which affect the development of AD (Bertram and other, 2010; Li et al.,
2008; Naj et al., 2010). Understanding the underlying biological process of the disease, and
identifying more potential genetic risk variants, could contribute to the development of disease-
modifying therapies.
On the other hand, the recent advancements in imaging technologies have provided more op-
portunities for understanding the complexity of how the brain connects, and at the same time,
enhancing and forming a more reliable basis for neuroimaging and human brain research (Mier
and Mier, 2015). By merging brain imaging with genetics, previous studies proposed different
ways of analyzing the data, to discover genetic factors that affect the structure and function of
the human brain. Significant efforts in this area have been made by the Enhancing Neuroimaging
Genetics through Meta-Analysis (ENIGMA) (Thompson et al., 2016) project. The methods of-
fered several diverse ways to link together two heterogeneous collections of data - brain imaging
and genetic information - depending on the hypothesis under study, and hence, the type of images
and genetic information.
Stein et al. (2010) used the T1 weighted Magnetic Resonance Imaging (MRI) scans from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI), while (Jack Jr et al., 2008) and developed a
voxel-based GWAS method (vGWAS) that tests the association of each location in the brain (each
voxel), with each SNP. To quantify the phenotype, they used the relative volume difference to a
mean template at each voxel, and their method, vGWAS, can be applied to other brain maps with
coordinate systems. Although vGWAS did not identify SNPs using a false discovery rate of 0.05,
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they highlighted some genes for further investigation. More recently, other studies on the genetics
of brain structure implemented a genome-wide association of the volume in some sub-cortical
regions, and successfully identified significant genetic variants (Stein et al., 2012; Hibar et al.,
2015). Additional efforts in the literature include the development of multivariate methods that
aim at identifying the imaging-genetics associations through applying sparse canonical correlations
to adjust for similarity patterns between and within different clinical stages of the disease (Fang
et al., 2016).
Connectomics (Hagmann et al., 2008), or the study of the brain connectome, is a novel advance-
ment in the field of neuroimaging. A structural or functional brain connectome is a representation
of the brain, and its connections, as one network. The connectome comprises nodes representing
different and distinct regions in the brain, and edges representing the functional or structural con-
nection between brain regions. More specifically, the edges of a structural connectivity network
are defined by the anatomical tracts connecting the brain regions (Rubinov and Sporns, 2010).
Those are extracted from diffusion weighted imaging (DWI), a type of imaging which detects the
diffusion of the water molecules in the brain. Furthermore, the connectome can be summarised
by several global and local network metrics (Rubinov and Sporns, 2010) which allow the study
of the brain as one entity (one scalar value), the comparison of different groups of participants,
as well as the study of variation between and within different brain regions. DWI is not the
only method to represent structural connectivity. Structural connectivity can be defined by using
T1 scans and voxel-based morphometry (VBM) (Good et al., 2001), a technique investigating
structural tissue concentration, especially in gray matter (GM). It has been demonstrated that
the morphology across the brain is governed by covariation of gray matter density among different
regions (Forsberg et al., 2019). In this way a structural connectome is constructed defining the
edges among brain regions as the correlation of GM morphology. This can complement the DWI
approach which is mostly based on white matter. Of particular interest are covariability hubs,
nodes of this network which have high degree centrality since they are the most representative of
the overall cortex (Forsberg et al., 2019; Tijms et al., 2012).
In an attempt to understand aging of the healthy brain, Wu et al. (2013) carried out a longitudinal
study of the structural connectome in healthy participants aged 51.1 ± 11.7. Their analysis
evaluated the association of the annual change in both the local and global network characteristics
with age, but no genetic investigation was carried out in relation to those longitudinal features.
However, they found some positive associations between age and connectivity measures at brain
regions corresponding to attention, mode and memory. In another study JahanshAD et al.
(2013) conducted a GWAS on dementia subjects using connectivity patterns as a phenotype,
and identified the genetic variant rs2618516 located in the SPON1 gene; however, this study
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considered cross sectional phenotype, collected at one specific time point. VBM-based GWAS
have also been carried out combining MCI, AD and control subjects at one specific time point
(Shen et al., 2010), identifying the ApoE gene and other SNPs related to ephrin receptor as
markers strongly associated with multiple brain regions.
In this paper, we used a dataset from ADNI (http://adni.loni.usc.edu/) to perform four quanti-
tative GWAS, with the longitudinal change in the brain connectome used as a phenotype. Our
choice of using the ADNI dataset was because the particular combination of data types needed
to run this analysis was available, in the context of AD. We used the absolute difference in the
longitudinal integration and segregation global network metrics to represent the change in struc-
tural brain connectivity defined by tractography. After obtaining the GWAS summary statistics
for all the SNPs typed in the original data, we aggregated their p-values using the PAthway SCor-
ing ALgorithm (PASCAL) software (Lamparter et al., 2016) and computed genome-wide gene
and pathway-scores. Our result identified a number of genes significantly associated with the
change in structural brain connectivity, including ANTXR2, OR5L1, IGF1, ZDHHC12, ENDOG
and JAK1. Most of those genes were previously reported to biologically manipulate the risk and
progression of certain neurodegenerative disorders, including Alzheimer’s disease (De Ferrari et al.,
2007; Kang et al., 2010; Young et al., 2012; Nicolas et al., 2013). Additionally, we investigated
whether there are additional changes in connectivity defined by GM covariability.
3.2 Methods
3.2.1 Datasets. Our analysis was conducted on the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) dataset publicly available at (adni.loni.usc.edu). The initiative was launched in 2003 as
a public-private partnership, led by Principal Investigator Michael W. Weiner, MD (see www.
adni-info.org for updates). To address the aim of our study, we combined two types of ADNI
datasets:
1) DWI volumes were taken at two-time points, at the baseline and after 12 months (we refer
to this as follow-up). In this set, we used a cohort comprised of 31 Alzheimer’s disease
patients (age: 76.5 ± 7.4 years), and 49 healthy elderly subjects (77.0±5.1) matched by
age, as well as 57 MCI subjects (age: 75.34 ± 5.93).
2) The PLINK binary files (BED/BIM/FAM) genotypic data for AD, controls and Early MCI.
The DWI and T1-weighted were obtained by using a GE Signa scanner 3T (General Electric,
Milwaukee, WI, USA). The T1-weighted scans were acquired with voxel size = 1.2 × 1.0 × 1.0
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mm3 TR = 6.984 ms; TE = 2.848 ms; flip angle=11◦). DWI were acquired at voxel size =
1.4 × 1.4 × 2.7 mm3, scan time = 9 min, and 46 volumes (5 T2-weighted images with no
diffusion sensitization b0 and 41 diffusion-weighted images b=1000 s/mm2).
3.2.2 Preprocessing of Diffusion Imaging Data. Imaging data have T1 and DWI co-registered.
To obtain the connectome; the AAL atlas (Tzourio-Mazoyer et al., 2002) is registered to the T1
volume of reference by using linear registration with 12 degrees of freedom. Despite the fact that
the AAL atlas has been criticized for functional connectivity studies (Gordon et al., 2014), it has
been useful in providing insights in neuroscience and physiology and it is believed to be sufficient
for our case study centered on global metrics. Tractographies for all subjects were generated
processing DWI data with the Python library Dipy (Garyfallidis et al., 2014). In particular, the
constant solid angle model was used (Aganj et al., 2010), and a deterministic algorithm called
Euler Delta Crossings (Garyfallidis et al., 2014) was used stemming from 2,000,000 seed-points
and stopping when the fractional anisotropy was smaller than < 0.2. Tracts shorter than 30 mm,
or in which a sharp angle (larger than 75◦) occurred, were discarded. To construct the connec-
tome, the graph nodes were determined using the 90 regions in the AAL atlas. Specifically, the
structural connectome was built as a binary representation when more than 3 connections were
given between two regions, for any pair of regions.
3.2.3 Preprocessing for the Gray Matter Analysis. The data for gray matter (GM) analysis
were obtained from the T1 volumes of the same subjects. The data have been preprocessed
following the optimized VBM protocol from FSL (Douaud et al., 2007). Briefly, volumes have
the skull stripped, bias field corrected, then are iteratively registered to a generated template in
the MNI space, and have the GM segmented. During the last iteration, data are non-linearly
registered to the generated template. The FSL-VBM protocol also introduces a compensation
for the contraction/enlargement due to the non-linear component of the transformation: each
voxel of each registered grey matter image is multiplied by the Jacobian of the warp field.
3.2.4 Brain Connectivity Metrics. To assess longitudinal changes, we evaluated the following
global network metrics at the two time points, at the baseline and follow-up. We then computed
the absolute difference between the two measures, at each of the network metrics.
To be in line with previous work on AD and connectomics (PrasAD et al., 2013; Brown et al.,
2011; JahanshAD et al., 2013), we focused on specific network segregation and integration
features. Segregation represents the ability of a network to form communities/clusters which are
well-organized (Deco et al., 2015), while, integration represents the network’s ability to propagate
information efficiently (Deco et al., 2015).
1) Louvain modularity is a community (cluster) detection method, which iteratively transforms
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the network into a set of communities; each consisting of a group of nodes. Louvain
modularity uses a two-step modularity optimization (Rubinov and Sporns, 2010). First, the
method optimizes the modularity locally and forms communities of nodes, and secondly,
it constructs a new network. The nodes of the new network are the communities formed
in the previous step. These two steps are repeated iteratively until maximum modularity
is obtained, and a hierarchy of communities is formed. For weighted graphs, Louvain












where Aij is the weight of the edge connecting nodes i and j from the adjacency matrix
A, ki and kj are the sums of weights of the edges connected to node i and j. respectively,
m = 1/(2Aij), ci and cj are the communities of nodes i and j, and δ is a simple delta
function.
2) Transitivity also quantifies the segregation of a network, and is computed at a global
network level as the total of all the clustering coefficients around each node in the network.
It reflects the overall prevalence of clustered connectivity in a network (Rubinov and Sporns,






i∈N ki(ki − 1)
, (3.2.2)
where tWi is the weighted geometric mean of triangles around node i, and ki its degree.
3) Weighted Global Efficiency is a network integration feature, and represents how effectively
the information is exchanged over a network. This feature can be calculated as the inverse










dWij , is the weighted shortest path length between node i and j, and n is the number of
nodes.
4) Characteristic Path Length measures the integrity of the network and how fast and easily
the information can flow within the network. The characteristic path length of the network
is the average of all the distances between every pair in the network (see Equation 4.2.2).







where, dij be the number of links (connections) which represent the shortest path between
node i and j.
An illustrative example of global network connectivity metrics is shown in Figure 3.1, the figure
consists of a segregated (left) and integration (right) network.
Figure 3.1: An illustrative figure of brain segregation (left) and brain integration (right). In these
two figures we have the same nodes and network structure. The brain segregation represents the
ability to form sub-networks as the communities on the left figures, while the integration of the
brain measures the act of bringing together the different part of the brain as one connected entity,
as the thick lines on the right figure.
3.2.5 Gray matter analysis. Connectivity from the GM point of view is defined by the anatomical
areas which covary in thickness or volume across the overall brain. Ultimately, the analysis
uses another network property given by a hub index described later. Before proceeding with
this analysis, a more traditional VBM pipeline was run (Winkler et al., 2014): The method,
called ”randomise”, performs a permutation test for the general linear model. It allows one to
compare voxelwise two populations. T-statistics and corrected p-values are then computed. The
comparison was carried out within the same populations (AD and control) at the two different
time-points, and comparing AD against control subjects.
GM connectivity analysis follows these steps: the GM segmented and registered volumes are
further subdivided into cubes of 3× 3× 3 voxels which now represent nodes of a network. In this
way, each network has on average 6614 nodes. Edges are defined by using the Pearson correlation
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rjm computed between two nodes/subvolumes vj and vm each time (Tijms et al., 2012):
rjm =
∑n





where v̄j, v̄m are the cubes’ mean values, and auto-correlations are set to zero. In the attempt to
reduce false positives and with the aim of considering only hubs, once the connectivity matrices
are constructed, these are binarized according to a threshold. We set this threshold as 2 standard
deviations above the mean, though other more sophisticated threshold choices exist (Tijms et al.,
2012; Forsberg et al., 2019). Then, for each node, the degree of connectivity is computed by
summing the binarized connections. In this way only the highly connected nodes (hubs) are
defined. Lastly, values are averaged first according to the Regions of Interests (ROIs; defined as
the structural segmentation of the brain for measuring connectivities) of the AAL atlas, and then
for the populations at different time points. Like for the traditional VBM analysis, given the GM
hubs defined at two time points we were interested in seeing whether connectivity changes occur
within the interval of observations, and whether those are related to the other types of structural
connectivity and gene expression.
3.2.6 Integration of the two datasets. To quantify the longitudinal change in brain connec-
tivity, we calculated the absolute difference between the baseline and follow-up for each brain
connectivity metric. We then merged the absolute differences with the PLINK fam file, matching
the two datasets by the subject ID.
3.2.7 Quality Control.
Quality Control: Individuals
After merging the two datasets into PLINK files, we performed some quality control procedures.
First, we applied quality control at individual-level and removed all poor samples, which were
identified using PLINK software and the following criteria:
1) Sex-check - here we identified all samples with ambiguous sex and removed them. We used
the flag –check-sex .
2) Identifying all the individuals with missing genotype data with the flag –missing. This is
to check the missingness rate of genotype information for each individual. In our data,
the percentage of missingness for all individuals fell within the range (0.002834, 0.00544),
since all subjects passed the threshold of 10% missingness.
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3) We then identified Related Subjects (with Identity By Descent (IBD) > 20%), all subjects
had IBD between 0.00 and 0.0526. We used a number of PLINK flags, including; –indep-
pairwise 50 5 0.2, –extract, –genome, –min and –genome-full
After applying those quality control steps, we had a total of 57 subjects (8 AD, 20 control and
29 MCI) remaining for the rest of the analysis. However, we used a quantitative trait to run the
GWAS, that is the change of global connectivity metrics over time.
Quality Control: Genotypes
We ran quality control on the genotypes, by filtering them in terms of their minor allele frequency
(MAF) with a threshold of 0.01. All SNPs with less than this threshold are considered rare SNPs
and were removed from the analysis. We also removed all SNPs that had missingness more than
33.33 or Genotype Call Rate < 66.67% - this was done in such a way that keeps only SNPs
with sample size no less than 38. In addition, SNPs which deviate from the Hardy-Weinberg
Equilibrium (HWE) were removed, these are SNPs that have p-values of less than 5e-7 in the
HWE test (Wigginton et al., 2005) (in total 351 SNPs did not satisfy the HWE). We used the
flags, –maf, –geno and –hwe, and in total 7111195 SNPs remained. Refer to Saykin et al. (2010)
for more information about how the genotype data was generated.
Quality Control Correcting for Population Stratification
In this quality control step, we checked for the multiple presence of subpopulations in our sample.
This is to make sure if we find significant variants, that the differences in allele frequencies is due
to the trait under study and controls for the different ethnic groups. Accounting for population
stratification helps to avoid false positives (Hamer and Sirota, 2000). Using multiple ancestry
reference genotypic information, we compared the genotypes of each study sample and estimated
its ancestry with the Multi-Dimensional Scaling (MDS) analysis (Egs, 2013). We observed that
most of our samples belong to the Caucasian population (CEU) and therefore, proceeded by only
selecting the Caucasian samples in our study. In Figure 3.2, we show the genotypes of our samples
compared with the reference data after the population stratification correction. We included all
57 samples as all belong to the CEU (Caucasian) ancestry.
All previous quality control procedures used here followed the ENIGMA protocol (Egs, 2013).
The genetic reference population used here contains 13,479,643 variants that were observed
more than once in the European population. These reference data were obtained by ENIGMA
from the 1KGP reference set (phase 1 release v3), and imputed.
Section 3.2. Methods Page 40
Figure 3.2: Quality control procedures: The plot shows the estimated ancestry of the genotypes
of each study sample (in red) after applying the Multi-Dimensional Scaling (MDS). It also com-
pares the genotype of the samples with a multiple ancestry reference. We observed that most
of our participants belong to the Caucasian population, denoted here as CEU. A description of
the reference population is found in the Quality Control Correcting for Population Stratification
sub-section.
Quantile Normalisation of Phenotypes
Figure 3.3 and Figure 3.4 indicate that our phenotypes are not symmetrically distributed, and
there are potential outliers. Linear models assume symmetric distribution of the response variable.
Therefore, to allow the use of linear models and conduct quantitative GWAS for our traits, we
first had to normalize our phenotypes. Here, we used PLINK2 (Chang et al., 2015) (www.
cog-genomics.org/plink/2.0/) to perform a quantile normalization (BolstAD et al., 2003) on our
phenotypes, using the flag –quantile-normalized.
3.2.8 Integrated Data Analysis.
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Figure 3.3: Distribution of global network metrics for controls, MCI and AD subjects, combined.
Shortcuts stand for; Louvain: Louvain modularity, global eff: global effeciency, and char path len:
characteristic path length
Genome-Wide Association Analysis
We performed four quantitative GWAS separately using PLINK software (Purcell et al., 2007)
(http://pngu.mgh.harvard.edu/purcell/plink/). A GWAS for each network connectivity metric
measured as the absolute difference between the baseline and follow-up was performed with 57
individuals, and a total of 7111195 SNPs.
Statistical Thresholds
To correct for multiple testing in this analysis, and unless otherwise stated, we rely on the
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Figure 3.4: Global network metrics scatter plots: The sub-figures show the distribution of the
absolute difference of the four network metrics (diagonal plots); as well as the pairwise correlation
between them (remaining plots). Each plot compares AD, MCI and controls.
where M is the number of tests of interest (e.g. SNPs, genes or pathways, more information in
the results section), and α is the desired significance level. The p-values are then compared with
the threshold α∗.
Imputation of GWAS Results
More quality control was done before the imputation of GWAS summary statistics using the
Functionally-informed Z-score Imputation (FIZI) Python tool (https://pypi.org/project/pyfizi/,
https://github.com/bogdanlab/fizi). Using the munge function, 4763 SNPs with duplicated rs
numbers and 85757 SNPs with N < 38.0 were removed with a remaining number of 6792416
SNPs. We then imputed the summary statistics with ImpG-Summary - Imputation from summary
statistics algorithm (Pasaniuc et al., 2014). In this step, we relied on the European 1000 Genomes
(Consortium et al., 2012) haplotypes as a reference panel and performed the Gaussian imputation
with FIZI. We managed to impute an additional 2222623 SNPs, all with a maf of < 0.01.
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Gene-Wide Scores and Pathway Analysis
After we obtained the GWAS association results, we used them as input for the PASCAL software
(Lamparter et al., 2016) to aggregate SNPs at a gene level, and hence, compute gene scores
for the four network measures. Along with the obtained association statistics PASCAL uses a
reference population from the 1000 Genomes Project to correct for linkage disequilibrium (LD)
between SNPs. We set PASCAL to compute the gene score as well as the pathway scores,
according to the max of chi-square statistics. We got a p-value for each gene, and for each gene
set (or, pathway) provided that there were SNPs present for that gene. Finally, we used Python
to plot the Manhattan plot, and R studio (RStudio Team, 2015) to plot the qq-plots. All steps
are summarized in the pipeline shown in Figure 3.5.
3.3 Results
3.3.1 Analysis Pipelines. In this work, we used a longitudinal imaging dataset, combined
with genetic variation information at the SNP-level. The sample consists of three groups which
represent three distinct clinical stages of Alzheimer’s disease. This includes healthy individuals
(controls), Early mild cognitive impairment (MCI), and Alzheimer’s disease. Aiming at studying
the genetic effect on the longitudinal change in the brain structure for those groups, we con-
ducted genome-wide tests of the associations between brain image features and different levels
of genetic variations. These image features were derived from an intensive map of the brain’s
neural connections. The overall pipeline followed is summarized in Figure 3.5.
3.3.2 Descriptive Statistics of Brain Imaging Features. Using the DWI images at both
baseline and a follow-up visit after 12 months, the brain connectome was constructed. We
obtained four global network metrics, as explained in the Methods section. We chose network
transitivity and Louvain modularity to represent network segregation, along with characteristic
path length and weighted global efficiency to represent the brain integration (Rubinov and Sporns,
2010).
Each of these four metrics quantitatively represents the whole brain network as a single value.
Figure 3.6 illustrates both the distribution of the network metrics in the data, in the baseline and
follow-up, for the three participant categories. The figure also shows the association patterns of
the metrics. A similar figure that illustrates the distribution of the absolute difference between
the baseline and follow-up metrics is shown in Figure 3.4, it compares the three groups in each
sub-figure. To determine how the differences between these connectivity metrics are distributed,
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Figure 3.5: The analysis pipeline: (a) The DWI images were collected at two time points, for
three clinical stages of AD. (b) The images were processed using distinct brain regions from the
Automated Anatomical Labeling (AAL) atlas, and two structural connectomes were constructed
for each participant at each time point. (c) Global connectivity metrics were computed, along
with the absolute difference between the baseline and follow-up measures. (d) The latter were
merged (as phenotypes) with the PLINK FAM files for all subjects present in both datasets. (e) All
essential quality control procedures were performed before GWAS analysis, besides the quantile
normalization of phenotypes. (f) GWAS was conducted using PLINK, and, (g) the resulting
summary statistics were used by PASCAL software to calculate the gene- and pathway-scores
accounting for LD patterns using a reference dataset.
we plotted four boxplots, as shown in Figure 3.3, for the three groups combined.
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Figure 3.6: Global network metrics scatter plots: The sub-plots compare the four global network
metrics before and after 12 months (baseline vs follow-up). Diagonal plots show the distribution
of the actual metrics in the baseline and follow-up, while the remaining plots show the correlation
between the metrics, for all participants. The numbers next to each sub-figure correspond to the
Pearson correlation coefficient.
To verify that the longitudinal change is consistent and not the result of artifacts, we initially
compared the imaging features between the two-time points. Table 3.1 shows the results of the
non-parametric Wilcoxon test between baseline and follow-up features. The test ranks the values
of the paired measurements and compares their central values. In this test, we used the AD
patients and controls, most of the metrics turned out to have significant longitudinal differences
in the AD brain, but not in a healthy brain. Figure 3.7 compares the four metrics at the two time
points, for each group individually, utilizing their boxplots.
We further investigated structural connectivity given by VBM, namely whether there is a structural
covariability change in the gray matter. Before doing this, a traditional VBM analysis was carried
out. In particular, we compared the AD against the control population at the two time points, and
the two populations individually compared to themselves at the two time points. The differences
between the groups were given by a t-test converted into corrected p-values (Winkler et al., 2014).
Between the same populations at different time points no significant voxels were found, but
comparing the two different populations, most of the brain regions were statistically significantly
different. Figure 3.8 show the t-statistics map of these differences. In line with previous work
(Wang et al., 2018), we identified the peak of statistical difference between AD and control
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Table 3.1: Non-parametric Wilcoxon test of the difference between brain connectivity features
at baseline and follow-up
Group P-values with ∗ are significant (< 0.05)
Network Metric Statistic P-value
AD Characteristic path length 107.0 0.0057∗
global efficiency 98.0 0.0033∗
Transitivity 226.0 0.6664
Louvain 114.0 0.0086∗
MCI Characteristic path length 612.5 0.0891
global efficiency 672.0 0.2196
Transitivity 760.0 0.5972
Louvain 712.0 0.3630
Control Characteristic path length 496.0 0.2465
global efficiency 55.0 0.1172
Transitivity 517.0 0.3421
Louvain 529.0 0.4062
Figure 3.7: Boxplots for global network metrics to compare AD and controls in the baseline
(green) and follow-up (yellow). The metrics are, Louvain modularity (a), transitivity (b), global
efficiency (c) and characteristic path length (d). It is evident that at least the means for the AD
population are different while for the others they are generally unvaried. The asterisk denotes
that there is a significant change from baseline to the follow-up visit (p-value< 0.05).
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subjects in the hippocampus/parahippocampus, followed by the cingulate cortex and the temporal
lobe at both time points. The hubs detection was conducted on the same segmented GM data
used in the VBM analysis, and again no significant differences were noted within the same
population comparing different time points. The average hubs index is reported in Figure 3.9,
and Figure 3.10 depicts the values averaged according to the ROIs of the AAL atlas, specifically
showing the hubs index for the AD population at baseline and followup (similar results were
obtained for the control population).
Here, the highest values, in line with similar results of previous studies on healthy volunteers,
were in the fronto-lateral cortex, cingolum, (Tijms et al., 2012) and basal ganglia (Forsberg
et al., 2019). Given the fact that no statistical difference was found for longitudinal changes,
both using the traditional VBM analysis and the cortical hubs, no feature of this kind was available
for the integrated analysis, which was therefore focused on the structural connectivity given by
the tractography.
Figure 3.8: T-statistics map of the comparison between the VBM features of AD and control
subjects. On the left (a) is the comparison at baseline, and (b) on the right for the followup. All
views are for both hemispheres, lateral and medial view. Highest values, depicted in red, were at
the hippocampus/parahippocampus, cingulate cortex and temporal lobe for both time points.
3.3.3 Integrated Analysis. After we obtained our phenotypes of interest, given by the longitu-
dinal changes of the features between the two time points, we prepared our data for genome-wide
association analysis (see Figure 3.5) by first integrating the phenotypes and genotypes.
The necessary quality control procedures that precede GWAS analysis were run as explained
in the Methods section. Briefly, they include cleaning the data such as removing all SNPs
with small sample sizes, and individuals with relatedness, as well as population stratification
correction. Figure 3.2 shows the plots after correcting for the population stratification. We
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Figure 3.9: Average normalized connectivity hubs, (a) on the left there is the average value at
baseline, and (b) on the right for the followup. All views are for both hemispheres, lateral and
medial view. Highest values, depicted in red, were at the cingulate cortex, fronto-lateral cortex
and basal ganglia, gray areas depict values of 0. The individual values averaged according to the
ROIs of the AAL atlas are reported Figure 3.10.
quantile-normalised our phenotypes to allow the use of the linear model in GWAS.
Genome-Wide Association Analysis
GWAS was conducted by regressing the normalised longitudinal changes of global connectivity
metrics (response variable) on the SNPs’ minor allele frequencies (independent variable), one
SNP at a time. Using PLINK (Purcell et al., 2007) we conducted four quantitative GWAS - one
for each network metric, after which we performed a Gaussian imputation of GWAS summary
results. Figure 3.11 shows the imputed GWAS results for the change in brain segregation metrics.
The Manhattan sub-plots appear on the left, while the corresponding quantile-quantile (qq)-plots
are on the right. Figure 3.12 shows the imputed GWAS results for brain integration metrics. The
x-axis of the Manhattan plot represents the physical location along the genome, while the y-axis
is the (− log 10(p− value)), and each dot represents a single SNP. In the qq-plots, the diagonal
line represents the expected (under the null hypothesis) distribution of p-values, and similar to
the Manhattan plot, each dot in the qq-plot represents a single SNP.
The top 15 SNPs, including the significantly associated SNPs obtained after imputation of GWAS
p-values for the absolute difference in Louvain modularity, transitivity, global efficiency and char-
acteristic path length, are shown in Tables 3.2, 3.3, 3.4 and 3.5, respectively. The actual GWAS
Manhattan plot for the absolute difference in segregation and integration metrics before imputa-
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Figure 3.10: Boxplots of hubs degree centrality averaged according to the single ROI of the
AAL atlas. On the left (a) are the values for the AD subjects at baseline, and (b) on the right
are the values for the AD subjects at follow-up.
tion is provided in Figure 3.13.
Gene and Pathway Scores
Using the imputed GWAS association results (p-values), we computed genome-wide gene scores,
along with the pathway (gene set) scores, using the PASCAL software (Lamparter et al., 2016).
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Figure 3.11: Imputation results of GWAS summary statistics for the change in segregation
metrics. Top plots represent the change in Louvain modularity phenotype Manhattan plot (a and
c) and quantile-quantile (qq)-plot (b and d). Bottom plots represents the change in transitivity
phenotype. Louvain modularity imputation results show small evidence of deviation of measures
before the tail of the distribution.
Figure 3.14 and Figure 3.15 show the gene scores obtained for brain segregation and integration
phenotypes, respectively.
Using the total number of genes in the human genome (20, 000) we calculated the threshold.
Therefore, we obtain the 5% gene-wide significance threshold by dividing the significance level
by the total number of genes (or, tests), i.e.,
0.05
20, 000
= 0.0000025 = 2.5E − 6,
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Figure 3.12: Imputation results of GWAS summary statistics for the change in integration
phenotypes. Top plots represent the change in global efficiency Manhattan plot (a and c) and
qq-plot (b and d), while the plots at the bottom represent the change in characteristic path length
phenotype. Both qq-plots show very little evidence of deviation before the tail of the distribution.
If we consider less power (90%) and 10% significance level, we get a gene-wide threshold of
0.10
20, 000
= 0.000005 = 5E − 6.
For each gene score result (and for both brain segregation and integration measures) we sorted
our results and constructed a table of the top 30 genes (Table 3.6). The table also shows the
5% and 10% significant genes. The gene CDH18, contains 3974 SNPs as per the data, was
significantly associated with Louvain modularity change over time (p-value ≈ 8.09E − 8). On
chromosome 11 and chromosome 15, a number of genes were associated with the change in brain
connectivity through transitivity, while chromosome 9 shows a number of significant association
results with characteristic path length.
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Table 3.2: Louvain modularity GWAS results: Top 15 SNPs
SNP Dashed line is the 5% threshold
Chr BP MAF Eff/Alt Type(R2) Statistic β P
rs144596626 5 19473852 0.0079 G/A imputed (0.717) 6.32 (z) 2.68e-10
rs146631242 5 19396212 0.0079 G/A imputed (0.717) 6.32 (z) 2.68e-10
rs35942723 2 67943399 0.0066 T/C imputed (0.7) 5.43 (z) 5.5e-08
rs2460661 5 98903041 0.0211 C/T imputed (0.65) 5.3 (z) 1.14e-07
rs144454897 3 45220242 0.0065 G/A imputed (0.839) -5.2 (z) 2.03e-07
rs12694279 2 213253406 C/A gwas (1) -5.992 (t) -1.19 4.85e-07
rs146293495 11 87983529 0.0066 C/T imputed (0.782) -5.01 (z) 0.00923 5.54e-07
rs145955468 4 182593928 0.0066 G/A imputed (0.818) 4.88 (z) 1.07e-06
rs185097390 4 182653779 0.0065 G/A imputed (0.818) 4.88 (z) 1.07e-06
rs149021889 5 19168938 0.0079 T/G imputed (0.603) 4.82 (z) 1.42e-06
rs189745822 7 130949241 0.00791 C/A imputed (0.805) -4.8 (z) 1.56e-06
rs193071172 7 130946162 0.00791 G/A imputed (0.805) -4.8 (z) 1.56e-06
rs150749209 7 42493974 0.0106 T/C imputed (0.714) -4.66 (z) 3.12e-06
rs189358029 17 43702340 0.0092 C/T imputed (0.437) 4.62 (z) 3.87e-06
rs8053032 16 75181579 G/C gwas (1) -5.199 (t) -0.9548 4.5e-06
Table 3.3: Transitivity GWAS results: Top 15 SNPs
SNP Dashed line is the 5% threshold
Chr BP MAF Eff/Alt Type(R2) Statistic β P
rs4617614 11 55537046 0.0079 C/T imputed (0.717) 5.54 (z) 3.11e-08
rs144573130 1 65415375 0.0079 C/T imputed (0.82) 5.53 (z) 3.27e-08
rs111650215 15 78828083 0.0066 A/G imputed (0.661) -5.43 (z) 5.69e-08
rs112671439 15 78819074 0.0066 T/C imputed (0.661) -5.43 (z) 5.69e-08
rs113809575 15 78833209 0.0066 G/A imputed (0.661) -5.43 (z) 5.69e-08
rs113882269 15 78833286 0.0066 A/G imputed (0.661) -5.43 (z) 5.69e-08
rs11912587 22 38371933 0.0171 A/C imputed (0.738) 5.37 (z) 7.81e-08
rs4459504 15 71883930 G/A gwas (1) 6.192(t) 0.8938 7.83e-08
rs144750443 5 89847749 0.0066 C/T imputed (0.745) -5.2 (z) 1.96e-07
rs3923493 15 71866632 T/C gwas (1) 5.973 (t) 0.9766 2e-07
rs2518679 14 31252534 0.0065 T/C imputed (0.679) 5.18 (z) 2.21e-07
rs61156477 14 31266735 0.0145 T/C imputed (0.679) 5.18 (z) 2.21e-07
rs77762911 14 31255027 0.0145 T/G imputed (0.679) 5.18 (z) 2.21e-07
rs8018229 14 31261372 0.0145 G/A imputed (0.679) 5.18 (z) 2.21e-07
rs147801202 2 19102920 A/ATG gwas (1) -5.939 (t) -1.049 2.91e-07
In the pathway results obtained for each metric and each chromosome, the total number of
pathways used at each step was 1078. Therefore, the 5% threshold is 0.000046382 = 4.6e− 5,
while the 10% threshold is 0.000092764 = 9.28e− 5. Table 3.8 reports all the significant results
as well as the top 20 pathways along the whole genome and in all the four phenotypes. As shown
in the table, REACTOME BIOLOGICAL OXIDATIONS pathway, which consists of genes involved
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Table 3.4: Global efficiency GWAS results: Top 15 SNPs
SNP Dashed line is the 5% threshold
Chr BP MAF Eff/Alt Type(R2) Statistic β P
rs112039371 4 126730783 0.0119 T/C imputed (0.775) -6.53 (z) 6.48e-11
rs114045002 4 126746229 0.0119 C/A imputed (0.775) -6.53 (z) 6.48e-11
rs76699517 4 126741800 0.0119 T/C imputed (0.775) -6.53 (z) 6.48e-11
rs78276525 4 126732179 0.0119 G/T imputed (0.775) -6.53 (z) 6.48e-11
rs78538713 4 126742275 0.0119 T/C imputed (0.775) -6.53 (z) 6.48e-11
rs78570105 4 126749594 0.0119 G/A imputed (0.775) -6.53 (z) 6.48e-11
rs7657714 4 126735951 0.0132 A/C imputed (0.792) -6.12 (z) 9.12e-10
rs113323321 4 80897619 0.0132 C/T imputed (0.743) 5.85 (z) 4.85e-09
rs192963808 12 102764731 0.0066 A/G imputed (0.694) 5.53 (z) 3.28e-08
rs146655189 12 102674455 0.0079 C/T imputed (0.717) 5.48 (z) 4.27e-08
rs148061827 10 109846291 0.0066 G/T imputed (0.678) 4.84 (z) 1.28e-06
rs2139572 12 102767660 0.0119 C/T imputed (0.657) 4.82 (z) 1.44e-06
rs149903755 14 100808726 0.0079 A/G imputed (0.804) -4.77 (z) 1.86e-06
rs149119261 10 108038891 0.0066 C/T imputed (0.762) 4.73 (z) 2.3e-06
rs62497351 8 17086601 G/T gwas (1) 5.278 (t) 1.402 2.48e-06
Table 3.5: Charactristic path length GWAS results: Top 15 SNPs
SNP Dashed line is the 5% threshold
Chr BP MAF Eff/Alt Type(R2) Statistic β P
rs112039371 4 126730783 0.0119 T/C imputed (0.775) -6.73 (z) 1.7e-11
rs114045002 4 126746229 0.0119 C/A imputed (0.775) -6.73 (z) 1.7e-11
rs76699517 4 126741800 0.0119 T/C imputed (0.775) -6.73 (z) 1.7e-11
rs78276525 4 126732179 0.0119 G/T imputed (0.775) -6.73 (z) 1.7e-11
rs78538713 4 126742275 0.0119 T/C imputed (0.775) -6.73 (z) 1.7e-11
rs78570105 4 126749594 0.0119 G/A imputed (0.775) -6.73 (z) 1.7e-11
rs7657714 4 126735951 0.0132 A/C imputed (0.792) -6.39 (z) 1.64e-10
rs10113946 9 131534333 0.0211 C/T imputed (0.725) -5.36 (z) 8.29e-08
rs11560592 9 131532694 0.0211 C/T imputed (0.725) -5.36 (z) 8.29e-08
rs28521006 9 131534909 0.0211 G/A imputed (0.725) -5.36 (z) 8.29e-08
rs35354551 20 2112390 C/T gwas (1) -6.089 (t) -1.107 1.31e-07
rs113323321 4 80897619 0.0132 C/T imputed (0.743) 5.22 (z) 1.83e-07
rs10122433 9 131577388 0.0224 A/C imputed (0.753) -5.18 (z) 2.25e-07
rs12236573 9 131555366 0.0224 G/A imputed (0.715) -5.03 (z) 5.01e-07
rs10115869 9 131652502 0.0237 G/A imputed (0.735) -5.03 (z) 5.03e-07
in oxidation pathways was significantly associated with the change in Louvain modularity at 5%
significance level (p-value=2.91E-5), on chromosome 10.
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Figure 3.13: Manhattan plots of GWAS results for the change in Louvain modularity (a) and
transitivity (b) global efficiency (c) and the change in characteristics path length (d) integration
and segregation connectivity metrics.
Figure 3.14: Manhattan plots of gene scores derived from imputed summary statistics for the
change in segregation metrics. Lovain modularity appears in plot (a), and transitivity is illustrated
by plot(b). The horizontal line represents the statistical threshold used here (2.5E − 6).
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Figure 3.15: Manhattan plots of gene scores derived from imputed summary statistics for the
change in integration metrics. Global efficiency is shown in plot (a), and characteristic path
length is illustrated by plot (b). The horizontal line represents the statistical threshold used here
(2.5E − 6).
Table 3.7: Significant associations between SNPs and global network metrics
SNP ID Results are sorted according to p-value
Chr (Gene) BP MAF Eff/Alt Type R2 P Phenotype
rs144596626 5 (CDH18) 19473743 0.0080 G/A imputed 0.717 2.68e-10 Louvain
rs146631242 5 19396103 0.0080 G/A imputed 0.717 2.68e-10 Lovain
rs112039371 4 125809628 0.0119 T/C imputed 0.775 6.48e-11 G Efficiency
rs114045002 4 125825074 0.0119 C/A imputed 0.775 6.48e-11 G Efficiency
rs76699517 4 125820645 0.0119 T/C imputed 0.775 6.48e-11 G Efficiency
rs78276525 4 125811024 0.0119 G/T imputed 0.775 6.48e-11 G Efficiency
rs78538713 4 125821120 0.0119 T/C imputed 0.775 6.48e-11 G Efficiency
rs78570105 4 125828439 0.0119 G/A imputed 0.775 6.48e-11 G Efficiency
rs7657714 4 125814796 0.0132 A/C imputed 0.792 9.12e-10 G Efficiency
rs113323321 4 (ANTXR2) 79976465 0.0132 C/T imputed 0.743 4.85e-09 G Efficiency
rs112039371 4 125809628 0.0119 T/C imputed 0.775 1.7e-11 C P Length
rs114045002 4 125825074 0.0119 C/A imputed 0.775 1.7e-11 C P Length
rs76699517 4 125820645 0.0119 T/C imputed 0.775 1.7e-11 C P Length
rs78276525 4 125811024 0.0119 G/T imputed 0.775 1.7e-11 C P Length
rs78538713 4 125821120 0.0119 T/C imputed 0.77 1.7e-11 C P Length
rs78570105 4 125828439 0.0119 G/A imputed 0.775 1.7e-11 C P Length
rs7657714 4 125814796 0.0132 A/C imputed 0.792 1.64e-10 C P Length
3.4 Discussion
Association studies of human genome variation and imaging features of the brain have led to
new discoveries in AD disease susceptibility. Previous GWAS and Next Generation Sequencing
(NGS) identified about 20 genetic loci risk factors associated with AD (Cuyvers and Sleegers,
2016). More recently, cross-sectional studies of GWAS of the brain connectome successfully
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identified correlations between genetic variants and both AD and dementia (JahanshAD et al.,
2013). Incorporating imaging features in a longitudinal setting with genetic information facili-
tates the identification of additional genetic risk factors which affect AD progression (Elsheikh
et al., 2018a). Here, we aim to identify the genetic variations which associate with AD brain
neurodegeneration over time. The latter is measured as the change in global network metrics of
the brain connectome of three clinical stages of AD.
In this study, we examine the significance of the change in the global network metrics over time,
through Wilcoxon test statistics (shown in Table 3.1). We tested the distribution of each metric
before and after one year, and only the AD brain showed a difference, compared to controls. We
proceeded with the analysis by conducting four quantitative genome-wide association tests, taking
the absolute difference in the metrics of brain network integration and segregation as individual
phenotypes. To our knowledge, this is the first study of its type, to compare longitudinal imaging
features of the connectome to genetic information. These connectivity features were obtained
from the structural connectomes defined by tractography. Structural connectomes derived by
covariation of cortical morphology was investigated, however, no statistically significant difference
at longitudinal level was detected. Despite the belief that covariation of cortical morphology is
related to anatomical connectivity of white matter (Pezawas et al., 2004), the technique was not
able to detect longitudinal differences in the interval of observation, most likely because these
differences are more visible in the ”within-brain” connectivity given by tractography, as previously
suggested(Forsberg et al., 2019). Therefore, these features cannot be used to perform a GWAS
focused on longitudinal changes. Nevertheless, previous GWAS focused on VBM features at one
time point (Shen et al., 2010) found an association with the ApoE gene and other SNPs related
to the ephrin receptor, which are known to be correlated with the loci descried below.
In this data, Louvain modularity analysis identified the SNP rs144596626 (p-value=2.68e-10),
in the CDH18 locus, as the most significant SNP to manipulating changes in brain segregation
(See Table 3.2 and Table 3.6). The CDH18 gene encodes a cadherin that mediates calcium-
dependent adhesion, playing an important role in forming the adheren junctions that bind cells.
The gene is located on chromosome 5, and it is reported to be highly expressed specifically in the
brain, with higher expression in different parts of the Central Nervous System (CNS), including
middle temporal gyrus, cerebellum and frontal cortex (Fagerberg et al., 2014). The gene is
associated with several neuropsychiatric disorders, as well as glioma, the most common CNV
tumor among adults (Bai et al., 2018). Looking at glioma cells, and through in vitro and in vivo
functional experiments, Bai et al. (2018) showed that CDH18 acts as a tumor suppressor through
the downstream gene target UQCRC2, and suggested targeting CDH18 in glioma treatment.
Moreover, CDH18 was reported in a meta-analysis of depression personality trait association as
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the nearest gene to rs349475 (Terracciano et al., 2010).
On the other hand, the change in weighted global efficiency metric over time was significantly
affected by the ANTXR2 gene in chromosome 4 (see Table 3.7), through the imputed SNP
rs113323321 (p-value = 4.85e−09) with imputation accuracy of 0.743. ANTXR2 or ANTXR cell
adhesion molecule 2 (also known as HFS ; ISH ; JHF ; CMG2 ; CMG-2) is well-known to be involved
in the development of Hyaline fibromatosis syndrome (HFS) through certain mutations. HFS is
a collection of rare recessive disorders forming an abnormal growth of hyalinized fibrous tissue; it
affects under-skin regions on the scalp, ears, neck, face, hands, and feet. Some studies reported
that ANTXR2 mutations manipulate the normal cell interactions with the extracellular matrix,
and its deleterious mutations play an essential role in causing the allelic disorders Juvenile hyaline
fibromatosis (JHF ) and infantile systemic hyalinosis (ISH) (Dowling et al., 2003; Hanks et al.,
2003). ANTXR2 interacts with the LRP6 (Low-Density Lipoprotein receptor-related protein 6)
gene, which is located in chromosome 12, and is known for its genetic correlation with ApoE.
Together, their genetic variants, along with the alteration in Wntβ signalling, might be involved
in the development of late-onset AD (De Ferrari et al., 2007).
The segregation of the brain has shown a strong relationship with the olfactory receptor (OR)
family 5 (specifically, OR5L1, OR5D13 and OR5D14 - see Table 3.6), located in chromosome 11,
through the change in brain transitivity metric. The OR act together with the odorant molecules
in the nose to produce a neuronal response that recognizes smell (O’Leary et al., 2015).
Our findings also suggest that the weighted global efficiency change over time significantly as-
sociates with the insulin-like growth factor 1 (IGF1) gene, as shown in Table 3.6. A previ-
ous study in mouse brain suggests neuroprotection in a mouse model can be obtained through
chronic combination therapy with EPO+IGF-I and cooperative activation of phosphatidylinositol
3-kinase/Akt/GSK-3beta signaling. However, they did not test their model in humans (Kang
et al., 2010).
At 10% significance level, we identified additional genes associated with Alzheimer’s brain seg-
regation and integration alterations. The gene ZDHHC12 (zinc finger DHHC-type containing
12), as with many others in chromosome 9 - including LOC100506100, ENDOG, TBC1D13 and
C9orf114 (p-value= 3.76839713E − 6, 4.175E − 6, 4.186E − 6 and 4.507E − 6, respectively)
showed a significant score (p-value=4.607E-6) in association with the change in characteristic
path length (see Table 3.6). In an in vitro experiment, (Mizumaru et al., 2009) showed that
ZDHHC12 was able to alter amyloid β-protein precursor (APP) metabolism, and that the failure
of AID/DHHC-12 to regulate the transportation or generation of APP in the neurons might result
in the early development of AD (Young et al., 2012). (Singh et al., 2004) also reported the role
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of Endonuclease G (ENDOG ) in mediating the pathogenesis of neurotoxicity and striatal neuron
death, through exposing the striatal neurons in mouse with Human immunodeficiency virus-1
(HIV-1) Tat1−72.
Located in chromosome 1, Janus kinase 1 (Jak1) shows a significant association with the change
in transitivity metric. The same phenotype was also reported with other significant gene scores
at 10% significance level (Table 3.6) such as the proteasome subunit alpha 4 (PSMA4) on
chromosome 15, AGPHD1, CHRNA5 and IREB2 (see Fig 3.14). The dysregulation of the inter-
cellular JAK-STAT signaling pathway, which activates Jak1 and the Janus kinase protein family,
is at the core of neurodegenerative diseases and other brain disorders (Nicolas et al., 2013).
JAK2/STAT3 activation, in particular, was illustrated to protect the neuron, while alteration of
the same pathway might play a role in developing neurodegenerative diseases.
We compared our results to previously identified genetic variants in association with Alzheimer’s
(specifically SNPs), all genetic variants with p-values less than 0.01, in all global network metrics,
are summarised in Table 3.9. We retrieved the AD SNP list from Ensembl Biomart online software
(Kinsella et al., 2011). Our study reported rs6026398 (β =-0.6496, p-value=0.000814) to be the
most significant SNP associated with the change in brain segregation through Louvain modularity.
The threshold we set here is 0.05
1324
, as we tested a total of 1324 pathways, though none of the
SNPs passed that threshold. Our explanation for this is that variants might play a significant role
in developing AD, but do not contribute that much to its progression over time. A way to take
this forward is to target all genes known to affect AD susceptibility and test, in a longitudinal
study design, which of them contribute to the progression of Alzheimer’s disease through the
imaging features. Another recommendation is to consider studying the longitudinal association
and consider whether any genetic variant has a biased contribution in different brain regions.
One of the main disadvantages of this work is the sample size. We suspect the underestimation
that appears in our initial GWAS results for all four phenotypes excluding transitivity, is due to
sample size (Figure 3.13). In a larger sample, our result is expected to be more robust and to
unveil more variants. However, to some extent, PASCAL (3.14 and 3.15) improved this and
unmasked some associations. It is worthwhile mentioning that, in this analysis, we used all the
ADNI samples which satisfy our selection criteria. We also considered looking at other datasets
(e.g UKBiobank and ENIGMA) but there was no data that matched our specific combination of
factors required.
Another concern here, is that our sample size was not sufficient to estimate the genetic correlation
and heritability of our phenotypes. Most of the heritability estimation methods requires large
sample sizes (at least ≈ 5k samples (Bulik-Sullivan et al., 2015; Finucane et al., 2015; Yang et al.,
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2010)) to yield robust estimates. Besides increasing the sample size, a good practice would be
considering more time-points and studying the effect of genes in a survival analysis study design.
In this work, we looked at the genetic variations taken at one time-point, and converted the
longitudinal imaging information into a single measurement to study their association. A possible
future focus would be to incorporate clinical and environmental factors such as hypertension and
dementia score as well as the gene-gene and gene-environment interactions.
In summary, we conducted a longitudinal study and proposed a fast and straightforward way to
quantify changes in the brain connectome through global connectivity measures of 1) segregation,
through Louvain modularity and transitivity, and 2) integration. For the latter, we used two
metrics including the characteristic path length and the weighted global efficiency. We conducted
a genome-wide analysis, starting with four quantitative GWAS, regressing the pre-mentioned
global network metric on all SNPs, and then computed the gene scores by aggregating the GWAS
summary statistics at a gene-wide level. In the ADNI sample we used here, and at a power
of 95%, despite the small sample size we identified significant SNPs and genes. The Louvain
modularity change was affected by the ANTXR2 gene, while through transitivity, the change in
brain connectivity is associated with OR5L1, OR5D13 and OR5LD14. On the other hand, the
integration of the brain is affected by IGF1. In previous studies, connectome changes in AD
have been identified, moreover, connectome genetics studies attempt to identify the association
between brain connectivity features with genetics. Results in this area are often limited to isolated
brain areas, or global connectivity measures, and in both cases, findings lack the understanding
of the molecular consequences, causes of the connectome changes, and its contribution to drug
development in AD. A greater understanding of the genetic contribution and relationship of these
genes and their effect over time through targeted studies, might facilitate the development of
drug therapy to reduce the disease progression.
Chapter 4
Relating Global and Local Connectome
Changes to Dementia and Targeted
Gene Expression in Alzheimer’s Disease
Abstract
Networks are present in many aspects of our lives, and networks in neuroscience have recently
gained much attention leading to novel representations of brain connectivity. Indeed, there is
still room for investigation of the genetic contribution to brain connectivity. The integration of
neuroimaging and genetics allows a better understanding of the effects of the genetic variations
on brain structural and functional connections, but few studies have successfully investigated the
longitudinal association of such a mutual interplay. Nevertheless, several Alzheimer’s disease-
associated genetic variants have been identified through omic studies, and the current work uses
whole-brain tractography in a longitudinal case-control study design and measures the structural
connectivity changes of brain networks to study the neurodegeneration of Alzheimer’s. This
is performed by examining the effect of targeted genetic risk factors on local and global brain
connectivity. In this chapter, we investigated the degree to which changes in brain connectivity
are affected by gene expression. More specifically, we used the most common brain connectivity
measures such as efficiency, characteristic path length, betweenness centrality, Louvain modularity
and transitivity (a variation of clustering coefficient). Furthermore, we examined the extent to
which Clinical Dementia Rating relates to brain connections longitudinally, as well as to gene
expression. Here, we show that the expression of PLAU and HFE genes increases the change in
betweenness centrality related to the fusiform gyrus and clustering coefficient of cingulum bundle
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Section 4.1. Introduction Page 64
over time, respectively. APP and BLMH gene expression associates with local connectivity.
We also show that betweenness centrality has a high contribution to dementia in distinct brain
regions. Our findings provide insights into the complex longitudinal interplay between genetics
and neuroimaging characteristics and highlight the role of Alzheimer’s genetic risk factors in the
estimation of regional brain connection alterations. These regional relationship patterns can be
useful for early disease treatment and neurodegeneration prediction.
4.1 Introduction
There are many factors which may affect the susceptibility to Alzheimer’s Disease (AD) and
various ways to measure the disease status. However, there is no single factor which can be used
to predict the disease risk sufficiently (Barnes and Yaffe, 2011). Genetics is believed to be the
most common risk factor in AD development (Gatz et al., 1997). Towards studying the etiology
of the disease, a number of genetic variants located in about 20 genes have been reported to
affect the disease through many cell-type specific biological functions (Gaiteri et al., 2016). Those
efforts resulted from omic studies such as Genome-Wide Associations Studies (GWAS). GWAS
highlighted dozens of multi-scale genetic variations associated with AD risk (Lambert et al., 2013;
Escott-Price et al., 2014; Elsheikh et al., 2020b).
From the early stages of studying the disease, the well known genetic risk factors of AD were found
to lie within the coding genes of proteins involved in amyloid-β(Aβ) processing. These include
the well-known Apolipoprotein E (ApoE ) gene that increases the risk of developing AD (Corder
et al., 1993), the Amyloid precursor protein (APP) (Goate et al., 1991), presenilin-1 (PSEN1)
and presenilin-2 (PSEN2) (Levy-Lahad et al., 1995; Rogaev et al., 1995). More recently, the
advancement in technologies and integration of genetic and neuroimaging datasets has taken
Alzheimer’s research steps further, and produced detailed descriptions of molecular and brain
aspects. Such studies have shown a great success in unveiling and replicating previous findings
(Medland et al., 2014; Elsheikh et al., 2018b). Shaw et al. (2007), for example, showed that
carriers of ApoE are more likely to lose brain tissue, measured as the cortical gray matter, than
non-carriers. Other studies have utilised the connectome (Hagmann et al., 2008) to study different
brain diseases through associating genetic variants to brain connectivity (Thompson et al., 2014).
A structural connectome is a representation of the brain as a network of distinct brain regions
(nodes) and their structural connections (edges), calculated as the number of anatomical tracts.
Those anatomical tracts are generally obtained by diffusion tensor imaging (DTI) (Alexander
et al., 2007), a method used for mapping and characterizing the diffusion of water molecules, in
three-dimensions, as a function of the location. This representation highlighted a network based
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organization of the brain with separated subnetworks (network segregation) which are connected
by a small number of edges (network integration) (Deco et al., 2015). Given such a “small-world”
representation of the brain, it is also possible to represent each individual brain as single scalar
metrics which summarize peculiar properties of segregation and integration (Rubinov and Sporns,
2010). Alternatively, those global metrics can also be used to quantify local properties of specific
nodes/areas. Early works demostrated that ApoE-4 carriers have an accelerated age-related loss
of global brain interconnectivity in AD subjects (Brown et al., 2011), and topological alterations
of both structural and functional brain networks are present even in healthy subjects carrying
the ApoE gene (Chen et al., 2015). A more recent study has shown association between ApoE
expression and brain segregation changes (Elsheikh et al., 2018a). Going beyond the ApoE gene,
JahanshAD et al. (2013) used a dataset from Alzheimer’s Disease Neuroimaging Initiative (ADNI)
to carry out a GWAS of brain connectivity measures and found an associated variant in F-spondin
(SPON1), previously known to be associated with dementia severity. A meta-analysis study also
showed the impact of ApoE, phosphatidylinositol binding clathrin assembly protein (PICALM),
clusterin (CLU), and bridging integrator 1 (BIN1) gene expression on resting state functional
connectivity in AD patients (Chiesa et al., 2017).
Moreover, AD is a common dementia-related illness; in the elderly, AD represents the most
progressive and common form of dementia. Accordingly, incorporating and assessing dementia
severity when studying AD provides more insights about the disease progression from a clinical
point of view. A reliable global rating of dementia severity is the Clinical Dementia Rating (CDR)
(Morris et al., 1997). This paper uses a dataset from ADNI (http://adni.loni.usc.edu/) and
presents an integrated association study of specific AD risk genes, dementia scores and structural
connectome characteristics. Here, we adapted a longitudinal case-control study design to mainly
examine the association of known AD risk gene expression with local and global connectivity
metrics. We also aim at testing the longitudinal effect of brain connectivity on different CDR
scores, and carrying out a multivariate analysis to study the longitudinal effect of gene expression
and connectome changes on CDR. Our approach can be summarized in the simplistic represen-
tation in Figure 4.1, where specific genes affect decreases in connectivity comparing baseline and
follow-up and this ultimately affects intellectual abilities and CDR scores. Although it is more
useful to extract the gene expression profiles from the brain, we used the gene expression from
blood samples in this work as provided by ADNI. Blood gives a general idea of what is happening
in the body, and can detect differences in gene expression. Moreover, blood samples are easy to
obtain and are noninvasive.
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Figure 4.1: Simplistic representation of our approach which relates connectome metrics of
segregation (disconnection), cognitive decline and gene expression.
4.2 Materials and Methods
4.2.1 Data Description. We used two sets of data from ADNI, which is available at adni.loni.usc.
edu. To fulfil our objectives, we merged neuroimaging, gene expression and CDR datasets for all
the participants with those three types of data at two time points available. We considered follow-
up imaging and CDR acquisition one year later than the baseline visit. Given those constraints,
we ended up with a total of 47 participants. We adopted a case-control study design; 11 of the
participants are AD patients, while 36 are controls. The data were matched by age, and the
distribution of age in AD ranges between 76.5±7.4 for cases, and 77.0±5.1 years in controls.
Imaging Data
For the imaging, we obtained the DTI volumes at two time points, the baseline and follow-up
visits, with one year in between. Along with the DTI, we used the T1-weighted images and
they were acquired using a GE Signa scanner 3T (General Electric, Milwaukee, WI, USA). The
T1-weighted scans were obtained with voxel size = 1.2 × 1.0 × 1.0mm3TR = 6.984ms; TE =
2.848 ms; flip angle= 11◦ ), while DTI obtained with voxel size = 1.4 × 1.4 × 2.7mm3 , scan
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time = 9 min, and 46 volumes (5 T2-weighted images with no diffusion sensitization b0 and 41
diffusion-weighted images b= 1000s/mm2).
Genetic Data Acquisition
We used the Affymetrix Human Genome U219 Array profiled expression dataset from ADNI. The
RNA was obtained from blood samples and normalised before hybridization to the array plates.
Partek Genomic Suite 6.6 and Affymetrix Expression Console were used to check the quality of
expression and hybridization (Saykin et al., 2015). The expression values were normalised using
the Robust Multi-chip Average (Irizarry et al., 2003), after which the probe sets were mapped
according to the human genome (hg19). Further quality control steps were performed by checking
the gender using specific gene expression, and predicting the Single Nucleotide Polymorphisms
from the expression data (Vawter et al., 2004; Schadt et al., 2012)
In this work, we targeted specific genes which have been reported to affect the susceptibility
of AD. We used the BioMart software from Ensembl to choose those genes by specifying the
phenotype as AD (Smedley et al., 2015). We obtained a total of 17 unique gene names and
retrieved a total of 65 probe sets from the genetic dataset we are using here.
Clinical Dementia Rating
The Clinical Dementia Rating, or CDR score is an ordinal scale used to rate the condition of
dementia symptoms. It range from 0 to 3, and is defined by five values: 0, 0.5, 1, 2 and 3,
ordered by severity, which stand for none, very mild, mild, moderate and severe, respectively.
The scores evaluate the cognitive state and functionality of participants. Here, we used the
main six scores of CDR; memory, orientation, judgement and problem solving, community affairs,
home and hobbies, and personal care. Besides the latter, we used a global score, calculated as
the sum of the six scores. We obtained the CDR scores at two time points in accordance with
the connectivity metrics time points.
Connectome Construction
Each DTI and T1 volume have been pre-processed performing Eddy current correction and skull
stripping. Given the fact that DTI and T1 volumes were already co-registered, the AAL atlas
(Tzourio-Mazoyer et al., 2002), and the T1 reference volume are linearly registered according to
12 degrees of freedom. Tractography for all subjects has been generated by processing the DTI
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data with a deterministic Euler approach (Garyfallidis et al., 2014), using 2,000,000 seed-points
and stopping when fractional anisotropy (FA) is smaller than 0.1 or a sharp angle (larger than
75◦). To construct the connectome, we assigned a binary representation in the form of a matrix
whenever more than three connections were present between two regions of the AAL, for any pair
of regions. Tracts shorter than 30 mm were discarded. The FA threshold was chosen in a such
a way that allows reasonable values of characteristic path length for the given atlas. Though
the AAL atlas has been criticized for functional connectivity studies (Gordon et al., 2014), it has
been useful in providing insights in neuroscience and physiology, and is believed to be sufficient
for our case study (Gordon et al., 2014).
4.2.2 Global and Local Connectivity Metrics. To quantify the overall efficiency and integrity
of the brain, we extracted global measures of connectivity from the connectome, represented
here in four values of network integration and segregation. Specifically, we used two network
integration metrics 1) the global efficiency (E; Equation 4.2.1), and 2) the weighted characteristic
path length (L; Equation 4.2.2). Both are used to measure the efficiency of which information is
circulated in a network. On the other hand, we used; 1) Louvain modularity (Q; Equation 4.2.3),
and 2) transitivity (T ; Equation 4.2.4) to measure the segregation of the brain, that is, the
capability of the network to shape sub-communities which are loosely connected to one another
while forming a densely connected sub-network within communities (Deco et al., 2015; Rubinov
and Sporns, 2010).
Suppose that n is the number of nodes in the network, N is the set of all nodes, the link (i, j)
connects node i with node j and aij define the connection status between node i and j, such
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where, dij =
∑
auv∈gi↔j auv, is the shortest path length between node i and j, and gi↔j is the






















i,j∈N aij, mi and mj are the modules containing node i and j, respectively, and










j,h∈N(aijaihajh) is the number of triangles around node i.
Using the AAL atlas, we constructed the following local brain network metrics at each region or
node. We used the local efficiency (Eloc,i; Equation 4.2.5), clustering coefficient (Ci; Equation
4.2.6) and betweenness centrality (bi; Equation 4.2.7) at each node to quantify the local con-
nectivity. Both local efficiency and clustering coefficient measure the presence of well-connected
clusters around the node, and they are highly correlated to each other. The betweenness central-
ity is the number of shortest paths which pass through the node, and measures the effect of the
node on the overall flow of information in the network (Rubinov and Sporns, 2010). The local
connectivity metrics used in this work, for a single node i, are defined as follows;
Eloc,i =
∑
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where, djh(Ni), is the length of the shortest path between node j and h - as defined in Equation,













where ρhj(i) is the weights of shoetest path between h and j that passes throgh i.
4.2.3 Statistical Analysis. We used different statistical methods as described below, and for
the multiple testing we relied on the Bonferroni correction(White et al., 2019; Narum, 2006).
Where applicable, the thresholds were obtained by dividing 0.05 by the number of tests.
Quantifying the Change in CDR and Connectivity Metrics
To determine the longitudinal change in CDR, local and global connectivity metrics, we calculated
the absolute difference between the first visit (the baseline visit) and the first visit after 12
months (the follow-up visit). Unless stated otherwise, this is the primary way of quantifying this
longitudinal change we used in the analysis.
Estimation of Gene Expression from Multiple Probe Sets
Different probe set expression values were present for each gene in the data. To estimate a
representative gene expression out of the probe set expression, we conducted a non-parametric
Mann-Whitney U test to evaluate whether the expression in AD was different from those of
controls. For each gene, we selected the probe set expression that has the lowest Mann-Whitney
U p-value. In this way, we selected the most differentially expressed probe sets in our data and
considered those for the remaining analysis.
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Spearman’s Rank Correlation Coefficient
To test the statistical significance of pair-wise undirected relationships, we used the Spearman’s
rank correlation coefficient (ρ). The Spearman coefficient is a non-parametric method which
ranks pairs of measurements and assesses their monotonic relationship. We report here the
coefficient ρ along with the corresponding p-value to evaluate the significance of the relationship.
A ρ of ±1 indicates a very strong relationship, while ρ = 0 means there is no relationship.
Quantile Regression
To model the directed relationship between two variables, we used the quantile regression model
(Koenker and Hallock, 2001). This model is used as an alternative to the linear regression when
assumptions of linear regression are not met. This fact allows the response and predictor variables
to have non-symmetric distribution. The quantile regression model estimates the conditional
median of the dependent variable given the independent variables. Besides, it can be used to
estimate any conditional quantile; and is therefore robust to outliers. In this work, we used the
second quantile; the median, to model the directed relationship between two variables using the
quantile regression.
Ridge Regression
For estimating the relationship between more than two variables, we used ridge regression (Hoerl
and Kennard, 1970). The basic idea behind this model is that it solves the least square function
penalizing it using the l2 norm regularization. More specifically, the ridge regression minimizes
the following objective function:




||y −Xβ||22 + α||β||22,
(4.2.8)
where y is the dependent (or response) variable, X is the independent variable (feature, or pre-
dictor), β is the ordinary least square coefficient (or, the slope), α is the regularization parameter,
βRidge is the ridge regression coefficient, argmin is the argument of minimum and it is respon-
sible for making the function attain the minimum and is L2(v) = ||v||2 represents the L2 norm
Section 4.3. Results Page 72
function (Strang et al., 1993). Moreover, we normalized the predictors to get a more robust
estimation of our parameters.
Software
We used Python 3.7.1 for this work; our code has been made available under the MIT License
https://choosealicense.com/licenses/mit/, and is accessible at https://github.com/elssam/RGLCG.
4.3 Results
4.3.1 Longitudinal Connectivity Changes and CDR. Initially, we used descriptive statistics
plots to visualize the data for the two populations of AD and matched control subjects. To
facilitate the integrated analysis, we looked into the different sets of data individually to have a
better understanding of the underlying statistical distribution of each, and chose the best analysis
methods accordingly. Firstly, we plotted the global and local connectivity metrics in a way that
illustrates the longitudinal change. Those longitunal changes are measured after 1 year followup
from baseline screening. The global connectivity metric box plots show the baseline and follow-
up distributions for both AD and controls for transitivity, Louvain modularity, characteristic path
length and global efficiency (Figure 4.2). The figure shows that the longitudinal changes in
connectome metrics are statistically significant among the AD subjects and not mere artifacts,
but not within the control population which seem to have non significant changes. In fact,
comparing all populations values, the only significant differences were for the AD group and for
the characteristic path length (p-value 0.0057), global efficiency (p-value 0.0033), and Louvain
modularity (p-value 0.0086).
Appendix Figures A1, A2 and A3 show the distribution of the local efficiency, clustering coefficient
and betweenness centrality connectivity metrics, respectively, at the baseline and follow-up (left
sub-figures), as well as their absolute differences (right sub-figures), at all atlas brain regions.
A list of the brain atlas region names, abbreviations and ids are available in Appendix Table
A1. Moreover, we show, in Figure 4.3, the scatter and violin plots of the six CDR scores, at
the baseline and follow-up. Those are the memory, orientation, judgement and problem solving,
community affairs, home and hobbies, and personal care scores which take the categorical values
illustrated in the Materials and Methods (and also in Figure 4.3).
Both global and local connectivity features show non-symmetric distribution in the baseline,
follow-up and absolute change between them. Therefore, we use non-parametric models and
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Figure 4.2: Box plots of the distribution of brain segregation and integration global connectivity
metrics comparing the two time points. The plots compare the baseline and follow-up distributions
for AD and controls for Louvin modularity (a), transitivity (b), characteristic path length (c) and
global efficiency (d).
statistical tests in the following analysis.
4.3.2 Gene Expression. We derived a list of 17 AD risk factor genes from BioMart, and retrieved
56 related probes sets. We performed a Mann-Whitney U test which aims at testing whether
a specific probe set expression is different between AD and controls. For each gene, we chose
the probe set that has the lowest p-value. Table 4.1 reports the selected probe set with the
smallest p-value, at each gene. After estimating the expression of the 17 genes, as explained in
the Materials and Methods, we plotted a heatmap of the related gene expression profiles showed
in Figure 4.4. Here, some of the genes appear to be highly expressed in the profiles (e.g. SORL1
and PSEN1), while others show very low expression (e.g. HFE and ACE ).
4.3.3 Association Analysis. We studied the undirected associations of the 17 gene expression
with the longitudinal change in global and local brain connectivity, as well as the associations
with longitudinal CDR and connectivity changes. The total sample size after integrating all the
datasets was 47 participants. Firstly, we performed an association analysis of gene expression with
the connectivity changes locally, at each Automated Anatomical Labeling (AAL) brain region. In
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Figure 4.3: Violin plots to illustrate the CDR scores (either 0: None, 0.5: very mild, 1: mild,
2: moderate or 3: severe) in the baseline (left violin plot) and follow-up (right violin plot) visits,
for AD (red dots) and controls (blue dots). The memory (CDMEMORY; a) and orientation
(CDORIENT; b) scores are represented by the top sub-figures, judgment and problem solving
(CDJUDGE; c) and community affairs (CDCOMMUN; d) are the middle sub-figures, while home
and hobbies (CDHOME; e) and personal care (CDCARE; f) are at the bottom. It is visible that
generally some AD subjects worsen their score, except for the CDCARE score where few improved
as a result to finding strategies after the diagnosis at baseline.
Table 4.2 we show the top results reported along with the Spearman correlation co-efficient. The
APP gene, ρ =-0.58, p-value=1.9e-05) and BLMH, ρ =0.57, p-value=2.8e-05) are the top and
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Figure 4.4: A heatmap of the estimated 17 gene expressions (values multiplied by 1000, each
line represents a participant) out of the 65 probe sets as explained in the Materials and Methods
section. The dark blue represents a high expression values, while the yellow represents low
expression. The SORL1 has the highest expression among the genes and HFE expression was
the lowest among other genes.
only significant genes in the list, and associate with the change in local efficiency at the right
middle temporal gyrus (Temporal Mid R AAL region) and clustering coefficient at the left Heschl
gyrus (Heschl L), respectively. Figure 4.5 shows the scatter plots related to the latter scenarios.
In Table 4.2, there is a similar pattern observed in association results between the clustering
coefficient and local efficiency, e.g. both metrics are associated with BLMH at the left Heschl
gyrus (Heschl L), APP at the right middle temporal gyrus (Temporal Mid R) and PLAU at the
right ngular gyrus (Angular R). We interpret this by the strong correlation that exists between
the local efficiency and clustering coefficient, at the baseline, follow-up and also, the absolute
change (see Appendix Figure A4). On the other hand, Appendix Table A2 reports the top results
of the association between gene expression and the change in brain global connectivity. In this
case there are no significant associations.
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Table 4.1: Mann-Whitney U test top results for the difference between AD and controls in
probe-set expression
Gene Top results
Chromosome Probe set id p-value
APBB2 4 11734823 a at 0.02575
MPO 17 11727442 at 0.38631
APP 21 11762804 x at 0.01396
ACE 17 11752871 a at 0.24478
PLAU 10 11717154 a at 0.01396
PAXIP1 7 11755176 a at 0.45499
HFE 6 11736346 a at 0.11881
SORL1 11 11743129 at 0.10912
A2M 12 11715363 a at 0.28592
NOS3 7 11725467 a at 0.04261
BLMH 17 11757556 s at 0.09356
ADAM10 15 11751180 a at 0.14278
PLD3 19 11715382 x at 0.17304
ApoE 19 11744068 x at 0.05962
PSEN1 14 11718678 a at 0.29453
PSEN2 1 11723674 x at 0.04862
ABCA7 19 11755091 a at 0.45499
4.3.4 Regressing Change in Local and Global Brain Connectivity on Gene Expression.
We analyzed the directed association through regressing the change in local connectivity (as a
dependant variable), at each AAL region, on gene expression using (as an independent variable
or predictor) a quantile regression model. Table 4.3 reports the top results, along with the
regression coefficient, p-values and t-test statistic. PLAU was the most significant gene affecting
the absolute change in betweenness centrality at left Fusiform gyrus (Fusiform L) with an increase
of 487.13 at each unit increase in PLAU expression (p-value= 3e − 06). This was followed by
the expression of HFE with an effect size of 0.1277 on the change in local efficiency at the
right anterior cingulate and paracingulate gyri (Cingulum Ant R). Those observed associations
are illustrated in Figure 4.6. Appendix Figures A5, A7 and A6 show the Manhattan plots for
the -log10 of the p-values corresponding to the quantile regression models of the change in local
efficiency, clustering coefficient and betweenness centrality, respectively.
Similarly, we regressed the absolute change of global connectivity measures on gene expression
values and the top results are shown in Appendix Table A3. All the results have p-values less
than the threshold we set (0.05
17
= 0.0029).
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Figure 4.5: A scatter plot of all the significant association results. The plots shows the asso-
ciations between; (a) BLMH expression and clustering coefficient in AAL region 79 (Heschl L),
(b) APP expression and local efficiency in brain region 86 (Temporal Mid R).
Table 4.2: Top results of Spearman associations between AD gene expression and local connec-
tivity metrics.
Gene Sorted by P-value. Dashed line: threshold= 0.05
17×90 = 3.27e− 05
Region Region id Metric ρ P-value
APP Temporal Mid R Region86 local eff -0.5805 1.9e-05
BLMH Heschl L Region79 cluster coef 0.5708 2.8e-05
PSEN1 Occipital Mid R Region52 b centrality -0.5598 4.3e-05
BLMH Heschl L Region79 local eff 0.5591 4.4e-05
APP Temporal Mid R Region86 cluster coef -0.5197 0.000182
PAXIP1 Amygdala L Region41 cluster coef 0.5064 0.000281
PLAU Angular R Region66 cluster coef 0.484 0.000567
PLAU Angular R Region66 local eff 0.4838 0.00057
ACE Postcentral L Region57 b centrality 0.4648 0.000998
ADAM10 Postcentral L Region57 local eff -0.4602 0.001133
PAXIP1 Parietal Sup L Region59 b centrality -0.4585 0.00119
PLAU Fusiform L Region55 b centrality 0.4564 0.001262
SORL1 Putamen R Region74 local eff -0.4528 0.001395
PSEN2 Frontal Inf Oper R Region12 local eff 0.4457 0.001693
PLAU Frontal Inf Oper L Region11 b centrality 0.4454 0.001704
ABCA7 Temporal Inf L Region89 local eff 0.442 0.001866
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Table 4.3: Top 50 quantile regression results of the change in local network metrics (y) on and
targeted Alzheimer’s Disease gene expression (x)
Region Sorted by p-value. Dashed line: threshold= 0.0517×90 = 3.27e− 05
Region R. id Beta Statistic P-value Metric
PLAU Fusiform L 55 487.1319 5.3836 3e-06 b centrality
HFE Cingulum Ant R 32 0.1277 4.8139 1.7e-05 local eff
PAXIP1 Parietal Sup L 59 -147.3175 -4.5608 3.9e-05 b centrality
HFE Cingulum Ant R 32 0.1662 3.9835 0.000246 cluster coef
APP Amygdala R 42 -0.1349 -3.8548 0.000365 local eff
PLAU Hippocampus L 37 0.1073 3.4801 0.001125 local eff
ADAM10 Postcentral L r57 -0.0871 -3.4376 0.001275 cluster coef
ApoE Frontal Inf Orb L 15 153.3117 3.3627 0.001584 b centrality
APBB2 Amygdala L 41 0.2054 3.3517 0.001635 cluster coef
ApoE Frontal Sup Medial L 23 0.1912 3.2788 0.002015 cluster coef
MPO Cingulum Mid L 33 0.0293 3.2465 0.00221 cluster coef
MPO Cingulum Mid L 33 0.0281 3.2143 0.00242 local eff
PLAU Cingulum Ant R 32 0.1428 3.1969 0.002543 local eff
ADAM10 Postcentral L 57 -0.0517 -3.1541 0.002867 local eff
ApoE Postcentral L 57 0.0806 3.0931 0.003398 local eff
PLD3 Olfactory R 22 -0.1268 -3.0463 0.003867 cluster coef
ABCA7 Frontal Inf Orb R 16 34.9538 2.9489 0.005043 b centrality
A2M Putamen R 74 -0.0543 -2.9171 0.005495 local eff
PLAU Hippocampus L 37 0.1472 2.9023 0.005717 cluster coef
HFE Frontal Inf Tri R 14 0.1852 2.8813 0.006047 cluster coef
HFE Frontal Inf Tri R 14 0.0926 2.8594 0.006411 local eff
APP Amygdala R 42 -0.1753 -2.8288 0.006953 cluster coef
ApoE Occipital Mid R 52 44.0624 2.7995 0.007512 b centrality
HFE Calcarine R 44 0.1403 2.7916 0.007669 cluster coef
APP Temporal Mid R 86 -0.0692 -2.7396 0.008787 cluster coef
APP Temporal Mid R 86 -0.0386 -2.7297 0.009016 local eff
PLD3 Olfactory R 22 -0.0987 -2.713 0.009413 local eff
A2M Olfactory R 22 -30.9342 -2.6919 0.009941 b centrality
APP Cuneus R 46 0.1443 2.6845 0.010131 cluster coef
PSEN1 Frontal Inf Tri L 13 -0.1344 -2.6492 0.01109 local eff
PSEN2 Temporal Mid L 85 0.0528 2.6465 0.011168 local eff
PSEN1 Frontal Inf Tri L 13 -0.2431 -2.6432 0.011262 cluster coef
PLAU Frontal Mid R 8 0.0854 2.6384 0.011401 local eff
ApoE Putamen L 73 372.8291 2.638 0.011411 b centrality
A2M Occipital Mid R 52 0.0535 2.6213 0.011907 cluster coef
APP Cuneus R 46 0.0798 2.6189 0.011979 local eff
ADAM10 Temporal Sup L 81 -0.1123 -2.6134 0.012147 cluster coef
ApoE SupraMarginal L 63 0.1158 2.5663 0.013677 local eff
HFE Calcarine R 44 0.0755 2.533 0.014866 local eff
PLAU Occipital Mid L 51 0.1268 2.5193 0.01538 cluster coef
MPO Pallidum R 76 0.024 2.5101 0.015732 local eff
ABCA7 Temporal Inf L 89 0.0249 2.5083 0.015804 local eff
A2M Occipital Mid R 52 0.0268 2.5023 0.01604 local eff
PLAU Hippocampus R 38 182.0756 2.5007 0.016105 b centrality
APP Frontal Med Orb L 25 0.1167 2.4968 0.01626 cluster coef
HFE Cingulum Post R 36 28.3207 2.4708 0.017334 b centrality
ACE Occipital Mid R 52 0.0433 2.4632 0.017659 local eff
NOS3 Olfactory L 21 -0.1615 -2.4596 0.017815 cluster coef
ABCA7 Temporal Inf L 89 0.0429 2.4374 0.018808 cluster coef
SORL1 Paracentral Lobule L 69 91.7443 2.4364 0.018855 b centrality
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Figure 4.6: Subfigure (a) higlights regions in the brain where significant associations - between
gene expression and longitudinal change in local connectivity metrics - were found, using quantile
regression (HFE and PLAU) and spearman associations (APP and BLMH). Each gene is plotted
at the AAL brain region where the association was significant; APP at Temporal Mid R, BLMH
at Heschl L, PLAU at Fusiform L and HFE at Cingulum Ant R. (b) and (c) are scatter plots to
visualize the association between PLAU gene expression and betweenness centrality in the left
fusiform gyrus (a), and between the expression of HFE gene with local efficiency in right anterior
cingulate gyrus (b). The red line on the plots represents the median (quantile) regression line,
while the blue line represents the ordinary least square line.
4.3.5 Additive Genetic Effect on Brain Regions. To visualize the overall contribution of
AD gene risk factors used in this work on distinct brain areas, we added up the -log10 p-values
for the gene expression coefficients at each of the 90 AAL regions. The p-values were obtained
from the quantile regression analysis between the gene expression values and each of the three
connectivity metrics - those are the absolute difference between baseline and follow-up of local
efficiency, clustering coefficient and betweenness. Figure 4.7 summarizes this by 1) representing
the brain connectome without edges for each one of the connectivity metric, 2) each node
represents a distinct AAL region and is annotated with the name of the region, 3) the size of
each node is the sum -log10 of the regression coefficient associated p-vales for all the genes. The
color is assigned automatically by the BrainNet Viewer. Overall, although the gene contributions
to the absolute change in local efficiency have a similar pattern to that of clustering coefficient,
the contribution to betweenness centrality change is relatively small.
4.3.6 Regressing the difference in CDR on the difference in Global and Local Con-
nectivity. To asses the directed and undirected association of the longitudinal measures of
global connectivity and CDR scores, we calculated the difference between baseline and follow-
up visits for both CDR and global connectivity metrics , i.e. CDRbaseline − CDRfollow−up and
metricbaseline −metricfollow−up, respectively. The Spearman and quantile regression results are
both shown in Table 4.4. We observe that the increase in overall brain segregation - through
transitivity- reduces the memory over time (β = −6.14e − 06, p-value= 0.0034). On the other
hand, there is a positive association between the brain integration - through global efficiency-
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Figure 4.7: Connectome representations showing the metric additive genetic effect at each AAL
node. The subfigures show the axial (top; (a), (b) and (c)), coronal (middle; (d), (e) and (f)),
and sagittal (bottom; (g), (h) and (i)) planes of the brain, the node size represents the local
efficiency (left; (a), (d) and (g)), clustering coefficient (middle; (b), (e) and (h)) and betweenness
centrality (right; (c), (f) and (i)). Colors of the nodes are automatically assigned by the BrainNet
Viewer. The acronyms of the brain regions are explained in Appendix Table A1.
and home and hobbies.
Similarly, in Appendix Table A4 we looked at the monotonic effect of local connectivity metrics on
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Table 4.4: Quantile regression results of the difference in CDR (y) with the difference in global
connectivity (x)
Global Metric Threshold= 0.05
6
= 0.00833. ∗ represents significant p-value.
CDMEMORY CDORIENT CDJUDGE CDCOMMUN CDHOME CDCARE
Q. Regression: β (p-value)
transitivity -6.14e-06 (0.0034∗) -1.8e-06 (nan) -3.2e-07 (nan) 8.4e-07 (0.9249) 4.13e-06 (0.7324) -3.1e-07 (nan)
global eff 1.3e-06 (0.8572) 3.36e-06 (0.9944) 3.5e-07 (0.9826) 3.09e-06 (0.3131) 9.5e-06 (0.1613) -2.5e-07 (nan)
louvain -2.64e-06 (0.1683) -6.84e-06 (0.0352) 1.21e-06 (0.0012∗) -1.01e-06 (0.8125) -2.16e-06 (0.9424) -6.3e-07 (0.1787)
char path len -5.8e-07 (0.8562) -8.3e-07 (0.8791) -8e-08 (0.8637) -8.3e-07 (0.0361) -2.14e-06 (0.0442) -2e-08 (nan)
Spearman: ρ (p-value)
transitivity -0.3395 (0.021) -0.0763 (0.6142) -0.0618 (0.6835) 0.0661 (0.6623) 0.161 (0.2851) -0.0081 (0.9574)
global eff 0.0483 (0.7497) 0.0056 (0.9707) 0.0505 (0.7388) 0.2685 (0.0712) 0.4145 (0.0042∗) -0.0263 (0.8625)
louvain -0.1955 (0.1928) -0.3119 (0.0349) 0.2077 (0.166) -0.0968 (0.522) -0.11 (0.4666) -0.0628 (0.6784)
char path len -0.1183 (0.4337) -0.0516 (0.7333) -0.0281 (0.8531) -0.2909 (0.0498) -0.3811 (0.009) -0.0065 (0.9658)
the seven CDR scores, both represented as the subtraction of the follow-up visit from the baseline
visit. The increase in betweenness centrality was shown to have different effects on the CDR score
over the one-year time period. For example, as the betweenness centrality decreases over time, the
judgement and problem solving increases in severity by 1.06e-08 over time (p-value=1.32e-17),
in the frontal lobe (Frontal Inf Oper L).
4.3.7 Multivariate Analysis: Ridge Regression. Additionally, we regressed the difference in
CDR visits (response variable; Y), one score at a time, on both the difference in global brain
connectivity (predictor; X1), one connectivity metric at a time and all gene expression values
(predictor; X2), using the ridge regression model. Table 4.5 reports the mean squared error (the
score column) and shows the top hits in the multiple ridge regression. It shows that the α (alpha
column) could not converge, using the cross-validation, when the response variables were the
judgment or personal care. However, the CDR score results show that genes and connectivity
metrics have a small effect (β) on the response variables (the change in CDR scores over time),
and the larger effects were observed when using the total CDR score (CDR diff) as a response
variable. The expression of genes have negative and positive effects on CDR change, and so
are the connectivity metrics. The expression of ApoE, for example, has a negative effect (β) of
−0.24 on the change in memory score, i.e. the memory rating decreases by 0.24 as the ApoE
expression increases. While if the expression of ApoE increases one unit, the home and hobbies
score increases, over time, by 0.12.
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4.4 Discussion
Our results show that Alzheimer’s risk genes can manipulate the amount of change observed
in the structural connectome, measured as the absolute difference of longitudinal connectivity
metrics. Here, we show that longitudinal regional connectivity metrics, global brain segregation
and integration have effects on the CDR scores. More specifically, we observe a consistent
decrease, over time, in the local efficiency - a connectivity metric that measures the efficient flow
of information around a node (a brain region) in its absence (Rubinov and Sporns, 2010) - in
response to the increase in APP expression, at the right middle temporal gyrus (Temporal Mid R;
see Table 4.2). The same connectivity metric increases over time as the expression of HFE
increases, at the right anterior cingulate and paracingulate gyri (see Table 4.3). Furthermore, as
the disease progresses, we observe a correlation between brain segregation and cognitive decline,
the latter is measured as CDR memory scores. While if the brain becomes more integrated, as
measured by global efficiency; it results in an improved growth of home and hobbies scores (see
Table 4.4).
Prescott et al. (2014) have investigated the differences in the structural connectome in three
clinical stages of AD, using a cross-sectional study design, and targeted regional brain areas that
are known to have increased amyloid plaque. Their work suggested that connectome damage
might occur at an earlier preclinical stage towards developing AD. Here, we further adapted a
longitudinal study design and incorporated known AD risk genes. We showed how the damage in
the connectome is associated with gene expression, and that the change in connectome affects
dementia, globally and locally - at distinct brain regions. Aside from our previous work (Elsheikh
et al., 2018a), which examined the ApoE associations with longitudinal global connectivity in AD
using longitudinal global connectivity metrics, this study, to the best of our knowledge, is the
first of its type to include gene expression data with global and local brain connectivity. However,
similar work has been done in schizophrenia structural brain connectivity, where longitudinal
magnetic resonance imaging features, derived from the DTI, were associated with higher genetic
risk for schizophrenia (Alloza et al., 2018).
The results obtained here align with findings in the literature of genetics and neuroimaging.
Specifically, Robson et al. (2004) studied the interaction of the C282Y allele HFE - the com-
mon basis of hemochromatosis - and found that carriers of ApoE-4, the C2 variant in TF and
C282Y are at higher risk of developing AD. Moreover, the HFE gene is known for regulating
iron absorption, which results in recessive genetic disorders, such as hereditary haemochromatosis
(Pilling et al., 2019). According to Pujol et al. (2002), the association between the harm avoid-
ance trait and right anterior cingulate gyrus volume was statistically significant. In their study,
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they examined the association between the morphology of cingulate gyrus and personality in 100
healthy participants. Personality was assessed using the Temperament and Character Inventory
questionnaire. Higher levels of harm avoidance were shown to increase the risk of developing AD
(Wilson et al., 2011). We show here that HFE expression affects the local efficiency at the right
anterior cingulate gyrus (see Table 4.3 and Figure 4.6). This might indicate a possible effect of
HFE expression on the personality of AD patient or the person at risk of developing the disease.
Moreover, in this study we found that the Plasminogen activator, urokinase (PLAU) expression
affects the betweenness centrality (a measure of the region’s (or node) contribution to the flow of
information in a network (Rubinov and Sporns, 2010)) in the left fusiform gyrus, over time (see
Table 4.3 and Figure 4.6). Although the functionality of this region is not fully understood, its
relationship with cognition and semantic memory was previously reported (Galton et al., 2001).
PLAU, on the other hand, was shown to be a risk factor in the development of late-onset AD
as a result of its involvement in the conversion of plasminogen to plasmin - a contributor to the
processing of APP - by the urokinase-type plasminogen activator (uPA) (Finckh et al., 2003).
When examining the linear associations between gene expression and local connectivity (see Table
4.2 and Figure 4.5), we found that the right middle temporal gyrus, known for its involvement in
cognitive processes including comprehension of language, negatively associates with APP expres-
sion. Additionally, the left Heschl gyrus positively correlates with bleomycin hydrolase (BLMH)
expression. In the human brain, the BLMH protein is found in the neocortical neurons and senile
plaques (Namba et al., 1999), microscopic decaying nerve terminals around the amyloid occurring
in the brain of AD patients. Some studies (Papassotiropoulos et al., 2000; Farrer et al., 1998)
have found that a variant in the BLMH gene, which leads to the Ile443→Val in the BLMH pro-
tein, increases the risk of AD; this was strongly marked in ApoE-4 carriers. The BLMH protein
can process the Aβ protein precursor and is involved in the production of Aβ peptide (Kajiya
et al., 2006).
Even though none of the AD risk genes showed a significant effect on the longitudinal change
in global connectivity (see Appendix Tables A3 and A2), the genes showed significant effects
on local connectivity changes at regional brain areas (see Table 4.3 and Table 4.2). The global
connectivity metrics of the brain, on the other hand, have shown promising results in affecting
the change observed in CDR scores, including memory, judgement and problem solving, as well
as home and hobbies, as shown in Table 4.4. Previous work studied the association between
genome-wide variants and global connectivity of Alzheimer’s brains, represented as brain integra-
tion and segregation, and found that some genes affect the amount of change observed in global
connectivity (Elsheikh et al., 2020b). This suggests that a generalisation of the current study at
a gene-wide level might warrant further analysis.
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Our work provides new possible insights, though replication on a larger sample size is required.
Indeed, one limitation here was the small sample size available. We needed to narrow down
our selection of participants to those attended both baseline and follow-up visits, and have CDR
scores, genetic and imaging information available. Another limitation is given by the use of only
two time points, the baseline and the first follow-up visit. This does not allow capturing the effects
of connectivity changes in a longer-term or studying the survival probabilities in AD. Extending
to more time points would have been useful, but it would have further reduced the dataset.
We foresee future work in using a more complex unified multi-scale model, to facilitate studying
the multivariate effect of clinical and genetic factors on the connectome, besides considering the
complex interplay of genetic factors.
In summary, in this chapter we conducted an association analysis of targeted gene expression with
various longitudinal brain connectivity features in AD. Aiming at estimating the neurodegeneration
of the connectome, we obtained local and global connectivity metrics at two visits, baseline and
follow-up, after 12 months. We calculated the change between the two visits and carried out an
association analysis, using quantile and ridge regression models to study the relationship between
gene expression and disease progression globally and regionally at distinct areas of the brain. We
tested the effect of the change in connectivity on the longitudinal CDR scores through quantile
regression. Furthermore, using a ridge regression model, we controlled for the genetic effects in
the previous settings to study the effect of connectivity changes on the CDR change.
The present analysis was conducted in AD using a longitudinal study design and highlighted the
role of PLAU, HFE, APP and BLMH in affecting how the pattern information is propagated in
particular regions of the brain, which might have a direct effect on a person’s recognition and
cognitive abilities. Furthermore, the results illustrated the effect of brain structural connections
on memory and cognitive process of reaching a decision or drawing conclusions. The findings
presented here might have implications for better understanding and diagnosis of the cognitive
deficits in AD and dementia.
Chapter 5
BiGen: Integrative Clinical and
Brain-Imaging Genetics Analysis Using
Structural Equation Model
Abstract
The identification of genetic variants associated with complex brain diseases has evolved in the
past decades. Studies in the field have taken different approaches and study designs includ-
ing genome-wide association studies. Neuroimaging and connectomics have also improved our
understanding of the structural connectivity of the human brain and produced reliable measure-
ments. Combining both neuroimaging and genetic characteristics significantly contributes to
understanding their complex role in affecting behaviour and cognition. Throughout this thesis
we used different analysis pipelines to study the association between imaging and genetics of two
different types of brain disease, Alzheimer’s disease and glioblastoma. In performing the analy-
ses, we identified the need for a unified model to study the complex interplay between genetic,
environmental and clinical, neuroimaging and phenotype features. In this chapter, we developed
BiGen, a mathematical model to measure the inter-correlation structure through the integration
of genetic, environmental, neuroimaging and disease measurements. We utilised the structural
equation model and used a path construct of latent variables to study the hidden association
between genes and brain-related diseases, mediated by connectivity characteristics. We applied
BiGen to simulated data and to the dataset from the Alzheimer’s Disease Neuroimaging Initiative.
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5.1 Introduction
Imaging genetics is a rapidly growing field that focuses on the identification of genetic variants
associated with complex brain diseases. In doing so, imaging genetics combines brain imaging
technology output with genetic data. Depending on the hypothesis of interest and data availabil-
ity, imaging genetics studies can focus on 1) the association between each location in the brain,
namely voxel, with each single nucleotide polymorphism (SNP), e.g. Voxelwise Genome-Wide
Association Study (vGWAS) (Stein et al., 2010; Shen et al., 2010), 2) the relationship between a
single phenotype, such as the hippocampus volume, these studies are called candidate phenotype
studies (Stein et al., 2012), or 3) consideration of multiple imaging endophenotype associations
with candidate genotypes.
Recently, brain connectivity and other magnetic resonance imaging (MRI) features have been
used as phenotypes in GWAS and other omic studies. Brain connectivity metrics are derived from
the connectome - a representation of the brain as a single network extracted from the diffusion
tensor imaging (DTI) (Sporns et al., 2005). The nodes of a connectome represent distinct regions
in the brain and the links are the water tracts connecting each pair of regions. Some studies
used GWAS with connectivity metrics to study the healthy brain (JahanshAD et al., 2013),
Alzheimer’s Disease (AD) (Elsheikh et al., 2020b), and other brain diseases (Alloza et al., 2018;
Thompson et al., 2010). Imaging genetics uses a variety of study designs that integrate specific
genetic information (Thompson et al., 2010), in this thesis and paper Elsheikh et al. (2019a), for
example, studied the effect of targeted gene expression on local and global connectivity features
in AD.
The recent imaging genetics literature has proposed multivariate methods to understand the influ-
ence of multidimensional genotypes on multi-phenotype imaging characteristics. As summarised
by Liu and Calhoun (2014); the multivariate methods in the field of imaging genetics need to con-
sider three factors; 1) the dimensionality of genotypes and intermediate neuroimaging phenotypes,
2) the importance of managing the confounding factors in order to reveal the imaging phenotypic
effects, 3) the population structure of the sample under study. Considering these criteria, previous
studies proposed multivariate analysis methods utilising sparse reduced-rank regression (Vounou
et al., 2010), sparse partial least square (Le Floch et al., 2012), parallel independent and principal
component analysis (Liu et al., 2009) and sparse canonical correlation analysis (Chi et al., 2013).
Other methods considered longitudinal multivariate imaging genetics pipelines to study the rela-
tionship of gene expression and genome-wide variants with brain connectivity metrics (Elsheikh
et al., 2018a, 2020b, 2019a; Lu et al., 2017).
The structural equation model (SEM) (Bollen and Long, 1993) is a multivariate technique that
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studies the complex causal relationship between a set of endogenous and exogenous latent con-
structs through measured or observed variables. SEM estimates the structural relationship be-
tween the latent variables using a set of multiple regression models and factor analysis. Recently,
SEM has been applied in the context of mapping genotype and phenotype in complex diseases and
imaging genetics. Specifically, SEM is a promising tool in merging gene regulatory networks with
post-GWAS approaches to improve the understanding of cell signaling, and metabolic pathway
translation into phenotypes (Nuzhdin et al., 2012). Grotzinger et al. (2018) proposed Genomic
SEM, a tool that identifies between-diseases similarity and genetic architecture, with an applica-
tion to psychiatric disorders. Huisman et al. (2018) applied the SEM to understand the spatial
change within brain regions affected by gene expression using a dataset from Alzheimer’s Disease
Neuroimaging Initiative (ADNI). They used healthy brain information from spatial transcriptome
datasets to identify the model construct.
Here, we propose a method to identify the causal effect of genetics on multiple phenotypes, includ-
ing neuroimaging and disease measures. We utilised the structural equation model to estimate the
association between various latent constructs, including disease, endophenotypes, covariants and
genetics. In our model, the latent variables were estimated using observed measurements and the
relationship between disease and genetics was estimated accounting for the intermediate effect of
neuroimaging endophenotype. The latent genetic variable was measured through observed gene
expression, considering the interaction of proteins, while the disease and endophenotype latent
variables were measured through the Clinical Dementia Ratings (CDR) and global connectivity
metrics, respectively. Moreover, we controlled for confounding factors through a separate latent
construct, inferred from some environmental factors. We applied the new tool to simulated data
and a dataset from ADNI.
5.2 Materials and Methods
In this section we describe our proposed SEM model, BiGen. The model has two parts, the
structural model and the measurement model which are described in the following sub-sections.
Thereafter we discuss the estimation of these models.
5.2.1 Structural Model. The structural model in a SEM relates the exogenous and endogenous
latent variables (construct) and studies their associations. The advantage of using latent variables
is to control for the measurement errors on the overall SEM. In BiGen, the structural model
consists of four latent variables, these are genetics, confounders, endophenotypes and disease.
These four latent constructs are measured through some genetic measurements, environmental
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and other risk factors, neuroimaging characteristics and disease measures of interest. See Figure
5.1 where latent variables are shown as circles.
Figure 5.1: The BiGen model showing the latent variables (in circles) and the observed mea-
surements (rectangles). The structural model shows latent variables and the relationship between
them, while the measurement models connects the measurement variables with latent constructs.
5.2.2 Measurement Model. The measurement model focuses on the relationship between
latent variables and their observed measurements (indicators). The measurements are shown as
rectangles in Figure 5.1. Specifically, in BiGen, the genetics and confounding factors constructs
relate to the endophenotypes. The endophenotypes have one direct relationship with the disease
construct. Moreover, the endophenotypes mediate between genetic (and confounding factors)
and the disease construct. This mediation is considered to account for the indirect effects of
genetic factors on the disease through the endophenotypes. BiGen analyses the effect of genetic-
endophenotype interaction on the disease.
5.2.3 Model Estimation. We applied the BiGen model to an AD dataset from ADNI. In
this case, the constructs were measured and inferred from a set of observed measurements.
Specifically, the genetics construct was measured through gene expression values that interact
with one another. These gene expression values correlate the measurements of other latent
variables with the genetics construct. The confounding factors are the random effects or other risk
factors that are not genetics. Here, other risk factors, if available, could be used as measurements
for the latter construct, such as blood pressure, cholesterol level and heart diseases. A set of
global connectivity metrics were used to measure the endophenotypes construct. In this work
we used the global connectivity metrics, namely, global efficiency, Louvain modularity, transitivity
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and characteristics path length. Finally, the disease construct was measured through a set of
clinical dementia ratings. Section 5.2.4 and Section 5.2.5 explain the simulated and AD datasets
in more detail, respectively.
The structural model consists of two exogenous constructs (Figure 5.1), these are genetics and
confounding factors, and two endogenous constructs, endophenotypes and disease. To estimate
the SEM we followed two estimation steps. In the first step, we estimated the latent variable
scores through an iterative algorithm that does not assume any distribution of the measurements
or constructs. In doing so, we adjusted the partial least squares (PLS) SEM iterative algorithm
proposed by Lohmöller (1989). The approach estimates the latent scores in four iterative steps
until a stop criteria is met. The second step estimates the path coefficients and outer weights
through ordinary least square models. This basic PLS algorithm has been applied successfully
to many fields, including advertising research (Henseler et al., 2012). In our model, we used
non-parametric methods and a summary of the steps we adopted is provided below.
In our first step, we followed a set of sub-steps that aim to estimate the latent scores iteratively
until convergence. More specifically, considering the notation shown in Figure 5.2, the first sub-
step is to estimate wij for all the measurement models connecting xij with yj. Initially, we
initialised these weights to 1, and updated them iteratively. The second sub-step is to estimate
the inner weights (bik; see Figure 5.2). This is followed by an approximation of the latent variables
(y∗i ), and in the last sub-step we estimate the outer weights. These four sub-steps are summarised
below. The tolerance is calculated at the end of each iteration, and this is simply the difference
between the current outer weight and the previous one. The threshold here was set to 1e− 6.
1. External approximation of latent variables, yi =
∑
wx
2. Estimation of inner weights, bik = ρik, then normalize.
3. Internal approximation of latent variables, y?i =
∑
by
4. Estimation of outer weights, w = ρxy? (where ρ is Spearman correlation coefficient), then
normalize.
As a second step, BiGen estimates the final path coefficients and outer weights through a (quan-
tile) regression model. Besides the inner model shown in Figure 5.1, BiGen calculates the inner
of the interaction terms: genetics×endophenotype and confounding factors×endophenotype and
estimates their effect on the disease.
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Figure 5.2: Notation used in model estimation. The left box represents the measurement model,
and the right box represents the structural model. The outer weights (wi1, wi2 . . . wij) connect
the indicators (xi1, xi2 . . . xij) to the latent variable yi. The inner weight (bik) associates the
latent variables in the structural model (yi and yk).
5.2.4 Simulated Data. We simulated a dataset to test BiGen and compare it to the PLS-
SEM. Firstly, we randomly generated a single continuous measurement variable of the disease
construct. We then created another two measurement variables with strong correlation with
the first measure, but with some randomness. We simulated three connectivity variables that
are associated with one another, and to the three measures of the disease measurements, with
some randomness. Similarly, we simulated the genetic and confounding factor measures (three
for each).
To simulate the variables, we used a random range of parameters. Specifically, we simulated
12 variables as described above, each follow a random distribution with different mean (ranges
between 100 and 300) and standard deviation (ranges between 2 and 18). Figure 5.3 shows the
distribution of the simulated data, while the pattern of association between the variables is shown
in Figure 5.4. The sample size of the simulated data is 5000.
5.2.5 Alzheimer’s Disease Dataset. We also applied our model to an AD dataset from ADNI
(available at adni.loni.usc.edu). Specifically, we used the information of ADNI participants as
measurement variables to fit our proposed model (as shown in Figure 5.1). For the 1) disease,
2) endophenotypes, 3) confounding factors and 4) genetics we used the following measurements;
1) three CDR measures, namely, memory, judgment and problem solving, and home and hobbies
scores, 2) the global connectivity metrics, namely, Louvain modularity, transitivity, global efficiency
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Figure 5.3: The distribution of all the simulated measurement variables used to fit the proposed
BiGen model.
and characteristics path length (all explained in Section 4.2.2), 3) the education level and gender
of participants, and 4) the expression of a set of genes that interact with one another, namely
APP, SORL1, ADAM10, ApoE and PSEN1. We obtained the expression values following the
same steps explained in 4.3.2. The protein-protein interaction data were derived from STRING
database (v11.0), accessed at https://string-db.org (Szklarczyk et al., 2014, 2018). We used the
absolute difference between the baseline and follow-up visits for the disease and endophenotypes
measurements. Figure 5.5 shows the distribution of all pre-described measurements, while Figure
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Figure 5.4: The association pattern between all the measurement variables from the simulated
data.
5.6 shows their association patterns. In total, we managed to obtain 46 samples.
Software
To conduct the analysis described here, we used Python 3.7.1 and made our scripts available
under the MIT License and accessible at: https://github.com/elssam/BiGen.
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Figure 5.5: The distribution of all the measurement variables obtained from ADNI dataset and
used to fit the proposed BiGen model.
5.3 Results
5.3.1 Evaluation using Simulated Data.
PLS-SEM
Using the simulated measurement variables described in Section 5.2.4 we fitted, firstly, the PLS-
SEM, the path coefficient and inner weights are both shown in matrices 5.3.1, and the interaction
terms (described in Section 5.2.3) inner weights are shown in matrix 5.3.2. We then fitted BiGen
(as described in 5.2.3) to the same data and obtained the path and inner weights that are shown
in matrices 5.3.3, similarly, we obtained the inner weights estimates for the interactions, this is
shown in matrix 5.3.4.
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Disease1 : 0.353 0. 0. 0.
Disease2 : 0.371 0. 0. 0.
Disease3 : 0.378 0. 0. 0.
Endo1 : 0. 0.359 0. 0.
Endo2 : 0. 0.347 0. 0.
Endo3 : 0. 0.357 0. 0.
Gene1 : 0. 0. 0.360 0.
Gene2 : 0. 0. 0.429 0.
Gene3 : 0. 0. 0.414 0.
Enviro1 : 0. 0. 0. 0.432
Enviro2 : 0. 0. 0. 0.411




Disease : 0. 0. 0. 0.
Endo : 0.959 0. 0. 0.
Genetics : 0. 0.878 0. 0.
Enviro 0. 0.892 0. 0.

(5.3.1)
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PLS-SEM wtih Interaction
inner
 Disease : 0. 0. 0.Gene Endo : -0.0293 0. 0.





0.353 0. 0. 0.
0.372 0. 0. 0.
0.378 0. 0. 0.
0. 0.360 0. 0.
0. 0.345 0. 0.
0. 0.357 0. 0.
0. 0. 0.358 0.
0. 0. 0.430 0.
0. 0. 0.414 0.
0. 0. 0. 0.432
0. 0. 0. 0.412




0. 0. 0. 0.
0.958 0. 0. 0.
0. 0.882 0. 0.




 0. 0. 0.0.01230 0. 0.
-0.00260 0. 0.
 (5.3.4)
5.3.2 Application to ADNI. Then, we applied both BiGen and SEM-PLS to the AD measure-
ment variables discussed in Section 5.2.5. Similarly, we considered the interaction model in both
applications. The path coefficient and inner weights obtained from applying the PLS-SEM are
both shown in matrices 5.3.5, while the interaction inner weights are shown in matrix 5.3.6. We
then fitted BiGen to the AD dataset and the results of the path and inner weights are shown in
matrices 5.3.7. We finally computed the inner weights estimates for the interactions (see matrix
5.3.8).
Generally, we observe that applying BiGen and PLS-SEM to the simulated data gave the same
results (compare: matrices 5.3.1 vs matrices 5.3.3, and matrix 5.3.2 vs matrix 5.3.4), however,
in the AD application the two models gave slightly, though not significantly different results
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(compare: matrices 5.3.5 vs matrices 5.3.7, and matrix 5.3.6 vs matrix 5.3.8). We observe
that BiGen produced different effects of the inner path (inner matrix 5.3.7) compared to PLS-
SEM (inner matrix 5.3.5) when applied to ADNI dataset. The overall effect of the genetic and
confounding factor latent constructs on the endophenotype are 0.113 and 0.216 in BiGen, while
they are -0.337 and -0.150 in PLS-SEM. Though none of these were statistically significant,
we observe that the contribution of genetic factors to the endophenotype are lower in BiGen,
the positive sign indicates the direction of the relationship. This might indicate that PLS-SEM
overestimates the inner path effect of genetic construct on the endophenotype and underestimates




Memory : 2.958e-01 0. 0. 0.
Judge : -6.640e-04 0. 0. 0.
Home : 9.039e-01 0. 0. 0.
T ransitivity : 0. -9.517e-02 0. 0.
Global eff : 0. -4.127e-01 0. 0.
Louvain : 0. 1.640e-01 0. 0.
Char path len : 0. 4.520e-01 0. 0.
APP : 0. 0. -1.659e-01 0.
SORL1 : 0. 0. 1.720e-01 0.
ADAM10 : 0. 0. 5.762e-01 0.
ApoE : 0. 0. -7.060e-01 0.
PSEN1 : 0. 0. 3.970e-01 0.
Educat : 0. 0. 0. 9.896e-01




Disease : 0. 0. 0. 0.
Endo : 0.280 0. 0. 0.
Genetics : 0. -0.337 0. 0.





 Disease : 0. 0. 0.Gene Endo : -0.1212 0. 0.
Enviro Endo : 0.1658 0. 0.
 (5.3.6)




Memory : 0.390 0. 0. 0.
Judge : -0.211 0. 0. 0.
Home : 0.839 0. 0. 0.
T ransitivity : 0. 0.063 0. 0.
Global eff : 0. -0.380 0. 0.
Louvain : 0. 0.310 0. 0.
Char path len : 0. 0.426 0. 0.
APP : 0. 0. -0.554 0.
SORL1 : 0. 0. 0.292 0.
ADAM10 : 0. 0. 0.079 0.
ApoE : 0. 0. -0.386 0.
PSEN1 : 0. 0. 0.444 0.
Educat : 0. 0. 0. 1.009




Disease : 0. 0. 0. 0.
Endo : 0.207 0. 0. 0.
Genetics : 0. 0.113 0. 0.
Enviro : 0. 0.216 0. 0.

(5.3.7)
Similarly, the interaction terms were smaller when we fit BiGen to the ADNI dataset compared to
PLS-SEM (compare the BiGen inner interaction terms in matrix 5.3.8 vs SEM-PLS inner inter-
action terms in matrix 5.3.6). Our overall explanation of these results, including the simulation
results, is that the simulated data are made to be symmetric and normally distributed, therefore,
both the PLS-SEM and BiGen models offer a similar performance, while in the ADNI application,
the pattern of distribution is not symmetric and the data types are different, which is always
the case in real life applications. However, we believe that more samples are needed to better
understand the performance of BiGen in the ADNI dataset.
Table 5.1 shows a brief comparison of the PLS-SEM and BiGen results in the application to
simulation and ADNI datasets. We note that both BiGen and PLS-SEM were fast (see the Time
column), even though the ADNI application needed more iterations in both models. To get the
interaction terms, the same calculations in the original model are performed, except that we need
to estimate different path coefficients in the second step (see Section 5.2.3).
BiGen with Interaction
inner
 Disease : 0. 0. 0.Gene Endo: 0.0014 0. 0.
Enviro Endo: -0.0068 0. 0.
 (5.3.8)
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Table 5.1: SEM, BiGen with and without interaction results for simulated and AD dataset.
Application Simulation AD
Iterations Tolerance Time∗,‡ Iterations Tolerance Time
SEM 2 7.918e− 08 202 ms+ 23 6.702e− 07 241 ms
SEM (interaction) 2 7.918e− 08 189 ms 23 6.702e− 07 184 ms
BiGen 2 1.367e− 07 502 ms 26 0.000 1.32 s†




‡ Program was ran using Jupyter nootebook in a Debian 9 operating system, model: Intel(R)
Core(TM) i5-3230M CPU @ 2.60GHz.
The main difference between the above results and what was done in Chapters 3 and 4 is that
here we did not explicitly test the pairwise associations of the observed measurement variables
(e.g, global connectivity vs gene expression), but rather, we tested their combined association
through the latent constructs (e.g. the effect of genetic on the endophenotype), this was finally
estimated by the inner weights, shown in the matrices above. For example, Table A2 shows that
global connectivity metrics associated with the expression of APP, ADAM10, ApoE and PSEN1
with correlation coefficients −0.2602 (characteristic path length), −0.236 (Louvain modularity),
−0.25 (characteristic path length) and −0.299 (transitivity). On the other hand, BiGen can
not measure the association in the same way, but rather, 1) we observe the contribution of
the previous gene expression on the genetic construct, these are −0.554, 0.079,−0.386, 0.444,
respectively (see outer matrix 5.3.7), 2) BiGen also allows measuring the effect of the genetic
construct on the endophenotype, and that was 0.113 (see inner matrix 5.3.7).
In Chapter 3 we conducted a GWAS on the ADNI dataset and integrated the summary statistics
obtained from GWAS at a gene-wide level, we found that some genes were significantly associated
with global connectivity metrics (e.g ANTXR2, IGF1 and OR5L1). However, to study the effect
of these genes using BiGen, we considered the protein-protein interactions, and incorporate other
factors shown in Figure 5.1. Additionally, In Chapter 4, we tried to test different hypotheses
individually, we tested the effect of gene expression on the connectivity metric using both quantile
regression and Spearman association coefficient, we then examined the effect of brain connectivity
on the CDR measurements, after which we tested their combined effect on the CDR measurements
using ridge regression. BiGen allows us to test all these hypotheses (including the interaction
terms between them) simultaneously in only two steps and with less computational complexity.
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5.4 Conclusion
The SEM is a commonly multivariate technique used in many scientific fields, it studies the
structural relationships between variables that are hard to measure directly. Analysing imaging
genetics data needs not only a multivariate technique, but also one that considers the complexity,
heterogeneity and multicollinearity of both the imaging and genetics parts. Here we propose
BiGen, a Python tool that analyses the structural relationship between four constructs simul-
taneously, these are, genetics and disease, mediated by the neuroimaging endophenotypes and
considering some environmental or confounding factors. All the four latent constructs are mea-
sured through observed indicators and the model is specifically made for brain-related disease,
with an application to Alzheimer’s disease through ADNI data. BiGen adjusts the PLS-SEM by
using non-parametric regression and association tests in estimating the path model and latent
variable scores, respectively. This causal predictive model is flexible, simple and computationally
inexpensive. Additionally, BiGen has a satisfactory performance in small samples and assumes no
distribution or hypothesis of the data.
Our model can easily be extended to include more indicators and constructs. For example, one
can add more imaging phenotypes, or rather, incorporate the local connectivity metrics to the
endophenotype latent construct. Moreover, the model is flexible to more complexity in the path
model, this is especially useful when studying the direct relationship between genetics and disease
phenotypes, or the gene-environment interaction effects on the disease or endphenotypes. Over
all, we propose that BiGen is suitable for unveiling the complex interplay between neuroimaging
and genetics in the context of brain-related diseases.
Although there are some limitations of SEM related to causality inference as a result of fitting
multiple linear models which require certain assumptions to be met (Rockman, 2008), our model
tries to avoid some through normalisation of the variables. However, the linearity assumptions of
the relationship between the dependent and independent variable remains unsolved here.
Chapter 6
General Discussion
In this thesis, we studied a brain disease with local lesions (we considered GBM), then we looked
at a widespread brain disease which affects the overall brain structure, we considered AD in
this part. We tested different hypotheses to understand the association between neuroimaging
characteristics (e.g. brain connectivity and tumour texture and spatial characteristics) and multi-
omic factors (including genome-wide variations and transcriptomic data). We observed the need
for one unified model to study the complex interplay between genetic, environmental and clinical,
neuroimaging and phenotype features. We introduced a novel model which can test complex
hypotheses in the field of imaging genetics, study the effect of interaction terms on the final
phenotype, and accommodate heterogeneous data types including phenotype measurements, brain
connectivity, environmental and multi-omic factors. Our model was fast, simple, flexible and
assumes no distribution of the data.
Our brains are vulnerable to different disorders that affect our everyday functionality, mental and
cognition abilities. Neurodegenerative diseases attack the neurones and consequently reflect in
a fast cognitive decay. Alzheimer’s disease (AD) is a neurodegnarative disease with an average
survival of 4 - 8 years after diagnosis (Gaugler et al., 2019). In the early disease stages, biological
changes in the brain start occurring slowly, these include the abnormal accumulation of tau beta-
amyloid proteins. AD progression is relatively slow at first, however, it worsens over time as it
approaches the later stages. The cognitive decline starts to become obvious and the change in
brain structure becomes measurable through MRI technologies. Even though AD’s risk increases
with age, AD is rather a complex disease which develops as a result of many factors, including
genetics.
The ongoing advancement in brain imaging techniques coupled with the vast genetic data avail-
able presents an opportunity for advancing research in the field of imaging genetics. Genome-wide
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Association Studies (GWAS) have shown success in identifying the genetics of Alzheimer’s disease
(Lambert et al., 2013; Escott-Price et al., 2014). Moreover, recent discoveries in neuroscience
have provided the field with better characterization of the brain through connectomics Hagmann
et al. (2008). The connectome summarises the brain as one network, extracted from the diffusion
tensor/weighted imaging. The nodes of a connectome segment the brain into distinct regions that
are connected through edges, these edges are formed/weighted by the water tracts connecting
each pair of regions. In many ways, connectomics are used to quantify and study the structural
connectivity in the brain; with a special success in understanding the mechanisms and characteris-
tics of AD (Brown et al., 2011; Elsheikh et al., 2018a). Using connectomic phenotypes in GWAS
and next generation sequencing research has successfully revealed disease-associated variants in
AD Cuyvers and Sleegers (2016). Despite the progress made, we lack an understanding of how
the AD connectome progresses over time in relation to the genetic factors.
While neurodegenerative diseases affect connectivity across the brain, brain tumors, on the other
hand, are a mass of abnormal cells, which originate in the brain and affect particular regions.
Malignant brain tumors are fast growing, and often recur after resection. Glioblastoma multiforme
(GBM) is the fourth grade of glioma brain tumor, which is malignant. It is caused by the glial cells
that support the nerve cell functionality in the brain. GBM is hard to treat and patients have a
median survival time of 11-15 months, eventually, it leads to death. In this project, we also studied
the diagnosis and prognosis in a highly heterogeneous population of patients with glioblastoma
(Elsheikh et al., 2018b). We used several radiomic methods to identify genetic differences between
tumors, by means of non-parametric Spearman associations. We used a publicly available dataset
from the Cancer Genome Atlas (TCGA) and the associated brain imaging from The Cancer
Imaging Archive (TCIA). Both datasets are well-vetted and publicly available. We used the multi-
modal MRI scans, provided by TCIA, to compute the spatial and texture features of GBM tumor,
and correlate this with gene-wide expression data. Our results found a group of genetic markers,
including EPGN, LRRC46, TCN1, OR2AE1, TUBA1C and ZNF284, whose expression strongly
correlate with some of spatial and radiomic tumor features, though no significant associations
were found.
On the other hand, we proposed simple ways to determine the longitudinal changes in the struc-
tural brain connectome using datasets of longitudinal diffusion weighted imaging and allele fre-
quencies in single nucleotide polymorphisms (Elsheikh et al., 2020b), using data provided by the
Alzheimer’s Disease Neuroimaging Initiative (ADNI). We evaluated the contribution of genetic
variations to the brain connectome changes in healthy individuals, early mild cognitive impaired
and Alzheimer’s patients. Specifically, we utilized the global connectivity metrics of the structural
connectome, namely the segregation and integration features (Rubinov and Sporns, 2010), at two
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time points to quantify the longitudinal changes. We used these to carry out a GWAS and utilised
the 1000 Genomes reference population to obtain the gene- and pathway-scores. We believe this
analysis is the first of its type to associate the longitudinal shift in the structural connectome
with whole genome variants besides our initial work in this thesis, which studies the correlation
between gene expression and connectivity metrics (Elsheikh et al., 2019a). Our analysis success-
fully identified genetic variants that associate with the structural connectivity changes in AD.
Some of the identified variants have been previously reported to be associated with the risk of
developing AD and other neurodegenerative diseases (De Ferrari et al., 2007; Kang et al., 2010;
Young et al., 2012; Nicolas et al., 2013).
Aiming to understand the effects of multiple factors on the progression of AD, we also conducted
an integrated association analysis of gene expression with longitudinal connectivity metrics and
dementia severity measures. We examined these associations globally and regionally at distinct
parts of the brain. These segments are based on the automated anatomical labeling segmentation
(Elsheikh et al., 2018a). We retrieved the risk genes that are known for their manipulation of
Alzheimer’s risk and examined the relationship of their expression with the change in clinical
dementia ratings and connectivity metrics. Moreover, using multivariate ridge regression, we
studied the effect of brain connectivity changes and gene expression on dementia progression,
using non-parametric associations and quantile regression. We show that expression of some gene,
namely, HFE, PLAU, BLMH and APP affect the brain activities in the right anterior cingulate,
Fusiform gyrus, Heschl gyrus and middle temporal gyrus in AD, respectively. Comparing these
patterns of association with previous discoveries (Robson et al., 2004; Pujol et al., 2002; Finckh
et al., 2003; Papassotiropoulos et al., 2000), our results suggest that the level at which these
genes are expressed can cause changes in the pattern of connectivity in the AD brain.
To improve such studies we also developed a distribution-free, robust, fast and unbiased imaging
genetics model, BiGen (Elsheikh et al., 2020a), using the idea of the partial least square (PLS)
structural equation model (SEM) Lohmöller (1989). The code is written in Python and is made
available and accessible online. BiGen integrates neuroimaging, multi-omic and clinical character-
istics to analyse brain-related diseases. We applied the model to Alzheimer’s dataset from ADNI
repository and tested it on simulated data. We examined different hypotheses to understand the
multivariate relationship and effect of genetic, endophenotypes - measured as brain connectivity
metrics - and other confounding factos on the disease phenotypes. Here we used a four-step
iterative algorithm to estimate the latent variables of the model, after which we estimated the
inner path parameters using a quantile regression and included some interaction terms.
In conclusion, we proposed non-parametric analysis pipelines and developed a robust method us-
ing the idea of SEM to study the effect of genetic variations on multi-dimensional neuroimaging
Page 104
phenotypes. We believe our findings and proposed model are useful in understanding the com-
plex molecular heterogeneity underlying glioblastoma and AD. Consequently, this can facilitate
a genetic diagnosis and personalized therapy. We also identified genes and variants that affect
the connectivity at particular anatomical regions in the brain, which is useful in uncovering the
effects of genetics on the brain connectivity structure for further improvement of patient care.
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Céline Bellenguez, Gyungah Jun, Anita L DeStefano, Joshua C Bis, Gary W Beecham, et al.
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease.
Nature genetics, 45(12):1452, 2013.
Philippe Lambin, Emmanuel Rios-Velazquez, Ralph Leijenaar, Sara Carvalho, Ruud GPM van
Stiphout, Patrick Granton, Catharina ML Zegers, Robert Gillies, Ronald Boellard, André
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Lai, Manuela Uda, David Schlessinger, Gonçalo R Abecasis, Luigi Ferrucci, et al. Genome-wide
association scan of trait depression. Biological psychiatry, 68(9):811–817, 2010.
Jigisha P Thakkar, Therese A Dolecek, Craig Horbinski, Quinn T Ostrom, Donita D Lightner,
Jill S Barnholtz-Sloan, and John L Villano. Epidemiologic and molecular prognostic review of
glioblastoma. Cancer Epidemiology and Prevention Biomarkers, 23(10):1985–1996, 2014.
Paul M Thompson, Nicholas G Martin, and Margaret J Wright. Imaging genomics. Current
opinion in neurology, 23(4):368, 2010.
Paul M Thompson, Jason L Stein, Sarah E Medland, Derrek P Hibar, Alejandro Arias Vasquez,
Miguel E Renteria, Roberto Toro, Neda Jahanshad, Gunter Schumann, Barbara Franke, et al.
The enigma consortium: large-scale collaborative analyses of neuroimaging and genetic data.
Brain imaging and behavior, 8(2):153–182, 2014.
Paul M Thompson, Derrek P Hibar, Jason L Stein, Gautam PrasAD, and Neda JahanshAD.
Genetics of the connectome and the enigma project. In Micro-, Meso-and Macro-Connectomics
of the Brain, pages 147–164. Springer, 2016.
Betty M Tijms, Peggy Seriès, David J Willshaw, and Stephen M Lawrie. Similarity-based extrac-
tion of individual networks from gray matter MRI scans. Cerebral cortex, 22(7):1530–1541,
2012.
Nathalie Tzourio-Mazoyer, Brigitte Landeau, Dimitri Papathanassiou, Fabrice Crivello, Olivier
Etard, Nicolas Delcroix, Bernard Mazoyer, and Marc Joliot. Automated anatomical labeling of
activations in spm using a macroscopic anatomical parcellation of the mni MRI single-subject
brain. Neuroimage, 15(1):273–289, 2002.
REFERENCES Page 127
Caroline Van Cauwenberghe, Christine Van Broeckhoven, and Kristel Sleegers. The genetic
landscape of Alzheimer disease: clinical implications and perspectives. Genetics in Medicine,
18(5):421, 2016.
Marquis P Vawter, Simon Evans, Prabhakara Choudary, Hiroaki Tomita, Jim Meador-Woodruff,
Margherita Molnar, Jun Li, Juan F Lopez, Rick Myers, David Cox, et al. Gender-specific gene
expression in post-mortem human brain: localization to sex chromosomes. Neuropsychophar-
macology, 29(2):373, 2004.
Roel GW Verhaak, Katherine A Hoadley, Elizabeth Purdom, Victoria Wang, Yuan Qi, Matthew D
Wilkerson, C Ryan Miller, Li Ding, Todd Golub, Jill P Mesirov, et al. Integrated genomic analysis
identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in pdgfra,
idh1, egfr, and nf1. Cancer cell, 17(1):98–110, 2010.
Peter M Visscher, Naomi R Wray, Qian Zhang, Pamela Sklar, Mark I McCarthy, Matthew A
Brown, and Jian Yang. 10 years of gwas discovery: biology, function, and translation. The
American Journal of Human Genetics, 101(1):5–22, 2017.
Maria Vounou, Thomas E Nichols, Giovanni Montana, Alzheimer’s Disease Neuroimaging Initia-
tive, et al. Discovering genetic associations with high-dimensional neuroimaging phenotypes:
A sparse reduced-rank regression approach. Neuroimage, 53(3):1147–1159, 2010.
Xun-Heng Wang, Yun Jiao, and Lihua Li. Mapping individual voxel-wise morphological connec-
tivity using wavelet transform of voxel-based morphology. PloS one, 13(7):e0201243, 2018.
M Watanabe, R Tanaka, and N Takeda. Magnetic resonance imaging and histopathology of
cerebral gliomas. Neuroradiology, 34(6):463–469, 1992.
Patrick Y Wen, David R Macdonald, David A Reardon, Timothy F Cloughesy, A Gregory Sorensen,
Evanthia Galanis, John DeGroot, Wolfgang Wick, Mark R Gilbert, Andrew B Lassman, et al.
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-
oncology working group. J Clin Oncol, 28(11):1963–1972, 2010.
Tonya White, Jan van der Ende, and Thomas E Nichols. Beyond bonferroni revisited: concerns
over inflated false positive research findings in the fields of conservation genetics, biology, and
medicine. Conservation Genetics, pages 1–11, 2019.
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Table A1: Full names of brain AAL atlas regions.
Regions
Regions abbr. regionLabels
Precentral L Precental gyrus PreCG.L region1
Precentral R Precental gyrus PreCG.R region2
Frontal Sup L Superior frontal gyrus;dorsolateral SFGdor.L region3
Frontal Sup R Superior frontal gyrus;dorsolateral SFGdor.R region4
Frontal Sup Orb L Superior frontal gyrus; orbital part ORBsup.L region5
Frontal Sup Orb R Superior frontal gyrus; orbital part ORBsup.R region6
Frontal Mid L Middle frontal gyrus MFG.L region7
Frontal Mid R Middle frontal gyrus MFG.R region8
Frontal Mid Orb L Middle frontal gyrus; orbital part ORBmid.L region9
Frontal Mid Orb R Middle frontal gyrus; orbital part ORBmid.R region10
Frontal Inf Oper L Inferior frontal gyrus;opercular part IFGoperc.L region11
Frontal Inf Oper R Inferior frontal gyrus;opercular part IFGoperc.R region12
Frontal Inf Tri L Inferior frontal gyrus;triangular part IFGtriang.L region13
Frontal Inf Tri R Inferior frontal gyrus;triangular part IFGtriang.R region14
Frontal Inf Orb L Inferior frontal gyrus; orbitalpart ORBinf.L region15
Frontal Inf Orb R Inferior frontal gyrus; orbitalpart ORBinf.R region16
Rolandic Oper L Rolandic operculum ROL.L region17
Rolandic Oper R Rolandic operculum ROL.R region18
Supp Motor Area L Supplementary motor area SMA.L region19
Supp Motor Area R Supplementary motor area SMA.R region20
Olfactory L Olfactory cortex OLF.L region21
Olfactory R Olfactory cortex OLF.R region22
Frontal Sup Medial L Superior frontal gyrus; medial SFGmed.L region23
Frontal Sup Medial R Superior frontal gyrus; medial SFGmed.R region24
Frontal Mid Orb L Superior frontal gyrus; medial orbital ORBsupmed.L region25
Frontal Mid Orb R Superior frontal gyrus; medial orbital ORBsupmed.R region26
Rectus L Gyrus rectus REC.L region27
Rectus R Gyrus rectus REC.R region28
Insula L Insula INS.L region29
Insula R Insula INS.R region30
Cingulum Ant L Anterior cingulate and paracingulate gyri ACG.L region31
Cingulum Ant R Anterior cingulate and paracingulate gyri ACG.R region32
Cingulum Mid L Median cingulate and paracingulate gyri DCG.L region33
Cingulum Mid R Median cingulate and paracingulate gyri DCG.R region34
Cingulum Post L Posterior cingulate gyrus PCG.L region35
Cingulum Post R Posterior cingulate gyrus PCG.R region36
Hippocampus L Hippocampus HIP.L region37
Hippocampus R Hippocampus HIP.R region38
ParaHippocampal L Parahippocampal gyrus PHG.L region39
ParaHippocampal R Parahippocampal gyrus PHG.R region40
Amygdala L Amygdala AMYG.L region41
Amygdala R Amygdala AMYG.R region42
Calcarine L Calcarine fissure and surrounding cortex CAL.L region43
Calcarine R Calcarine fissure and surrounding cortex CAL.R region44
Cuneus L Cuneus CUN.L region45
Cuneus R Cuneus CUN.R region46
Lingual L Lingual gyrus LING.L region47
Lingual R Lingual gyrus LING.R region48
Occipital Sup L Superior occipital gyrus SOG.L region49
Occipital Sup R Superior occipital gyrus SOG.R region50
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Table A1: Full names of brain AAL atlas regions (continued).
Regions
Regions abbr. regionLabels
Occipital Mid L Middle occipital gyrus MOG.L region51
Occipital Mid R Middle occipital gyrus MOG.R region52
Occipital Inf L Inferior occipital gyrus IOG.L region53
Occipital Inf R Inferior occipital gyrus IOG.R region54
Fusiform L Fusiform gyrus FFG.L region55
Fusiform R Fusiform gyrus FFG.R region56
Postcentral L Postcentral gyrus PoCG.L region57
Postcentral R Postcentral gyrus PoCG.R region58
Parietal Sup L Superior parietal gyrus SPG.L region59
Parietal Sup R Superior parietal gyrus SPG.R region60
Parietal Inf L Inferior parietal; but supramarginal and angular gyri IPL.L region61
Parietal Inf R Inferior parietal; but supramarginal and angular gyri IPL.R region62
SupraMarginal L Supramarginal gyrus SMG.L region63
SupraMarginal R Supramarginal gyrus SMG.R region64
Angular L Angular gyrus ANG.L region65
Angular R Angular gyrus ANG.R region66
Precuneus L Precuneus PCUN.L region67
Precuneus R Precuneus PCUN.R region68
Paracentral Lobule L Paracentral lobule PCL.L region69
Paracentral Lobule R Paracentral lobule PCL.R region70
Caudate L Caudate nucleus CAU.L region71
Caudate R Caudate nucleus CAU.R region72
Putamen L Lenticular nucleus; putamen PUT.L region73
Putamen R Lenticular nucleus; putamen PUT.R region74
Pallidum L Lenticular nucleus; pallidum PAL.L region75
Pallidum R Lenticular nucleus; pallidum PAL.R region76
Thalamus L Thalamus THA.L region77
Thalamus R Thalamus THA.R region78
Heschl L Heschl gyrus HES.L region79
Heschl R Heschl gyrus HES.R region80
Temporal Sup L Superior temporal gyrus STG.L region81
Temporal Sup R Superior temporal gyrus STG.R region82
Temporal Pole Sup L Temporal pole: superior temporal gyrus TPOsup.L region83
Temporal Pole Sup R Temporal pole: superior temporal gyrus TPOsup.R region84
Temporal Mid L Middle temporal gyrus MTG.L region85
Temporal Mid R Middle temporal gyrus MTG.R region86
Temporal Pole Mid L Temporal pole: middle temporal gyrus TPOmid.L region87
Temporal Pole Mid R Temporal pole: middle temporal gyrus TPOmid.R region88
Temporal Inf L Inferior temporal gyrus ITG.L region89
Temporal Inf R Inferior temporal gyrus ITG.R region90
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Table A2: Top 20 Spearman association results of the change in global network metrics with
targeted Alzheimer’s Disease gene expressions. Threshold= 0.5
17
= 0.0029
Gene Results are sorted according to p-value
ρ P-value Global Feature
PAXIP1 0.3889 0.0069 transitivity
PLAU -0.3824 0.008 global eff
ACE -0.3696 0.0106 transitivity
PLAU -0.3523 0.0151 char path len
ABCA7 -0.3492 0.0161 char path len
PSEN1 -0.299 0.0412 transitivity
APP -0.2602 0.0774 char path len
PLAU -0.2542 0.0847 louvain
APOE -0.2506 0.0893 char path len
ADAM10 -0.2365 0.1095 louvain
ACE 0.2291 0.1213 louvain
NOS3 -0.2207 0.1359 char path len
NOS3 -0.2202 0.1369 global eff
ABCA7 -0.2164 0.1441 global eff
HFE -0.2012 0.1752 char path len
Table A3: Top quantile regression results of the change in global network metrics and targeted
Alzheimer’s Disease gene expressions. Threshold= 0.5
17
= 0.0029.
Gene Results are sorted according to p-value
Beta Statistic P-value Metric
PAXIP1 0.0155 2.1179 0.039738 transitivity
PSEN1 -0.0366 -2.0821 0.04305 transitivity
A2M 0.0178 1.9728 0.054679 louvain
PLAU -0.0157 -1.9288 0.06008 global eff
APBB2 0.0166 1.7579 0.085573 louvain
ABCA7 0.0077 1.5185 0.135881 transitivity
BLMH 0.0101 1.3476 0.184529 transitivity
ACE -0.0162 -1.2618 0.213524 transitivity
ADAM10 -0.0147 -1.2538 0.21638 louvain
APOE -0.0555 -1.1673 0.249246 char path len
PLD3 -0.0096 -1.1433 0.258978 transitivity
ABCA7 -0.0156 -1.1367 0.261684 char path len
SORL1 0.0147 1.1278 0.265372 transitivity
APOE -0.0099 -1.1048 0.275101 global eff
HFE -0.0161 -1.0436 0.302239 louvain
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Table A4: Quantile regression top results of regressing CDR scores on the local connectivity
metrics.
CDR Results are sorted according to p-value. Threshold= 0.05
6×90 = 9.26e− 05
Metric Region Region id β P-value
CDJUDGE betweencentrality Frontal Inf Oper L region11 -1.06e-08 1.3246e-17
CDCOMMUN betweencentrality Frontal Inf Tri L region13 1.162e-07 1.0377e-16
CDCOMMUN betweencentrality Pallidum R region76 6.79e-08 1.5932e-16
CDCARE betweencentrality Pallidum R region76 1.21e-08 2.5409e-15
CDCARE betweencentrality Frontal Inf Tri L region13 -2.35e-08 4.3817e-15
CDCARE betweencentrality Rolandic Oper R region18 -5e-09 5.5180e-14
CDCARE betweencentrality Frontal Mid Orb L region9 8.35e-08 6.8455e-14
CDCARE betweencentrality Frontal Inf Tri R region14 1.538e-07 4.6868e-13
CDMEMORY betweencentrality Pallidum R region76 9.8e-09 1.8588e-12
CDMEMORY betweencentrality Heschl R region80 -1.431e-07 7.9135e-12
CDHOME betweencentrality Pallidum R region76 2.34e-08 1.0339e-10
CDORIENT betweencentrality Rolandic Oper R region18 3.566e-07 2.8690e-10
CDCOMMUN betweencentrality Frontal Sup Medial L region23 1.2e-08 2.2249e-09
CDMEMORY betweencentrality Frontal Mid Orb L region9 1.53e-08 2.7792e-09
CDHOME betweencentrality Frontal Inf Tri L region13 7.55e-08 2.8144e-09
CDCARE local eff Parietal Sup L region59 -2.8362e-06 4.5150e-09
CDCARE betweencentrality Caudate R region72 -2.7e-09 5.9383e-08
CDCARE betweencentrality Frontal Sup Medial L region23 1.81e-08 8.4091e-08
CDCOMMUN betweencentrality Precentral L region1 5.6e-09 8.8635e-08
CDCARE betweencentrality Frontal Sup Orb L region5 -6.8e-09 9.1463e-08
CDCARE betweencentrality Occipital Inf L region53 3.2e-09 1.0397e-07
CDJUDGE betweencentrality Insula R region30 -1.9e-09 1.0927e-07
CDORIENT betweencentrality Angular R region66 -2.58e-08 1.3192e-07
CDHOME betweencentrality Frontal Sup Medial L region23 7.28e-08 1.4609e-07
CDMEMORY betweencentrality Angular L region65 9.69e-08 1.5599e-07
CDCOMMUN betweencentrality Occipital Inf L region53 8e-09 1.6902e-07
CDCOMMUN betweencentrality Occipital Sup R region50 8.8e-09 1.8204e-07
CDCARE betweencentrality Cingulum Post R region36 3.55e-08 2.6603e-07
CDCARE betweencentrality Angular L region65 5.9e-09 3.2401e-07
CDCARE betweencentrality Frontal Inf Oper R region12 -4.9e-09 3.9313e-07
CDMEMORY betweencentrality Frontal Inf Oper R region12 1.72e-08 4.2464e-07
CDJUDGE betweencentrality Precentral R region2 2.4e-09 4.2576e-07
CDJUDGE betweencentrality Paracentral Lobule R region70 5.1e-09 4.5211e-07
CDCARE local eff Caudate L region71 7.203e-07 6.0570e-07
CDMEMORY betweencentrality Occipital Mid R region52 -1.45e-08 7.3061e-07
CDJUDGE betweencentrality SupraMarginal R region64 -1.35e-08 7.3933e-07
CDJUDGE betweencentrality Calcarine L region43 1.2e-09 8.0399e-07
CDCARE betweencentrality Precentral L region1 3.9e-09 1.0015e-06
CDCARE local eff Thalamus R region78 -1.6719e-06 1.1912e-06
CDCARE betweencentrality ParaHippocampal L region39 8.1e-09 1.2821e-06
CDMEMORY betweencentrality Precentral L region1 4.9e-09 1.4549e-06
CDJUDGE betweencentrality Cingulum Mid L region33 5e-10 1.8206e-06
CDORIENT betweencentrality Amygdala R region42 2.7e-08 2.0376e-06
CDCARE betweencentrality Cuneus R region46 2.6e-09 2.1374e-06
CDJUDGE local eff Occipital Mid L region51 -1.3593e-06 2.5568e-06
CDCARE betweencentrality Occipital Sup R region50 2.4e-09 2.7811e-06
CDCARE betweencentrality SupraMarginal R region64 2.35e-08 2.8475e-06
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Table A4: Quantile regression top results of regressing CDR scores on the local connectivity
metrics (continued).
CDR Results are sorted according to p-value. Threshold= 0.05
6×90 = 9.26e− 05
Metric Region Region id β P-value
CDCARE cluster coef Parietal Sup L region59 -1.5812e-06 3.0162e-06
CDCARE betweencentrality Precentral R region2 6.4e-09 3.0711e-06
CDJUDGE betweencentrality Cuneus R region46 8e-10 3.1560e-06
CDMEMORY betweencentrality Precentral R region2 1.21e-08 4.0628e-06
CDCARE betweencentrality Occipital Mid L region51 -2e-09 4.7259e-06
CDCARE betweencentrality Temporal Inf R region90 -8e-10 5.1879e-06
CDCOMMUN betweencentrality Temporal Pole Sup R region84 1.7e-09 5.2490e-06
CDCARE local eff Paracentral Lobule R region70 4.028e-07 5.3093e-06
CDCARE betweencentrality Olfactory R region22 2.5e-09 6.1963e-06
CDCARE betweencentrality Pallidum L region75 2.8e-09 6.6154e-06
CDJUDGE betweencentrality Postcentral L region57 -4e-10 6.6330e-06
CDCARE betweencentrality Frontal Med Orb L region25 -5.5e-09 6.7257e-06
CDCARE betweencentrality Parietal Inf L region61 -7.6e-09 6.8700e-06
CDCARE local eff Calcarine L region43 -1.3701e-06 6.9599e-06
CDCARE betweencentrality Cingulum Mid L region33 9e-10 7.0795e-06
CDHOME betweencentrality Precentral L region1 6.5e-09 7.2322e-06
CDJUDGE cluster coef Occipital Mid L region51 -7.789e-07 7.5340e-06
CDCARE betweencentrality Olfactory L region21 1.2e-09 1.0177e-05
CDCARE betweencentrality Paracentral Lobule L region69 2.9e-09 1.0179e-05
CDORIENT betweencentrality Frontal Sup Medial L region23 4.18e-08 1.1987e-05
CDCARE cluster coef Thalamus R region78 -9.55e-07 1.2007e-05
CDMEMORY betweencentrality Frontal Sup Orb L region5 -2.3e-09 1.3418e-05
CDCARE betweencentrality Frontal Sup Medial R region24 -2.2e-09 1.3753e-05
CDMEMORY betweencentrality Thalamus L region77 4.6e-09 1.4079e-05
CDCARE betweencentrality Putamen R region74 -6.6e-09 1.4768e-05
CDCOMMUN betweencentrality Putamen R region74 -1.1e-09 1.7248e-05
CDCARE local eff Amygdala R region42 -1.2503e-06 1.7740e-05
CDCARE betweencentrality Thalamus L region77 -7e-10 1.7820e-05
CDJUDGE betweencentrality Frontal Inf Orb R region16 6e-10 1.7857e-05
CDJUDGE cluster coef Temporal Mid L region85 6.814e-07 1.7954e-05
CDJUDGE betweencentrality Pallidum L region75 6e-10 1.9036e-05
CDCARE local eff Lingual L region47 -1.3648e-06 1.9534e-05
CDCARE betweencentrality Putamen L region73 -9e-10 2.0543e-05
CDCARE local eff Frontal Mid Orb L region9 -9.801e-07 2.0693e-05
CDJUDGE local eff Temporal Mid L region85 1.1769e-06 2.4200e-05
CDJUDGE cluster coef Frontal Sup Orb L region5 5.54e-07 2.5902e-05
CDCARE betweencentrality Temporal Pole Sup L region83 -2.4e-09 2.7526e-05
CDJUDGE local eff Calcarine L region43 -5.122e-07 2.7953e-05
CDJUDGE cluster coef Cuneus R region46 -6.206e-07 2.8360e-05
CDCARE betweencentrality Frontal Med Orb R region26 1.1e-09 2.9931e-05
CDCARE betweencentrality Rectus L region27 1.7e-09 3.1086e-05
CDCARE betweencentrality Temporal Pole Sup R region84 4e-10 3.2473e-05
CDCARE local eff Precentral R region2 -1.7287e-06 3.3132e-05
CDJUDGE local eff Frontal Sup Orb L region5 7.069e-07 3.3295e-05
CDCARE cluster coef Precuneus L region67 -1.3847e-06 3.3801e-05
CDJUDGE cluster coef Olfactory L region21 3.541e-07 3.5295e-05
CDCARE cluster coef Occipital Sup L region49 -1.2676e-06 3.5428e-05
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Table A4: Quantile regression top results of regressing CDR scores on the local connectivity
metrics (continued).
CDR Results are sorted according to p-value. Threshold= 0.05
6×90 = 9.26e− 05
Metric Region Region id β P-value
CDJUDGE cluster coef Calcarine L region43 -4.54e-07 3.7033e-05
CDJUDGE local eff Cuneus R region46 -1.0686e-06 3.7315e-05
CDCARE local eff Occipital Sup L region49 -2.3923e-06 3.9588e-05
CDCOMMUN betweencentrality Frontal Sup Orb R region6 1e-09 4.0230e-05
CDCARE betweencentrality Rolandic Oper L region17 6.2e-08 4.0397e-05
CDJUDGE betweencentrality Insula L region29 2e-10 4.3809e-05
CDR diff betweencentrality Frontal Sup Medial L region23 0.0037021312 4.5916e-05
CDCOMMUN cluster coef Precuneus L region67 -1.9329e-06 4.9971e-05
CDCARE local eff Occipital Mid L region51 -1.4926e-06 5.3963e-05
CDCARE betweencentrality Temporal Inf L region89 2e-10 5.5267e-05
CDCARE betweencentrality Amygdala L region41 -1.1e-09 5.6693e-05
CDCARE betweencentrality Frontal Inf Orb L region15 -8e-10 5.6717e-05
CDJUDGE betweencentrality Putamen R region74 3e-10 5.8176e-05
CDCARE local eff Parietal Inf L region61 1.8772e-06 5.9063e-05
CDORIENT local eff Caudate L region71 2.6838e-06 5.9186e-05
CDCARE local eff ParaHippocampal L region39 -6.989e-07 6.0628e-05
CDCARE cluster coef Paracentral Lobule L region69 -3.682e-07 6.0769e-05
CDHOME betweencentrality Cingulum Mid L region33 1.12e-08 6.2336e-05
CDCARE local eff Temporal Pole Sup R region84 -2.5008e-06 6.4671e-05
CDCARE betweencentrality Calcarine R region44 -2.3e-09 7.4457e-05
CDCARE betweencentrality ParaHippocampal R region40 -1.2e-09 7.5724e-05
CDMEMORY local eff Temporal Mid L region85 4.7978e-06 7.5984e-05
CDORIENT betweencentrality Thalamus L region77 3.7e-09 8.3093e-05
CDCARE cluster coef Parietal Inf L region61 9.696e-07 8.3094e-05
CDCARE betweencentrality Precuneus L region67 1.3e-09 8.9269e-05
CDJUDGE local eff Precentral R region2 -1.0795e-06 8.9400e-05
CDCOMMUN betweencentrality Cingulum Mid L region33 1.8e-09 8.9822e-05
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Figure A1: The top figure shows the distribution of local efficiency along the 90 AAL brain
regions in the baseline (purple) vs in the follow-up (green). The bottom figure shows the distri-
bution of the differences between the baseline and follow-up measures of local efficiency of the
AD (blue) vs controls (yellow), along the 90 AAL brain regions.
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Figure A2: The top figure shows the distribution of clustering coefficient along the 90 AAL
brain regions in the baseline (purple) vs in the follow-up (green). The bottom figure shows the
distribution of the differences between the baseline and follow-up measures of clustering coefficient
of the AD (blue) vs controls (yellow), along the 90 AAL brain regions.
Page 138
Figure A3: The top figure shows the distribution of betweenness centrality along the 90 AAL
brain regions in the baseline (purple) vs in the follow-up (green). The bottom figure shows
the distribution of the differences between the baseline and follow-up measures of betweenness
centrality of the AD (blue) vs controls (yellow), along the 90 AAL brain regions.
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Figure A4: Spearman correlations between the three local connectivity metrics; local efficiency,
clustering coefficient and betweenness centrality, at baseline (suffix: baseline), follow-up (suf-
fix: followup) and the absolute difference between them (no suffix). The calculation of Sperman’s
coefficient combines all 90 brain regions. The plot illustrates the very strong relationship between
the clustering coefficient and local efficiency at baseline, follow-up and the absolute difference
between the two visits.
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Figure A5: The figure shows the quantile regression model coefficient − log 10p-values. The
model regresses the change in the local coefficient (dependant variable) on a single gene at a
time (independent variable), at each of the 90 brain regions as in the AAL atlas (x axis).
Figure A6: The figure shows the quantile regression model coefficient − log 10p-values. The
model regresses the change in the betweenness centrality (dependant variable) on a single gene
at a time (independent variable), at each of the 90 brain regions as in the AAL atlas (x axis).
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Figure A7: The figure shows the quantile regression model coefficient − log 10p-values. The
model regresses the change in the local coefficient (dependant variable) on a single gene at a
time (independent variable), at each of the 90 brain regions as in the AAL atlas (x axis).
